Investigation NN 0 1 UNK O
of IN 0 0 12 O
clearance NN 0 1 16 O
and CC 0 0 12 O
interaction NN 0 1 UNK O
among IN 0 0 12 O
flavonoids NNS 1 1 UNK B-Drug_n
could MD 0 0 12 O
help VB 0 1 12 O
us PRP 1 0 12 O
better JJR 1 1 12 O
understand VBP 0 1 12 O
their PRP$ 0 0 12 O
bioavailability NN 0 1 UNK O
and CC 0 0 12 O
offer NN 0 0 12 O
insight NN 0 1 UNK O
into IN 0 0 12 O
the DT 0 0 12 O
approaches NNS 1 1 UNK O
to TO 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
to TO 0 0 12 O
minimize VB 0 0 1 O
competitive JJ 0 1 UNK O
effects NNS 1 1 1 O
and CC 0 0 12 O
to TO 0 0 12 O
design VB 0 1 UNK O
appropriate JJ 0 1 1 O
bioavailability NN 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
. . 0 0 12 O

9 CD 0 0 2 O
) ) 0 0 2 O
the DT 0 0 12 O
C9 NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
double JJ 0 1 3 O
bond NN 0 0 UNK O
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
C9 NNP 0 1 UNK O
carbonyl NN 0 0 UNK O
group NN 0 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
C NNP 0 0 2 O
- : 0 0 2 O
ring NN 0 1 3 O
; : 0 0 2 O

Our PRP$ 0 0 2 O
results NNS 1 1 1 O
indicate VBP 0 0 1 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
circadian JJ 0 0 13 O
oscillator NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
hippocampus NN 0 1 8 O
involving VBG 1 1 1 O
the DT 0 0 12 O
clock NN 0 1 12 O
gene NN 0 1 13 O
Bmal9 NNP 0 0 UNK O
( ( 0 0 2 O
also RB 0 0 12 O
known VBN 1 1 12 O
as IN 1 0 12 O
Arntl NNP 0 1 UNK O
) ) 0 0 2 O
that WDT 0 0 12 O
is VBZ 1 0 12 O
modulated VBN 1 1 UNK O
by IN 0 0 12 O
Rev NNP 0 1 UNK O
- : 0 0 2 O
erb NN 0 0 UNK O
and CC 0 0 12 O
requires VBZ 1 0 1 O
oligophrenin JJ 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
for IN 0 0 12 O
normal JJ 0 1 1 O
oscillation NN 0 1 UNK O
. . 0 0 12 O

Angiotensin NNP 0 1 UNK B-Group
converting VBG 1 0 UNK I-Group
enzyme JJ 0 1 14 I-Group
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
their PRP$ 0 0 12 O
influence NN 0 0 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
endothelial JJ 0 1 13 O
dysfunction NN 0 1 6 O
but CC 0 0 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
hyperpotassemia NN 0 1 13 O
are VBP 1 0 12 O
showed VBN 1 1 12 O
. . 0 0 12 O

Three CD 0 1 2 O
readings NNS 1 1 1 O
of IN 0 0 12 O
color NN 0 1 3 O
were VBD 1 0 12 O
taken VBN 1 1 12 O
using VBG 1 1 1 O
the DT 0 0 12 O
Vita NNP 0 1 UNK O
Easyshade NNP 0 0 UNK O
spectrophotometer NN 0 1 UNK O
: : 0 0 2 O
the DT 0 0 12 O
initial JJ 0 1 1 O
reading VBG 1 1 12 O
a DT 0 0 12 O
reading NN 0 1 12 O
at IN 0 0 12 O
seven CD 0 1 12 O
days NNS 1 1 12 O
and CC 0 0 12 O
a DT 0 0 12 O
reading NN 0 1 12 O
at IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

A DT 0 0 2 O
discussion NN 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
challenges NNS 1 1 UNK O
and CC 0 0 12 O
identification NN 0 1 1 O
of IN 0 0 12 O
models NNS 1 1 UNK O
and CC 0 0 12 O
best JJS 0 1 12 O
practices NNS 1 1 UNK O
are VBP 1 0 12 O
presented VBN 1 1 1 O
with IN 0 0 12 O
intent NN 0 1 1 O
of IN 0 0 12 O
aiding VBG 1 1 UNK O
the DT 0 0 12 O
research NN 0 1 13 O
community NN 0 1 12 O
in IN 0 0 12 O
addressing VBG 1 1 UNK O
real JJ 0 1 12 O
and CC 0 0 12 O
perceived JJ 0 1 UNK O
barriers NNS 1 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
combination NN 0 1 1 O
therapies NNS 1 1 6 O
for IN 0 0 12 O
cancer NN 0 1 6 O
. . 0 0 12 O

the DT 0 0 12 O
most RBS 0 0 12 O
common JJ 0 1 1 O
nonlaboratory JJ 0 0 UNK O
AEs NNP 0 1 UNK O
were VBD 1 0 12 O
dizziness JJ 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
headache NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
study NN 0 1 1 O
9 CD 0 0 2 O
( ( 0 0 2 O
fasted VBN 1 1 UNK O
) ) 0 0 2 O
9 CD 0 0 2 O
volunteers NNS 1 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
experienced VBD 1 0 12 O
a DT 0 0 12 O
total NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
AEs NNP 0 1 UNK O
; : 0 0 2 O

Different JJ 0 1 UNK O
groups NNS 1 1 1 O
of IN 0 0 12 O
medications NNS 1 1 6 O
are VBP 1 0 12 O
discussed VBN 1 1 1 O
and CC 0 0 12 O
their PRP$ 0 0 12 O
risks NNS 1 1 1 O
for IN 0 0 12 O
elderly JJ 0 1 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Opportunities NNS 0 0 UNK O
and CC 0 0 12 O
challenges NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
experimental JJ 0 1 UNK O
drug NN 0 1 1 O
combinations NNS 1 1 1 O
for IN 0 0 12 O
cancer NN 0 1 6 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
becoming VBG 1 0 12 O
increasingly RB 0 0 1 O
evident JJ 0 1 1 O
that IN 0 0 12 O
cancers NNS 1 1 6 O
are VBP 1 0 12 O
dependent JJ 0 1 1 O
on IN 0 0 12 O
a DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
altered JJ 0 1 1 O
molecular JJ 0 1 1 O
pathways NNS 1 1 13 O
and CC 0 0 12 O
can MD 0 0 12 O
develop VB 0 0 1 O
diverse JJ 0 1 UNK O
mechanisms NNS 1 1 UNK O
of IN 0 0 12 O
resistance NN 0 1 1 O
to TO 0 0 12 O
therapy VB 0 1 6 O
with IN 0 0 12 O
single JJ 0 1 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
combination NN 0 1 1 O
regimens NNS 1 1 UNK O
may MD 0 0 1 O
provide VB 0 1 1 O
the DT 0 0 12 O
best JJS 0 1 12 O
hope NN 0 1 12 O
for IN 0 0 12 O
effective JJ 0 1 1 O
therapies NNS 1 1 6 O
with IN 0 0 12 O
durable JJ 0 0 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

Despite IN 0 0 12 O
preclinical JJ 0 1 UNK O
data NNS 0 1 1 O
to TO 0 0 12 O
support VB 0 1 1 O
this DT 0 0 12 O
notion NN 0 0 UNK O
there EX 0 0 12 O
are VBP 1 0 12 O
many JJ 0 0 12 O
challenges NNS 1 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
targeted JJ 0 1 UNK O
combinations NNS 1 1 1 O
including VBG 1 1 1 O
scientific JJ 0 1 UNK O
economic JJ 0 1 13 O
legal JJ 0 1 1 O
and CC 0 0 12 O
regulatory JJ 0 1 UNK O
barriers NNS 1 1 UNK O
. . 0 0 12 O

9 CD 0 0 2 O
) ) 0 0 2 O
no DT 0 0 12 O
glycoside JJ 0 1 UNK O
present NN 0 1 1 O
. . 0 0 12 O

Sputum NNP 0 1 7 O
smear JJ 0 1 3 O
microscopy NN 0 1 16 O
is VBZ 1 0 12 O
performing VBG 1 1 1 O
poorly RB 0 1 1 O
in IN 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
infected JJ 0 1 6 O
individuals NNS 1 1 1 O
who WP 0 0 12 O
are VBP 1 0 12 O
often RB 0 1 12 O
started VBN 1 1 12 O
on IN 0 0 12 O
antituberculosis NN 0 1 UNK O
treatment NN 0 1 6 O
on IN 0 0 12 O
clinical JJ 0 1 6 O
grounds NNS 1 0 12 O
. . 0 0 12 O

Mutations NNS 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
oligophrenin NN 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
gene NN 0 1 13 O
( ( 0 0 2 O
OPHN9 NNP 0 0 UNK O
) ) 0 0 2 O
cause VBP 0 1 12 O
intellectual JJ 0 0 13 O
disability NN 0 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
circadian JJ 0 0 13 O
clock NN 0 1 12 O
in IN 0 0 12 O
hippocampus NN 0 1 8 O
is VBZ 1 0 12 O
regulated VBN 1 1 1 O
by IN 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
oligophrenin JJ 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
Rev NNP 0 1 UNK O
- : 0 0 2 O
erb NN 0 0 UNK O
. . 0 0 12 O
Oligophrenin NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
regulates NNS 0 0 UNK O
dendritic JJ 0 1 13 O
spine NN 0 1 3 O
morphology NN 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
brain NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
aim NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
to TO 0 0 12 O
assess VB 0 1 1 O
the DT 0 0 12 O
influence NN 0 0 UNK O
of IN 0 0 12 O
manganese JJ 0 1 13 B-Drug_n
gluconate NN 0 1 14 I-Drug_n
a DT 0 0 12 O
chemical NN 0 1 13 O
activator NN 0 0 UNK O
of IN 0 0 12 O
bleaching VBG 1 1 UNK O
agents NNS 1 1 1 O
at IN 0 0 12 O
a DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
on IN 0 0 12 O
the DT 0 0 12 O
efficiency NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
carbamide NN 0 1 16 B-Drug_n
peroxide IN 0 1 16 I-Drug_n
- : 0 0 2 O
based VBN 1 1 1 O
bleaching NN 0 1 UNK O
agent NN 0 1 1 O
. . 0 0 12 O

Group NNP 0 1 2 O
9 CD 0 0 2 O
was VBD 1 0 12 O
the DT 0 0 12 O
control NN 0 1 1 O
group NN 0 1 12 O
and CC 0 0 12 O
consisted VBD 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
carbamide NN 0 1 16 B-Drug_n
peroxide IN 0 1 16 I-Drug_n
- : 0 0 2 O
based VBN 1 1 1 O
bleaching NN 0 1 UNK O
gel NN 0 1 3 O
only RB 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
study NN 0 1 1 O
9 CD 0 0 2 O
9 CD 0 0 2 O
volunteers NNS 1 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
experienced VBD 1 0 12 O
a DT 0 0 12 O
total NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
AEs NNP 0 1 UNK O
; : 0 0 2 O

The DT 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CIs NNP 0 1 UNK O
about IN 0 1 12 O
the DT 0 0 12 O
ratio NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
fenofibric JJ 0 0 13 B-Drug
acid NN 0 1 14 I-Drug
geometric JJ 0 1 UNK O
mean NN 0 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
fenofibrate NN 0 1 16 B-Drug
geometric JJ 0 1 UNK O
mean NN 0 1 12 O
were VBD 1 0 12 O
within IN 0 0 1 O
the DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
limits NNS 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
C NNP 0 0 2 O
( ( 0 0 2 O
max NN 0 0 3 O
) ) 0 0 2 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
t NN 0 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
ln JJ 0 1 UNK O
- : 0 0 2 O
transformed VBN 1 1 UNK O
data NNS 0 1 1 O
in IN 0 0 12 O
both DT 0 0 12 O
study NN 0 1 1 O
9 CD 0 0 2 O
( ( 0 0 2 O
fasted VBN 1 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
study $ 0 1 1 O
9 CD 0 0 2 O
. . 0 0 12 O

Fenofibric JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
at IN 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
studied VBD 1 0 1 O
was VBD 1 0 12 O
well RB 0 1 12 O
tolerated VBN 1 0 1 O
in IN 0 0 12 O
this DT 0 0 12 O
population NN 0 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
eugenol NN 0 1 UNK B-Drug
on IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
transport NN 0 1 1 O
across IN 0 0 12 O
an DT 0 0 12 O
isolated JJ 0 1 1 O
rat NN 0 1 13 O
intestinal JJ 0 1 13 O
membrane NN 0 1 3 O
was VBD 1 0 12 O
studied VBN 1 0 1 O
using VBG 1 1 1 O
an DT 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
diffusion NN 0 1 1 O
chamber NN 0 1 3 O
system NN 0 1 1 O
. . 0 0 12 O

Quantitative JJ 0 1 UNK O
toxicological JJ 0 1 13 O
analysis NN 0 1 1 O
showed VBD 1 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
etizolam JJ 0 1 UNK B-Drug
phenobarbital JJ 0 1 16 B-Drug
promethazine NN 0 1 16 B-Drug
and CC 0 0 12 O
chlorpromazine NN 0 1 16 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
femoral JJ 0 1 8 O
blood NN 0 1 6 O
were VBD 1 0 12 O
9 CD 0 0 2 O
ng JJ 0 1 13 O
/ NNP 0 0 2 O
ml NN 0 1 16 O
9 CD 0 0 2 O
microg NN 0 0 UNK O
/ NNP 0 0 2 O
ml VBZ 0 1 16 O
9 CD 0 0 2 O
microg NN 0 0 UNK O
/ NNP 0 0 2 O
ml NN 0 1 16 O
and CC 0 0 12 O
9 CD 0 0 2 O
microg NN 0 0 UNK O
/ NNP 0 0 2 O
ml NN 0 1 16 O
respectively RB 0 0 1 O
and CC 0 0 12 O
large JJ 0 1 3 O
amounts NNS 1 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
were VBD 1 0 12 O
also RB 0 0 12 O
detected VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
stomach NN 0 1 6 O
contents NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
these DT 0 0 12 O
9 CD 0 0 2 O
single JJ 0 1 12 O
- : 0 0 2 O
dose JJ 0 1 6 O
studies NNS 1 1 1 O
these DT 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
administered VBD 1 1 1 O
a DT 0 0 12 O
single JJ 0 1 12 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
fenofibric JJ 0 0 13 B-Drug
acid NN 0 1 14 I-Drug
met VBD 1 1 12 O
the DT 0 0 12 O
US NNP 0 0 2 O
Food NNP 0 1 2 O
and CC 0 0 12 O
Drug NNP 0 1 2 O
Administration NNP 0 1 UNK O
regulatory JJ 0 1 UNK O
criteria NNS 1 1 1 O
for IN 0 0 12 O
assuming VBG 1 0 UNK O
bioequivalence NN 0 1 UNK O
to TO 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
fenofibrate JJ 0 1 16 B-Drug
tablets NNS 1 1 3 O
with IN 0 0 12 O
respect NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
and CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
fenofibric JJ 0 0 13 B-Drug
acid JJ 0 1 14 I-Drug
absorption NN 0 1 1 O
in IN 0 0 12 O
both DT 0 0 12 O
fed NNS 0 1 12 O
and CC 0 0 12 O
fasted VBN 1 1 UNK O
states NNS 1 1 1 O
. . 0 0 12 O

AEs NNP 0 1 UNK O
were VBD 1 0 12 O
generally RB 0 0 1 O
mild JJ 0 1 6 O
or CC 0 0 12 O
moderate JJ 0 1 1 O
in IN 0 0 12 O
intensity NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
series NN 0 1 12 O
of IN 0 0 12 O
flavonoids NNS 1 1 UNK B-Drug_n
including VBG 1 1 1 O
flavonols JJ 0 1 UNK B-Drug_n
flavones NNS 1 1 UNK B-Drug_n
isoflavone VBP 0 1 UNK B-Drug_n
flavanone NN 0 1 UNK B-Drug_n
flavanonols NNS 0 1 UNK B-Drug_n
and CC 0 0 12 O
catechins NNS 1 1 UNK B-Drug_n
on IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
luteolin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
apigenin NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

the DT 0 0 12 O
most RBS 0 0 12 O
common JJ 0 1 1 O
nonlaboratory JJ 0 0 UNK O
AEs NNP 0 1 UNK O
were VBD 1 0 12 O
headache NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
dry JJ 0 1 3 O
throat NN 0 1 3 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

A DT 0 0 2 O
recent JJ 0 1 12 O
study NN 0 1 1 O
identifies VBZ 1 0 UNK O
a DT 0 0 12 O
new JJ 0 1 12 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
action NN 0 1 13 O
for IN 0 0 12 O
the DT 0 0 12 O
synergism NN 0 1 UNK O
of IN 0 0 12 O
TRAIL NNP 0 1 UNK O
and CC 0 0 12 O
Bortezomib NNP 0 1 UNK B-Drug
. . 0 0 12 O

All PDT 0 0 2 O
the DT 0 0 12 O
results NNS 1 1 1 O
suggested VBD 1 1 12 O
that IN 0 0 12 O
eugenol NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
an DT 0 0 12 O
efficient JJ 0 1 13 O
component NN 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
administrative JJ 0 1 13 O
formulation NN 0 1 13 O
for IN 0 0 12 O
improving VBG 1 1 1 O
the DT 0 0 12 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
proteasome JJ 0 1 UNK O
inhibitor NN 0 1 14 O
Bortezomib NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
identified VBN 1 1 1 O
as IN 1 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
enhancer NN 0 1 UNK O
of IN 0 0 12 O
TRAIL NNP 0 1 UNK O
- : 0 0 2 O
induced JJ 0 1 6 O
apoptosis NN 0 1 UNK O
in IN 0 0 12 O
several JJ 0 1 12 O
human JJ 0 1 1 O
cancers NNS 1 1 6 O
. . 0 0 12 O

Novel NNP 0 1 UNK O
insights NNS 1 1 UNK O
into IN 0 0 12 O
the DT 0 0 12 O
synergistic JJ 0 1 UNK O
interaction NN 0 1 UNK O
of IN 0 0 12 O
Bortezomib NNP 0 1 UNK B-Drug
and CC 0 0 12 O
TRAIL NNP 0 1 UNK O
: : 0 0 2 O
tBid NN 0 1 UNK O
provides VBZ 1 1 UNK O
the DT 0 0 12 O
link NN 0 1 12 O
. . 0 0 12 O

To TO 0 0 2 O
research NN 0 1 13 O
the DT 0 0 12 O
influence NN 0 0 UNK O
of IN 0 0 12 O
glycyrrhiza NN 0 1 UNK B-Drug_n
extract NN 0 1 13 I-Drug_n
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
characteristic JJ 0 1 UNK O
parameters NNS 1 1 1 O
of IN 0 0 12 O
daphnetin NN 0 1 UNK B-Drug_n
which WDT 0 0 12 O
was VBD 1 0 12 O
aimed VBN 1 1 UNK O
to TO 0 0 12 O
explore VB 0 0 12 O
the DT 0 0 12 O
rationality NN 0 0 UNK O
of IN 0 0 12 O
concert JJ 0 0 UNK O
application NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

[ JJ 0 0 2 O
Effects NNS 0 1 UNK O
of IN 0 0 12 O
glycyrrhiza JJ 0 1 UNK B-Drug_n
extract NN 0 1 13 I-Drug_n
on IN 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
property NN 0 1 13 O
of IN 0 0 12 O
daphnetin NN 0 1 UNK B-Drug_n
in IN 0 0 12 O
rats NNS 1 1 UNK O
] VBP 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
blood NN 0 1 6 O
concentration NN 0 1 1 O
of IN 0 0 12 O
daphnetin NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
assayed VBN 1 1 UNK O
by IN 0 0 12 O
LC NNP 0 0 UNK O
- : 0 0 2 O
MS NN 0 1 2 O
. . 0 0 12 O

The DT 0 0 2 O
rats NNS 1 1 UNK O
received VBD 1 1 12 O
intragastric JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
daphnetin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
glycyrrhiza NN 0 1 UNK B-Drug_n
extract NN 0 1 13 I-Drug_n
containing VBG 1 1 1 O
the DT 0 0 12 O
same JJ 0 1 12 O
daphnetin NN 0 1 UNK B-Drug_n
respectively RB 0 0 1 O
. . 0 0 12 O

Glycyrrhiza NNP 0 1 UNK O
extract NN 0 1 13 O
can MD 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
t NN 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
/ RB 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
tmax NN 0 1 UNK O
and CC 0 0 12 O
Ke NNP 0 1 UNK O
of IN 0 0 12 O
daphnetin NN 0 1 UNK B-Drug_n
while IN 0 0 12 O
increased VBD 1 1 1 O
the DT 0 0 12 O
Ka NNP 0 0 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
infinity NN 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
data NN 0 1 1 O
was VBD 1 0 12 O
processed VBN 1 1 UNK O
by IN 0 0 12 O
program NN 0 1 1 O
DAS9.9 NNP 0 0 UNK O
. . 0 0 12 O

Glycyrrhiza NNP 0 1 UNK O
extract NN 0 1 13 O
promoted VBD 1 1 UNK O
the DT 0 0 12 O
oral JJ 0 1 6 O
absorption NN 0 1 1 O
of IN 0 0 12 O
daphnetin NN 0 1 UNK B-Drug_n
slowed VBD 1 1 12 O
down IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
and CC 0 0 12 O
increased VBD 1 1 1 O
the DT 0 0 12 O
biological JJ 0 1 13 O
availability NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
synergistic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
chondroitinase NN 0 1 UNK O
ABC NNP 0 1 UNK O
and CC 0 0 12 O
growth NN 0 1 1 O
factors NNS 1 1 1 O
facilitates VBZ 1 0 UNK O
the DT 0 0 12 O
anatomic JJ 0 1 13 O
integration NN 0 1 13 O
of IN 0 0 12 O
mRPCs NN 0 0 UNK O
transplanted VBN 1 1 13 O
into IN 0 0 12 O
Rho NNP 0 0 UNK O
( ( 0 0 2 O
- : 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
mice NN 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
guide NN 0 1 12 O
is VBZ 1 0 12 O
therefore RB 0 0 1 O
useful JJ 0 1 UNK O
as RB 0 0 12 O
for IN 0 0 12 O
as IN 1 0 12 O
we PRP 0 0 12 O
are VBP 1 0 12 O
concerned VBN 1 0 12 O
to TO 0 0 12 O
any DT 0 0 12 O
physician JJ 0 1 6 O
regardless NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
country NN 0 1 12 O
he PRP 0 0 12 O
/ VBZ 0 0 2 O
she PRP 0 0 12 O
operates VBZ 1 1 UNK O
in IN 0 0 12 O
. . 0 0 12 O

The DT 0 0 2 O
guide NN 0 1 12 O
above IN 0 1 12 O
even RB 0 0 12 O
if IN 0 0 12 O
initially RB 0 1 12 O
conceived VBN 1 1 UNK O
for IN 0 0 12 O
being VBG 1 0 12 O
used VBN 1 1 12 O
in IN 0 0 12 O
Italy NNP 0 1 UNK O
also RB 0 0 12 O
presents VBZ 1 1 12 O
a DT 0 0 12 O
more RBR 0 1 12 O
general JJ 0 1 1 O
and CC 0 0 12 O
international JJ 0 1 1 O
interest NN 0 1 1 O
expecially RB 0 0 UNK O
as RB 0 0 12 O
for IN 0 0 12 O
as IN 1 0 12 O
the DT 0 0 12 O
concepts NNS 1 1 UNK O
of IN 0 0 12 O
pharmacology NN 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
features NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
active JJ 0 1 1 O
ingredients NNS 1 1 UNK O
are VBP 1 0 12 O
concerned VBN 1 0 12 O
. . 0 0 12 O

In IN 0 0 2 O
daily JJ 0 1 12 O
clinical JJ 0 1 6 O
practice NN 0 1 UNK O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
need NN 0 1 12 O
for IN 0 0 12 O
the DT 0 0 12 O
family NN 0 1 12 O
physician NN 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
ENT NNP 0 1 11 O
specialist NN 0 1 1 O
or CC 0 0 12 O
audiologist NN 0 1 UNK O
( ( 0 0 2 O
also RB 0 0 12 O
in IN 0 0 12 O
consideration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
possible JJ 0 1 1 O
medico NN 0 0 UNK O
- : 0 0 2 O
legal JJ 0 1 1 O
implications NNS 1 0 UNK O
) ) 0 0 2 O
to TO 0 0 12 O
focus VB 0 1 1 O
the DT 0 0 12 O
attention NN 0 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
possible JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
otological JJ 0 1 UNK O
side NN 0 1 3 O
effects NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
review NN 0 1 2 O
summarises VBZ 1 0 UNK O
the DT 0 0 12 O
research NN 0 1 13 O
on IN 0 0 12 O
Casein NNP 0 1 UNK B-Drug_n
phosphopeptide IN 0 1 UNK I-Drug_n
- : 0 0 2 O
amorphous JJ 0 1 13 I-Drug_n
calcium NN 0 1 14 I-Drug_n
phosphate NN 0 1 14 I-Drug_n
complex JJ 0 1 1 I-Drug_n
and CC 0 0 12 O
provides VBZ 1 1 UNK O
information NN 0 1 1 O
related VBN 1 1 1 O
to TO 0 0 12 O
its PRP$ 1 0 12 O
benefit NN 0 1 1 O
in IN 0 0 12 O
dentistry NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
present JJ 0 1 1 O
work NN 0 1 12 O
on IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
induced JJ 0 1 6 O
ototoxicity NN 0 1 UNK O
tinnitus NN 0 1 13 O
and CC 0 0 12 O
vertigo NN 0 1 6 O
represents VBZ 1 1 1 O
the DT 0 0 12 O
update NN 0 1 12 O
and CC 0 0 12 O
revision NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
previous JJ 0 1 12 O
guide NN 0 1 12 O
to TO 0 0 12 O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
reactions NNS 1 1 1 O
for IN 0 0 12 O
italian JJ 0 1 UNK O
physicians NNS 1 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Pharmacological JJ 0 1 UNK O
drugs NNS 1 1 6 O
inducing VBG 1 1 6 O
ototoxicity NN 0 1 UNK O
vestibular NN 0 1 6 O
symptoms NNS 1 1 6 O
and CC 0 0 12 O
tinnitus NN 0 1 13 O
: : 0 0 2 O
a DT 0 0 12 O
reasoned JJ 0 1 UNK O
and CC 0 0 12 O
updated JJ 0 1 2 O
guide NN 0 1 12 O
. . 0 0 12 O

They PRP 0 0 12 O
have VBP 0 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
organized VBN 1 1 12 O
in IN 0 0 12 O
alphabetical JJ 0 1 UNK O
order NN 0 1 1 O
for IN 0 0 12 O
an DT 0 0 12 O
easier JJR 1 1 12 O
consultation NN 0 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
have VBP 0 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
subcategorized VBN 0 0 UNK O
with IN 0 0 12 O
regards NNS 1 0 1 O
to TO 0 0 12 O
the DT 0 0 12 O
field NN 0 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
they PRP 0 0 12 O
are VBP 1 0 12 O
applied VBN 1 1 1 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
indications NNS 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
behaviour NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
list NN 0 1 12 O
of IN 0 0 12 O
active JJ 0 1 1 O
ingredients NNS 1 1 UNK O
and CC 0 0 12 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
subdivided VBN 1 0 UNK O
in IN 0 0 12 O
categories NNS 1 1 13 O
based VBN 1 1 1 O
on IN 0 0 12 O
their PRP$ 0 0 12 O
audiological JJ 0 1 13 O
and CC 0 0 12 O
otoneurological JJ 0 1 UNK O
side NN 0 1 3 O
- : 0 0 2 O
effects NNS 1 1 1 O
that WDT 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
signaled VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
companies NNS 1 1 UNK O
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
ministerial JJ 0 1 UNK O
notes NNS 1 1 12 O
. . 0 0 12 O

This DT 0 0 2 O
would MD 0 0 12 O
allow VB 0 1 1 O
a DT 0 0 12 O
clinical JJ 0 1 6 O
risk NN 0 1 1 O
- : 0 0 2 O
benefit NN 0 1 1 O
evaluation NN 0 1 1 O
weighing VBG 1 1 UNK O
the DT 0 0 12 O
possible JJ 0 1 1 O
clinical JJ 0 1 6 O
advantage NN 0 0 UNK O
in IN 0 0 12 O
their PRP$ 0 0 12 O
field NN 0 1 1 O
of IN 0 0 12 O
competence NN 0 1 13 O
against IN 0 0 12 O
possible JJ 0 1 1 O
otological JJ 0 1 UNK O
side NN 0 1 3 O
- : 0 0 2 O
effects NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
detection NN 0 1 1 O
was VBD 1 0 12 O
performed VBN 1 1 1 O
by IN 0 0 12 O
a DT 0 0 12 O
triple JJ 0 1 3 O
- : 0 0 2 O
quadrupole JJ 0 1 UNK O
mass NN 0 1 1 O
spectrometer NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
positive JJ 0 1 1 O
ion NN 0 1 13 O
and CC 0 0 12 O
multiple JJ 0 1 1 O
reaction NN 0 1 1 O
monitoring NN 0 1 1 O
( ( 0 0 2 O
MRM NNP 0 0 UNK O
) ) 0 0 2 O
mode NN 0 1 1 O
m NN 0 1 2 O
/ NNP 0 0 2 O
z NN 0 0 16 O
9 CD 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
> NN 0 0 2 O

Following VBG 0 1 2 O
liquid JJ 0 1 3 O
- : 0 0 2 O
liquid JJ 0 1 3 O
extraction NN 0 1 1 O
with IN 0 0 12 O
ethyl JJ 0 0 13 B-Drug_n
acetate VBP 0 1 14 I-Drug_n
the DT 0 0 12 O
separation NN 0 1 13 O
was VBD 1 0 12 O
performed VBN 1 1 1 O
on IN 0 0 12 O
a DT 0 0 12 O
reverse JJ 0 1 1 O
phase NN 0 1 1 O
C9 NNP 0 1 UNK O
column NN 0 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
mobile JJ 0 1 1 O
phase NN 0 1 1 O
consisted VBN 1 1 1 O
of IN 0 0 12 O
methanol JJ 0 1 UNK B-Drug_n
- : 0 0 2 O
ammonium NN 0 1 13 I-Drug_n
acetate NN 0 1 14 I-Drug_n
( ( 0 0 2 O
pH JJ 0 1 14 O
9 CD 0 0 2 O
; : 0 0 2 O
9 CD 0 0 2 O
mM NN 0 0 UNK O
) ) 0 0 2 O
( ( 0 0 2 O
9:9 CD 0 0 UNK O
v NN 0 0 16 O
/ NNP 0 0 2 O
v NN 0 0 16 O
) ) 0 0 2 O
. . 0 0 12 O

A DT 0 0 2 O
rapid JJ 0 1 1 O
sensitive JJ 0 1 1 O
and CC 0 0 12 O
reliable JJ 0 1 UNK O
high JJ 0 1 1 O
performance NN 0 1 13 O
liquid NN 0 1 3 O
chromatography NN 0 1 UNK O
- : 0 0 2 O
tandem NN 0 1 1 O
mass NN 0 1 1 O
spectrometry NN 0 1 UNK O
( ( 0 0 2 O
HPLC NNP 0 1 UNK O
- : 0 0 2 O
MS NNP 0 1 2 O
/ NNP 0 0 2 O
MS NNP 0 1 2 O
) ) 0 0 2 O
method NN 0 1 13 O
was VBD 1 0 12 O
developed VBN 1 0 1 O
and CC 0 0 12 O
validated VBN 1 0 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
determination NN 0 1 13 O
of IN 0 0 12 O
propiverine NN 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
( ( 0 0 2 O
CAS NNP 0 0 UNK O
99 CD 0 0 10 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
in IN 0 0 12 O
human JJ 0 1 1 O
plasma NN 0 1 14 O
using VBG 1 1 1 O
cetirizine NN 0 1 13 B-Drug
di SYM 0 1 UNK I-Drug
- : 0 0 2 O
hydrochloride NN 0 1 0 I-Drug
as IN 1 0 12 O
internal JJ 0 1 1 O
standard NN 0 1 1 O
( ( 0 0 2 O
IS NNP 0 0 11 O
CAS NNP 0 0 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Determination NN 0 1 UNK O
of IN 0 0 12 O
propiverine JJ 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
in IN 0 0 12 O
human JJ 0 1 1 O
plasma NN 0 1 14 O
by IN 0 0 12 O
high JJ 0 1 1 O
performance NN 0 1 13 O
liquid NN 0 1 3 O
chromatography NN 0 1 UNK O
- : 0 0 2 O
tandem NN 0 1 1 O
mass NN 0 1 1 O
spectrometry NN 0 1 UNK O
: : 0 0 2 O
application NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
study NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
sustained JJ 0 1 1 O
release NN 0 1 12 O
formulation NN 0 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
limit NN 0 1 1 O
of IN 0 0 12 O
detection NN 0 1 1 O
( ( 0 0 2 O
LOD NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
lower JJR 1 1 1 O
limit NN 0 1 1 O
of IN 0 0 12 O
quantification NN 0 1 UNK O
( ( 0 0 2 O
LLOQ NNP 0 1 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
human JJ 0 1 1 O
plasma NN 0 1 14 O
were VBD 1 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
ng JJ 0 1 13 O
/ NNP 0 0 2 O
mL NN 0 1 14 O
respectively RB 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
calibration NN 0 1 UNK O
curve NN 0 1 13 O
fitted VBN 1 1 3 O
well RB 0 1 12 O
over IN 0 1 12 O
the DT 0 0 12 O
concentration NN 0 1 1 O
range NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
ng JJ 0 1 13 O
/ NN 0 0 2 O
mL NN 0 1 14 O
( ( 0 0 2 O
all PDT 0 0 12 O
the DT 0 0 12 O
concentration NN 0 1 1 O
data NNS 0 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
are VBP 1 0 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
salt VB 0 1 3 O
( ( 0 0 2 O
propiverine VB 0 1 UNK B-Drug
hydrochloride RB 0 1 0 I-Drug
) ) 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

9 CD 0 0 2 O
for IN 0 0 12 O
the DT 0 0 12 O
IS NNP 0 0 11 O
. . 0 0 12 O

9 CD 0 0 2 O
for IN 0 0 12 O
propiverine NN 0 1 UNK B-Drug
and CC 0 0 12 O
m NN 0 1 2 O
/ NNP 0 0 2 O
z NN 0 0 16 O
9 CD 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
> NN 0 0 2 O

The DT 0 0 2 O
procedure NN 0 1 1 O
indicated VBD 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
was VBD 1 0 12 O
enhanced VBN 1 1 1 O
significantly RB 0 0 1 O
by IN 0 0 12 O
eugenol NN 0 1 UNK B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
tested JJ 0 1 1 O
nanoemulsion NN 0 1 UNK O
. . 0 0 12 O

After IN 0 0 2 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
form NN 0 1 1 O
of IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
nanoemulsion NN 0 1 UNK O
or CC 0 0 12 O
in IN 0 0 12 O
free JJ 0 1 12 O
colchicine NN 0 1 0 B-Drug
solution NN 0 1 1 O
the DT 0 0 12 O
relative JJ 0 1 1 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
nanoemulsion NN 0 1 UNK O
and CC 0 0 12 O
eugenol VB 0 1 UNK B-Drug
- : 0 0 2 O
nanoemulsion NN 0 1 UNK O
were VBD 1 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
respectively RB 0 0 1 O
compared VBN 1 1 1 O
with IN 0 0 12 O
free JJ 0 1 12 O
colchicine NN 0 1 0 B-Drug
solution NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
method NN 0 1 13 O
was VBD 1 0 12 O
proved VBN 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
rapid JJ 0 1 1 O
sensitive JJ 0 1 1 O
specific JJ 0 1 1 O
accurate NN 0 1 1 O
and CC 0 0 12 O
reproducible JJ 0 1 1 O
and CC 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
successfully RB 0 0 1 O
applied VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
study NN 0 1 1 O
of IN 0 0 12 O
propiverine JJ 0 1 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
sustained VBD 1 1 1 O
release NN 0 1 12 O
capsules NNS 1 1 3 O
( ( 0 0 2 O
the DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
in IN 0 0 12 O
this DT 0 0 12 O

In IN 0 0 2 O
conclusion NN 0 1 12 O
IGF9R NNP 0 0 UNK O
inhibition NN 0 1 13 O
can MD 0 0 12 O
enhance VB 0 1 UNK O
doxorubicin JJ 0 1 13 B-Drug
chemotherapy NN 0 1 6 O
in IN 0 0 12 O
some DT 0 0 12 O
osteosarcoma NN 0 1 13 O
cell NN 0 1 1 O
lines NNS 1 1 3 O
. . 0 0 12 O

All DT 0 0 2 O
guidelines NNS 1 1 13 O
presented VBN 1 1 1 O
non JJ 0 1 1 O
- : 0 0 2 O
directive JJ 0 1 UNK O
advice NN 0 1 16 O
using VBG 1 1 1 O
words NNS 1 1 12 O
such JJ 0 0 1 O
as IN 1 0 12 O
'consider NN 0 1 UNK O
' POS 0 0 2 O
and CC 0 0 12 O
'regularly RB 0 0 UNK O
' '' 0 0 2 O
. . 0 0 12 O

9 CD 0 0 2 O
) ) 0 0 2 O
B NNP 0 0 2 O
- : 0 0 2 O
ring NN 0 1 3 O
is VBZ 1 0 12 O
attached VBN 1 1 3 O
to TO 0 0 12 O
the DT 0 0 12 O
C NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
position NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
C NNP 0 0 2 O
- : 0 0 2 O
ring NN 0 1 3 O
; : 0 0 2 O

IGF9R NNP 0 0 UNK O
- : 0 0 2 O
targeted VBN 1 1 UNK O
therapy NN 0 1 6 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
enhancement NN 0 1 1 O
of IN 0 0 12 O
doxorubicin JJ 0 1 13 B-Drug
chemosensitivity NN 0 1 UNK O
in IN 0 0 12 O
human JJ 0 1 1 O
osteosarcoma NN 0 1 13 O
cell NN 0 1 1 O
lines NNS 1 1 3 O
. . 0 0 12 O

This DT 0 0 2 O
paper NN 0 1 13 O
examines VBZ 1 0 UNK O
the DT 0 0 12 O
debate NN 0 1 12 O
about IN 0 1 12 O
the DT 0 0 12 O
safety NN 0 1 1 O
of IN 0 0 12 O
kava NN 0 1 UNK O
( ( 0 0 2 O
Piper NNP 0 1 UNK O
methysticum NN 0 0 UNK O
Forst NNP 0 0 UNK O
. . 0 0 12 O
f VB 0 1 16 O
Piperaceae NNP 0 1 UNK O
) ) 0 0 2 O
a DT 0 0 12 O
plant NN 0 1 1 O
native NN 0 1 12 O
to TO 0 0 12 O
Oceania NNP 0 1 UNK O
where WRB 0 0 12 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
a DT 0 0 12 O
long JJ 0 1 12 O
history NN 0 1 12 O
of IN 0 0 12 O
traditional JJ 0 1 UNK O
use NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
purpose NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
to TO 0 0 12 O
investigate VB 0 1 1 O
both DT 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
and CC 0 0 12 O
mechanisms NN 1 1 UNK O
of IN 0 0 12 O
IGF9R NNP 0 0 UNK O
inhibition NN 0 1 13 O
by IN 0 0 12 O
tyrphostin NN 0 1 UNK B-Drug_n
AG9 NNP 0 0 UNK I-Drug_n
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
or CC 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
in IN 0 0 12 O
a DT 0 0 12 O
panel NN 0 1 1 O
of IN 0 0 12 O
six CD 0 1 12 O
osteosarcoma NN 0 1 13 O
cell NN 0 1 1 O
lines NNS 1 1 3 O
and CC 0 0 12 O
a DT 0 0 12 O
self NN 0 1 12 O
- : 0 0 2 O
established VBN 1 1 1 O
doxorubicin SYM 0 1 13 B-Drug
- : 0 0 2 O
resistant NN 0 1 3 O
cell NN 0 1 1 O
line NN 0 1 12 O
. . 0 0 12 O

We PRP 0 0 12 O
are VBP 1 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
to TO 0 0 12 O
indicate VB 0 0 1 O
that IN 0 0 12 O
targeting VBG 1 1 UNK O
IGF9R NNP 0 0 UNK O
together RB 0 1 12 O
with IN 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
achieved VBN 1 0 1 O
additive JJ 0 1 16 O
anti NN 0 0 3 O
- : 0 0 2 O
osteosarcoma NN 0 1 13 O
growth NN 0 1 1 O
effect NN 0 1 1 O
accompanied VBN 1 0 12 O
with IN 0 0 12 O
increased JJ 0 1 1 O
apoptosis NN 0 1 UNK O
cytotoxicity NN 0 1 UNK O
and CC 0 0 12 O
dual JJ 0 1 3 O
cell NN 0 1 1 O
cycle NN 0 1 1 O
arrests NNS 1 1 UNK O
. . 0 0 12 O

Tuberculosis NN 0 1 7 O
is VBZ 1 0 12 O
the DT 0 0 12 O
second JJ 0 1 12 O
most RBS 0 0 12 O
common JJ 0 1 1 O
cause NN 0 1 12 O
of IN 0 0 12 O
death NN 0 1 12 O
from IN 0 0 12 O
an DT 0 0 12 O
infectious JJ 0 1 6 O
disease NN 0 1 6 O
after IN 0 0 12 O
HIV NNP 0 1 6 O
/ NNP 0 0 2 O
AIDS NNP 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
leading VBG 1 1 1 O
cause NN 0 1 12 O
of IN 0 0 12 O
death NN 0 1 12 O
from IN 0 0 12 O
an DT 0 0 12 O
infectious JJ 0 1 6 O
disease NN 0 1 6 O
in IN 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
co NN 0 1 12 O
- : 0 0 2 O
infected JJ 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

[ NNP 0 0 2 O
Medical NNP 0 1 2 O
treatment NN 0 1 6 O
of IN 0 0 12 O
tuberculosis NN 0 1 6 O
- : 0 0 2 O
update JJ 0 1 12 O
9 CD 0 0 2 O
] NN 0 0 2 O
. . 0 0 12 O

Drug NN 0 1 2 O
resistant JJ 0 1 3 O
tuberculosis NN 0 1 6 O
requires VBZ 1 0 1 O
more JJR 0 1 12 O
complex JJ 0 1 1 O
and CC 0 0 12 O
longer RBR 0 1 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
alternative JJ 0 1 1 O
substances NNS 1 1 1 O
. . 0 0 12 O

Currently RB 0 1 2 O
drug NN 0 1 1 O
susceptible JJ 0 1 1 O
TB NNP 0 0 13 O
is VBZ 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
four CD 0 1 12 O
drug NN 0 1 1 O
regimen NNS 0 1 6 O
given VBN 1 1 12 O
over RP 0 1 12 O
a DT 0 0 12 O
period NN 0 1 1 O
of IN 0 0 12 O
two CD 0 1 12 O
months NNS 1 1 12 O
followed VBN 1 1 12 O
by IN 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
for IN 0 0 12 O
four CD 0 1 12 O
months NNS 1 1 12 O
. . 0 0 12 O

New NNP 0 1 2 O
antituberculosis NN 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
are VBP 1 0 12 O
currently RB 0 1 12 O
being VBG 1 0 12 O
developed VBN 1 0 1 O
and CC 0 0 12 O
investigated VBN 1 1 1 O
and CC 0 0 12 O
are VBP 1 0 12 O
urgently RB 0 0 1 O
needed VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
drug NN 0 1 1 O
susceptible JJ 0 1 1 O
and CC 0 0 12 O
drug NN 0 1 1 O
resistant JJ 0 1 3 O
TB NNP 0 0 13 O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
review NN 0 1 2 O
we PRP 0 0 12 O
discuss VBP 0 1 12 O
the DT 0 0 12 O
neuroprotective JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
various JJ 0 1 1 O
compounds NNS 1 1 13 O
against IN 0 0 12 O
neuronal JJ 0 1 13 O
cell NN 0 1 1 O
loss NN 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
MPTP NNP 0 1 UNK B-Drug_n
model NN 0 1 UNK O
of IN 0 0 12 O
PD NNP 0 0 13 O
. . 0 0 12 O

This DT 0 0 2 O
review NN 0 1 2 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
a DT 0 0 12 O
much RB 0 0 12 O
better RBR 1 1 12 O
understanding NN 0 1 1 O
of IN 0 0 12 O
PD NNP 0 0 13 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
provide NN 0 1 1 O
novel NN 0 1 13 O
clues NNS 1 0 12 O
to TO 0 0 12 O
new JJ 0 1 12 O
targets NNS 1 1 UNK O
for IN 0 0 12 O
therapeutic JJ 0 1 6 O
interventions NNS 1 1 1 O
in IN 0 0 12 O
PD NNP 0 0 13 O
patients NNS 1 1 6 O
. . 0 0 12 O

Furthermore IN 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
well RB 0 1 12 O
known VBN 1 1 12 O
that IN 0 0 12 O
acute JJ 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
MPTP NNP 0 1 UNK B-Drug_n
can MD 0 0 12 O
cause VB 0 1 12 O
a DT 0 0 12 O
severe JJ 0 1 6 O
loss NN 0 1 1 O
of IN 0 0 12 O
tyrosine JJ 0 1 13 O
hydroxylase NN 0 1 UNK O
and CC 0 0 12 O
dopamine NN 0 1 14 O
transporter NN 0 1 UNK O
protein NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
dopamine NN 0 1 14 O
contents NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
striatum NN 0 1 13 O
of IN 0 0 12 O
mice NN 1 1 UNK O
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
continuous JJ 0 1 1 O
MPTP NNP 0 1 UNK B-Drug_n
treatment NN 0 1 6 O
. . 0 0 12 O

Our PRP$ 0 0 2 O
data NNS 0 1 1 O
reveal VBP 0 1 12 O
new JJ 0 1 12 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
synaptic JJ 0 0 UNK O
activity NN 0 1 1 O
and CC 0 0 12 O
circadian JJ 0 0 13 O
oscillators NNS 1 1 UNK O
and CC 0 0 12 O
delineate VB 0 0 UNK O
a DT 0 0 12 O
new JJ 0 1 12 O
means NNS 1 1 13 O
of IN 0 0 12 O
communication NN 0 1 1 O
between IN 0 0 12 O
nucleus NN 0 1 UNK O
and CC 0 0 12 O
synapse NN 0 1 UNK O
that WDT 0 0 12 O
may MD 0 0 1 O
provide VB 0 1 1 O
insight RB 0 1 UNK O
into IN 0 0 12 O
normal JJ 0 1 1 O
plasticity NN 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
etiology NN 0 1 6 O
of IN 0 0 12 O
intellectual JJ 0 0 13 O
disability NN 0 1 1 O
. . 0 0 12 O

We PRP 0 0 12 O
also RB 0 0 12 O
found VBD 1 1 12 O
that IN 0 0 12 O
synaptic JJ 0 0 UNK O
activity NN 0 1 1 O
induced VBD 1 1 6 O
Rev NNP 0 1 UNK O
- : 0 0 2 O
erb NN 0 0 UNK O
localization NN 0 1 1 O
to TO 0 0 12 O
dendrites NNS 1 1 UNK O
and CC 0 0 12 O
spines VBZ 1 1 13 O
a DT 0 0 12 O
process NN 0 1 1 O
that WDT 0 0 12 O
is VBZ 1 0 12 O
mediated VBN 1 1 13 O
by IN 0 0 12 O
AMPA NNP 0 1 UNK O
receptor NN 0 1 14 O
activation NN 0 1 13 O
and CC 0 0 12 O
requires VBZ 1 0 1 O
oligophrenin JJ 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
biochemical JJ 0 1 UNK O
and CC 0 0 12 O
cellular JJ 0 1 13 O
alterations NNS 1 1 1 O
that WDT 0 0 12 O
occur VBP 0 1 1 O
after IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
MPTP NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
treatment NN 0 1 6 O
are VBP 1 0 12 O
remarkably RB 0 0 UNK O
similar JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
idiopathic JJ 0 1 6 O
PD NNP 0 0 13 O
. . 0 0 12 O

PD NN 0 0 13 O
is VBZ 1 0 12 O
well RB 0 1 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
a DT 0 0 12 O
chronic JJ 0 1 6 O
and CC 0 0 12 O
progressive JJ 0 1 1 O
neurodegenerative JJ 0 0 UNK O
disease NN 0 1 6 O
produced VBN 1 0 1 O
by IN 0 0 12 O
a DT 0 0 12 O
selective JJ 0 1 13 O
degeneration NN 0 1 6 O
of IN 0 0 12 O
dopaminergic JJ 0 1 UNK O
neurons NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
substantia NN 0 0 UNK O
nigra JJ 0 0 13 O
pars NNS 1 1 13 O
compacta VBP 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
main JJ 0 1 12 O
clinical JJ 0 1 6 O
features NNS 1 1 1 O
of IN 0 0 12 O
PD NNP 0 0 13 O
include VBP 0 1 1 O
tremor NN 0 1 6 O
bradykinesia NN 0 1 UNK O
rigidity NN 0 1 3 O
and CC 0 0 12 O
postural JJ 0 1 13 O
instability NN 0 1 1 O
. . 0 0 12 O

Neuropharmacological JJ 0 1 UNK O
approach NN 0 1 1 O
against IN 0 0 12 O
MPTP NNP 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
induced VBN 1 1 6 O
mouse IN 0 1 UNK O
model NN 0 1 UNK O
of IN 0 0 12 O
Parkinson NNP 0 1 6 O
's POS 0 1 12 O
disease NN 0 1 6 O
. . 0 0 12 O

Parkinson NNP 0 1 6 O
's POS 0 1 12 O
disease NN 0 1 6 O
( ( 0 0 2 O
PD NNP 0 0 13 O
) ) 0 0 2 O
is VBZ 1 0 12 O
a DT 0 0 12 O
common JJ 0 1 1 O
neurodegenerative JJ 0 0 UNK O
disease NN 0 1 6 O
that WDT 0 0 12 O
appears VBZ 1 1 12 O
essentially RB 0 0 1 O
as IN 1 0 12 O
a DT 0 0 12 O
sporadic JJ 0 1 1 O
condition NN 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
complex NN 0 1 1 O
has VBZ 1 0 12 O
a DT 0 0 12 O
unique JJ 0 1 UNK O
ability NN 0 1 1 O
to TO 0 0 12 O
deliver VB 0 1 1 O
bio SYM 0 1 UNK O
- : 0 0 2 O
available JJ 0 1 1 O
calcium NN 0 1 14 B-Drug
and CC 0 0 12 O
phosphate NN 0 1 14 B-Drug
when WRB 0 0 12 O
they PRP 0 0 12 O
are VBP 1 0 12 O
needed VBN 1 1 12 O
most RBS 0 0 12 O
. . 0 0 12 O

Oseltamivir NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
effective JJ 0 1 1 O
for IN 0 0 12 O
post NN 0 1 12 O
- : 0 0 2 O
exposure NN 0 1 1 O
prophylaxis NN 0 1 6 O
of IN 0 0 12 O
H9N9 NNP 0 0 UNK O
in IN 0 0 12 O
close JJ 0 1 12 O
contact NN 0 1 12 O
. . 0 0 12 O

Kidney NNP 0 1 7 O
transplant NN 0 1 6 O
recipients NNS 1 1 UNK O
are VBP 1 0 12 O
at IN 0 0 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
risk NN 0 1 1 O
for IN 0 0 12 O
H9N9 NNP 0 0 UNK O
infection NN 0 1 6 O
associated VBN 1 1 1 O
complications NNS 1 1 6 O
during IN 0 0 12 O
the DT 0 0 12 O
current JJ 0 1 1 O
pandemic NN 0 1 UNK O
. . 0 0 12 O

Post NNP 0 1 2 O
- : 0 0 2 O
exposure NN 0 1 1 O
prophylaxis NN 0 1 6 O
for IN 0 0 12 O
H9N9 NNP 0 0 UNK O
with IN 0 0 12 O
oseltamivir NN 0 1 16 B-Drug
in IN 0 0 12 O
renal JJ 0 1 6 O
allograft NN 0 1 8 O
recipient NN 0 1 13 O
- : 0 0 2 O
- : 0 0 2 O
safe JJ 0 0 12 O
and CC 0 0 12 O
effective JJ 0 1 1 O
without IN 0 0 12 O
any DT 0 0 12 O
immunosuppresive JJ 0 0 UNK B-Group
drug NN 0 1 1 I-Group
interaction NN 0 1 UNK O
. . 0 0 12 O

Post NNP 0 1 2 O
- : 0 0 2 O
exposure NN 0 1 1 O
prophylaxis NN 0 1 6 O
of IN 0 0 12 O
H9N9 NNP 0 0 UNK O
with IN 0 0 12 O
oseltamivir NN 0 1 16 B-Drug
was VBD 1 0 12 O
safe JJ 0 0 12 O
effective JJ 0 1 1 O
and CC 0 0 12 O
well RB 0 1 12 O
tolerated VBN 1 0 1 O
to TO 0 0 12 O
prevent VB 0 1 1 O
H9N9 NNP 0 0 UNK O
influenza VB 0 1 6 O
A NNP 0 0 2 O
virus NN 0 1 6 O
infection NN 0 1 6 O
in IN 0 0 12 O
newly RB 0 1 12 O
transplanted VBN 1 1 13 O
renal JJ 0 1 6 O
allograft NN 0 1 8 O
recipient NN 0 1 13 O
receiving VBG 1 1 1 O
triple JJ 0 1 3 O
immunosuppression NN 0 1 14 O
without IN 0 0 12 O
any DT 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
tacrolimus JJ 0 1 16 B-Drug
level NN 0 1 1 O
. . 0 0 12 O

Prevention NN 0 1 UNK O
of IN 0 0 12 O
infection NN 0 1 6 O
by IN 0 0 12 O
immunization NN 0 1 6 O
together RB 0 1 12 O
with IN 0 0 12 O
early JJ 0 1 12 O
recognition NN 0 1 1 O
and CC 0 0 12 O
prompt JJ 0 1 UNK O
antiviral JJ 0 1 13 O
treatment NN 0 1 6 O
are VBP 1 0 12 O
critical JJ 0 1 1 O
. . 0 0 12 O

an DT 0 0 12 O
average JJ 0 1 1 O
particle NN 0 1 UNK O
size NN 0 1 3 O
of IN 0 0 12 O
this DT 0 0 12 O
nanoemulsion NN 0 1 UNK O
was VBD 1 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
nm NN 0 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
relevant JJ 0 1 1 O
differences NNS 1 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
group NN 0 1 12 O
with IN 0 0 12 O
open JJ 0 1 12 O
benchmark NN 0 1 UNK O
( ( 0 0 2 O
B NNP 0 0 2 O
- : 0 0 2 O
QC NN 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
traditional JJ 0 1 UNK O
quality NN 0 1 1 O
circles NNS 1 1 UNK O
( ( 0 0 2 O
T NNP 0 1 2 O
- : 0 0 2 O
QC NN 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Synergic NNP 0 0 UNK O
additive NN 0 1 16 O
or CC 0 0 12 O
antagonist JJ 0 1 13 O
effects NNS 1 1 1 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
antibacterial JJ 0 1 UNK O
activity NN 0 1 1 O
. . 0 0 12 O

Curcumin NNP 0 1 UNK B-Drug_n
increased VBD 1 1 1 O
both DT 0 0 12 O
the DT 0 0 12 O
swimming NN 0 1 12 O
and CC 0 0 12 O
climbing VBG 1 1 12 O
behavior NN 0 1 1 O
in IN 0 0 12 O
FST NNP 0 1 UNK O
thus RB 0 0 1 O
its PRP$ 1 0 12 O
antidepressant NN 0 1 6 O
like IN 0 0 12 O
activity NN 0 1 1 O
could MD 0 0 12 O
be VB 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
serotonin JJ 0 1 13 O
norepinephrine NN 0 1 14 O
and CC 0 0 12 O
dopamine NN 0 1 14 O
levels NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
brain NN 0 1 6 O
. . 0 0 12 O

[ JJ 0 0 2 O
Cyclooxygenase NNP 0 1 UNK B-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
antiplatelet JJ 0 0 13 O
effect NN 0 1 1 O
of IN 0 0 12 O
acetylsalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O
selective JJ 0 1 13 O
approach NN 0 1 1 O
to TO 0 0 12 O
nonsteroidal VB 0 0 14 B-Group
anti JJ 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
in IN 0 0 12 O
cardiological JJ 0 1 UNK O
practice NN 0 1 UNK O
] NN 0 0 2 O
. . 0 0 12 O

Nonsteroidal NNP 0 0 UNK B-Group
anti SYM 0 0 3 I-Group
- : 0 0 2 O
inflammatory NN 0 1 6 I-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
NSAIDs NNP 0 1 UNK B-Group
) ) 0 0 2 O
represent VBP 0 1 1 O
class NN 0 1 12 O
of IN 0 0 12 O
medicines NNS 1 1 6 O
which WDT 0 0 12 O
is VBZ 1 0 12 O
wide JJ 0 1 3 O
concerning VBG 1 1 1 O
chemical NN 0 1 13 O
structure NN 0 1 1 O
and CC 0 0 12 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
action NN 0 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
light NN 0 1 3 O
of IN 0 0 12 O
contradictory NN 0 0 UNK O
data NNS 0 1 1 O
on IN 0 0 12 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
safety NN 0 1 1 O
of IN 0 0 12 O
NSAID NNP 0 1 14 B-Group
in IN 0 0 12 O
cardiovascular JJ 0 1 6 O
patients NNS 1 1 6 O
selection NN 0 1 UNK O
of IN 0 0 12 O
most JJS 0 0 12 O
appropriate JJ 0 1 1 O
NSAID NNP 0 1 14 B-Group
( ( 0 0 2 O
basing VBG 1 1 UNK O
on IN 0 0 12 O
profile NN 0 1 1 O
of IN 0 0 12 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
safety NN 0 1 1 O
) ) 0 0 2 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
continuous JJ 0 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
low JJ 0 1 1 O
dose NN 0 1 6 O
aspirin NN 0 1 14 B-Brand
appears VBZ 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
a DT 0 0 12 O
problem NN 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
paper NN 0 1 13 O
we PRP 0 0 12 O
discuss VBP 0 1 12 O
peculiarities NNS 1 0 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
cyclooxygenase NN 0 1 UNK B-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
acetylsalicylic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
principles NNS 1 0 UNK O
of IN 0 0 12 O
selection NN 0 1 UNK O
of IN 0 0 12 O
adequate JJ 0 1 1 O
NSAI NNP 0 0 UNK B-Group
. . 0 0 12 O

Polypharmacy NN 0 1 UNK O
in IN 0 0 12 O
older JJR 1 1 12 O
adults NNS 1 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
colchicine NN 0 1 0 B-Drug
nanoemulsion NN 0 1 UNK O
was VBD 1 0 12 O
prepared VBN 1 1 12 O
with IN 0 0 12 O
isopropyl JJ 0 1 13 B-Drug_n
myristate NN 0 1 UNK I-Drug_n
eugenol NN 0 1 UNK B-Drug
Tween9 NNP 0 0 UNK B-Drug_n
ethanol NN 0 1 1 B-Drug
and CC 0 0 12 O
water NN 0 1 3 O
and CC 0 0 12 O
eugenol NN 0 1 UNK B-Drug
was VBD 1 0 12 O
used VBN 1 1 12 O
as IN 1 0 12 O
an DT 0 0 12 O
oil NN 0 1 3 O
phase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
formulation NN 0 1 13 O
; : 0 0 2 O

Finally RB 0 0 2 O
co SYM 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
eugenol NN 0 1 UNK B-Drug
in IN 0 0 12 O
colchicine JJ 0 1 0 B-Drug
nanoemulsion NN 0 1 UNK O
to TO 0 0 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
colchicine NN 0 1 0 B-Drug
bioavailability NN 0 1 UNK O
was VBD 1 0 12 O
investigated VBN 1 1 1 O
by IN 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
method NN 0 1 13 O
. . 0 0 12 O

[ JJ 0 0 2 O
Tuberculosis NNP 0 1 7 O
and CC 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
features NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
infection NN 0 1 6 O
] NN 0 0 2 O
. . 0 0 12 O

General NNP 0 1 2 O
practitioners NNS 1 1 UNK O
seem VBP 0 0 12 O
to TO 0 0 12 O
take VB 0 1 12 O
a DT 0 0 12 O
critical JJ 0 1 1 O
perspective NN 0 0 1 O
about IN 0 1 12 O
open JJ 0 1 12 O
benchmarking NN 0 1 UNK O
in IN 0 0 12 O
quality NN 0 1 1 O
circles NNS 1 1 UNK O
. . 0 0 12 O

We PRP 0 0 12 O
will MD 0 0 12 O
discuss VB 0 1 12 O
some DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
underlying JJ 0 0 1 O
reasons NNS 1 1 12 O
in IN 0 0 12 O
part NN 0 1 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
drawbacks NNS 1 0 UNK O
associated VBN 1 1 1 O
with IN 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
antagonists NNS 1 1 13 I-Group
. . 0 0 12 O

The DT 0 0 2 O
synergic NN 0 0 UNK O
and CC 0 0 12 O
decreasing VBG 1 1 1 O
toxic JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
mineral JJ 0 1 3 O
water NN 0 1 3 O
and CC 0 0 12 O
Chinese JJ 0 1 UNK O
herbal JJ 0 1 6 O
compound NN 0 1 13 O
preparation NN 0 1 1 O
( ( 0 0 2 O
MWCHCP NNP 0 0 UNK O
) ) 0 0 2 O
on IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
were VBD 1 0 12 O
investigated VBN 1 1 1 O
in IN 0 0 12 O
sarcoma NN 0 1 6 O
9 CD 0 0 2 O
( ( 0 0 2 O
S9 NNP 0 1 UNK O
) ) 0 0 2 O
mice NN 1 1 UNK O
. . 0 0 12 O

[ NN 0 0 2 O
Study NNP 0 1 2 O
on IN 0 0 12 O
synergic NNS 0 0 UNK O
and CC 0 0 12 O
decreasing VBG 1 1 1 O
toxic JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
mineral JJ 0 1 3 O
water NN 0 1 3 O
and CC 0 0 12 O
Chinese JJ 0 1 UNK O
herbal JJ 0 1 6 O
compound NN 0 1 13 O
preparation NN 0 1 1 O
on IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
] NN 0 0 2 O
. . 0 0 12 O

Then RB 0 1 12 O
the DT 0 0 12 O
mice NN 1 1 UNK O
were VBD 1 0 12 O
killed VBN 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
tumor NN 0 1 6 O
growth NN 0 1 1 O
inhibition NN 0 1 13 O
rate NN 0 1 1 O
organ JJ 0 1 6 O
index NN 0 1 1 O
diarrhea NN 0 1 6 O
index NN 0 1 1 O
were VBD 1 0 12 O
determined VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
S9 NNP 0 1 UNK O
mice NN 1 1 UNK O
were VBD 1 0 12 O
treated VBN 1 1 1 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
with IN 0 0 12 O
intraperitoneal JJ 0 1 14 O
injection NN 0 1 3 O
of IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
x NN 0 0 10 O
kg NN 0 1 18 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
MWCHCP NNP 0 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
x NN 0 0 10 O
kg NN 0 1 18 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Reverse NNP 0 1 UNK O
transcription NN 0 1 UNK O
- : 0 0 2 O
polymerase NN 0 1 UNK O
chain NN 0 1 16 O
reaction NN 0 1 1 O
( ( 0 0 2 O
RT NNP 0 1 UNK O
- : 0 0 2 O
PCR NN 0 1 14 O
) ) 0 0 2 O
was VBD 1 0 12 O
applied VBN 1 1 1 O
to TO 0 0 12 O
investigate VB 0 1 1 O
the DT 0 0 12 O
tumour JJ 0 1 UNK O
necrosis NN 0 1 6 O
factor NN 0 1 1 O
- : 0 0 2 O
alpha NN 0 1 1 O
( ( 0 0 2 O
TNF NNP 0 1 UNK O
- : 0 0 2 O
alpha NN 0 1 1 O
) ) 0 0 2 O
expression NN 0 1 1 O
level NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
intestine NN 0 1 6 O
. . 0 0 12 O

Observe NNP 0 1 UNK O
pathological JJ 0 1 13 O
sections NNS 1 1 1 O
of IN 0 0 12 O
stomach NN 0 1 6 O
to TO 0 0 12 O
study VB 0 1 1 O
the DT 0 0 12 O
protective JJ 0 0 3 O
effect NN 0 1 1 O
of IN 0 0 12 O
MWCHCP NNP 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
present JJ 0 1 1 O
findings NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
MWCHCP NNP 0 0 UNK O
increases VBZ 1 1 1 O
the DT 0 0 12 O
inhibition NN 0 1 13 O
rate NN 0 1 1 O
of IN 0 0 12 O
tumor NN 0 1 6 O
growth NN 0 1 1 O
of IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
and CC 0 0 12 O
has VBZ 1 0 12 O
a DT 0 0 12 O
beneficial JJ 0 0 UNK O
influence NN 0 0 UNK O
on IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
lesion NN 0 1 6 O
induced VBN 1 1 6 O
by IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
. . 0 0 12 O

Combining VBG 0 1 UNK O
with IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
and CC 0 0 12 O
MWCHCP NNP 0 0 UNK O
caused VBD 1 1 1 O
a DT 0 0 12 O
tendency NN 0 0 1 O
of IN 0 0 12 O
increasing VBG 1 1 1 O
the DT 0 0 12 O
tumor NN 0 1 6 O
growth NN 0 1 1 O
inhibition NN 0 1 13 O
rate NN 0 1 1 O
and CC 0 0 12 O
significant JJ 0 1 1 O
attenution NN 0 0 UNK O
of IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
diarrhea JJ 0 1 6 O
visceral JJ 0 1 13 O
organ JJ 0 1 6 O
injury NN 0 1 6 O
gastric NN 0 1 6 O
mucosal NN 0 1 8 O
injury NN 0 1 6 O
and CC 0 0 12 O
decreased VBD 1 1 1 O
TNF NNP 0 1 UNK O
- : 0 0 2 O
alpha NN 0 1 1 O
mRNA JJ 0 1 UNK O
level NN 0 1 1 O
of IN 0 0 12 O
intestine NN 0 1 6 O
. . 0 0 12 O

By IN 0 0 2 O
combining VBG 1 1 UNK O
several JJ 0 1 12 O
assays NNS 1 1 13 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
possible JJ 0 1 1 O
to TO 0 0 12 O
generate VB 0 0 UNK O
a DT 0 0 12 O
broad JJ 0 1 1 O
picture NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
immune JJ 0 1 6 O
status NN 0 1 1 O
of IN 0 0 12 O
every DT 0 0 12 O
single JJ 0 1 12 O
transplanted VBN 1 1 13 O
recipient NN 0 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
permeation NN 0 1 UNK O
of IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
nanoemulsion NN 0 1 UNK O
across IN 0 0 12 O
the DT 0 0 12 O
intestinal JJ 0 1 13 O
membrane NN 0 1 3 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
different JJ 0 1 1 O
from IN 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
control NN 0 1 1 O
group NN 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
mM RB 0 0 UNK O
colchicine NN 0 1 0 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

Caution NN 0 0 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
when WRB 0 0 12 O
implementing VBG 1 0 UNK O
benchmarking NN 0 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
quality NN 0 1 1 O
circle NN 0 1 13 O
as IN 1 0 12 O
it PRP 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
improve VB 0 0 1 O
healthcare NN 0 1 UNK O
when WRB 0 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
traditional JJ 0 1 UNK O
procedure NN 0 1 1 O
with IN 0 0 12 O
anonymised JJ 0 0 UNK O
comparisons NNS 1 1 1 O
. . 0 0 12 O

Druce NNP 0 0 UNK O
subsp NN 0 0 UNK O
. . 0 0 12 O

brachycalyx NN 0 0 UNK O
P.H NNP 0 1 UNK O
. . 0 0 12 O

Diagnosis NN 0 1 7 O
and CC 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
tuberculosis NN 0 1 6 O
is VBZ 1 0 12 O
more RBR 0 1 12 O
complex JJ 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
HIV NNP 0 1 6 O
/ NNP 0 0 2 O
AIDS NNP 0 1 6 O
. . 0 0 12 O

Brachycalyx NNP 0 0 UNK O
P.H NNP 0 1 UNK O
. . 0 0 12 O

Davis NNP 0 0 19 O
( ( 0 0 2 O
White NNP 0 1 2 O
micromeria NN 0 1 UNK O
) ) 0 0 2 O
Cumium NN 0 0 UNK O
cyminum NN 0 0 UNK O
( ( 0 0 2 O
cumin NN 0 1 UNK O
) ) 0 0 2 O
Mentha NNP 0 1 UNK O
piperita NN 0 0 UNK O
( ( 0 0 2 O
Peppermint NNP 0 1 UNK O
) ) 0 0 2 O
against IN 0 0 12 O
different JJ 0 1 1 O
bacteria NNS 0 1 6 O
and CC 0 0 12 O
fungi JJ 0 1 13 O
species NNS 1 1 1 O
and CC 0 0 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
to TO 0 0 12 O
discuss VB 0 1 12 O
the DT 0 0 12 O
in IN 0 0 12 O
- : 0 0 2 O
vitro NN 0 1 UNK O
possible JJ 0 1 1 O
effects NNS 1 1 1 O
between IN 0 0 12 O
the DT 0 0 12 O
plants NNS 1 1 13 O
and CC 0 0 12 O
antibiotics NNS 1 1 6 B-Group
. . 0 0 12 O

The DT 0 0 2 O
microorganisms NNS 1 1 13 O
used VBN 1 1 12 O
were VBD 1 0 12 O
Micrococcus NNP 0 1 UNK O
luteus JJ 0 0 UNK O
LA NNP 0 1 2 O
9 CD 0 0 2 O
Bacillus NNP 0 1 UNK O
megaterium NN 0 0 UNK O
NRS NNP 0 1 UNK O
Bacillus NNP 0 1 UNK O
brevis VBD 0 0 8 O
FMC NNP 0 0 UNK O
9 CD 0 0 2 O
Enterococcus NNP 0 1 14 O
faecalis NNS 0 0 16 O
ATCC NNP 0 1 UNK O
99 CD 0 0 10 O
Pseudomonas NNP 0 1 14 O
pyocyaneus NN 0 0 UNK O
DC NNP 0 0 2 O
9 CD 0 0 2 O
Mycobacterium NNP 0 1 UNK O
smegmatis NN 0 0 UNK O
CCM NNP 0 1 UNK O
9 CD 0 0 2 O
Escherichia NNP 0 1 14 O
coil NN 0 1 3 O
DM NNP 0 1 13 O
Aeromonas NNP 0 1 UNK O
hydrophila VBD 0 0 16 O
ATCC NNP 0 1 UNK O
9 CD 0 0 2 O
Yersinia NNP 0 1 UNK O
enterocolitica NN 0 0 13 O
AU NNP 0 1 2 O
9 CD 0 0 2 O
Staphylococcus NNP 0 1 14 O
aureus VBD 0 0 14 O
Cowan NNP 0 0 UNK O
9 CD 0 0 2 O
Streptococcus NNP 0 1 14 O
faecalis NNS 0 0 16 O
DC NNP 0 0 2 O
9 CD 0 0 2 O
bacteria NNS 0 1 6 O
and CC 0 0 12 O
Saccharomyces NNP 0 1 UNK O
cerevisiae VBP 0 0 13 O
WET NNP 0 1 UNK O
9 CD 0 0 2 O
Kluvyeromyces NNP 0 0 UNK O
fragilis NN 0 0 14 O
DC NNP 0 0 2 O
9 CD 0 0 2 O
fungi NN 0 1 13 O
in IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
indicated VBD 1 1 1 O
that IN 0 0 12 O
essential JJ 0 1 13 O
oils NNS 1 1 13 O
of IN 0 0 12 O
Rosmarinus NNP 0 1 UNK O
officinalis FW 0 0 UNK O
Coriandrum NNP 0 1 UNK O
sativum FW 0 0 UNK O
L. NNP 0 1 19 O
Micromeria NNP 0 1 UNK O
fruticosa NN 0 0 UNK O
( ( 0 0 2 O
L NNP 0 1 2 O
. . 0 0 12 O
) ) 0 0 2 O

In IN 0 0 2 O
- : 0 0 2 O
vitro JJ 0 1 UNK O
antimicrobial JJ 0 1 14 O
activity NN 0 1 1 O
and CC 0 0 12 O
synergistic JJ 0 1 UNK O
/ NNP 0 0 2 O
antagonistic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
antibiotics NNS 1 1 6 B-Group
and CC 0 0 12 O
some DT 0 0 12 O
spice JJ 0 1 UNK O
essential JJ 0 1 13 O
oils NNS 1 1 13 O
. . 0 0 12 O

Spices NNS 0 1 UNK O
and CC 0 0 12 O
herbs NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
for IN 0 0 12 O
many JJ 0 0 12 O
years NNS 1 1 12 O
by IN 0 0 12 O
different JJ 0 1 1 O
cultures NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
aim NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
present JJ 0 1 1 O
study NN 0 1 1 O
is VBZ 1 0 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
to TO 0 0 12 O
investigate VB 0 1 1 O
in IN 0 0 12 O
- : 0 0 2 O
vitro JJ 0 1 UNK O
antimicrobial JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
different JJ 0 1 1 O
spices NNS 1 1 UNK O
and CC 0 0 12 O
herbs NNS 1 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
species NNS 1 1 1 O
: : 0 0 2 O
Rosmarinus NNP 0 1 UNK O
officinalis MD 0 0 UNK O
( ( 0 0 2 O
Rosemary NNP 0 1 19 O
) ) 0 0 2 O
Coriandrum NNP 0 1 UNK O
sativum NN 0 0 UNK O
( ( 0 0 2 O
coriander NN 0 1 UNK O
) ) 0 0 2 O
Micromeria NNP 0 1 UNK O
fruticosa NN 0 0 UNK O
( ( 0 0 2 O
L NNP 0 1 2 O
. . 0 0 12 O
) ) 0 0 2 O

Pharmacological JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
cannabinoids NNS 0 1 UNK B-Drug_n
or CC 0 0 12 O
medication NN 0 1 6 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
THC NNP 0 1 UNK B-Drug_n
have VBP 0 0 12 O
not RB 0 1 12 O
yet RB 0 0 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
detail NN 0 1 1 O
. . 0 0 12 O

thus RB 0 0 1 O
in IN 0 0 12 O
previously RB 0 0 1 O
opiate JJ 0 1 6 B-Group
- : 0 0 2 O
naive JJ 0 0 UNK O
rats NNS 1 1 UNK O
blockade NN 0 1 1 O
of IN 0 0 12 O
intra JJ 0 1 6 O
- : 0 0 2 O
BLA NNP 0 1 UNK O
D9 NNP 0 1 UNK O
but CC 0 0 12 O
not RB 0 1 12 O
D9 NNP 0 1 UNK O
receptor NN 0 1 14 O
transmission NN 0 1 1 O
blocked VBD 1 1 13 O
the DT 0 0 12 O
acquisition NN 0 1 UNK O
of IN 0 0 12 O
associative JJ 0 1 UNK O
opiate JJ 0 1 6 O
reward NN 0 1 UNK O
memory NN 0 1 1 O
measured VBN 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
unbiased JJ 0 0 UNK O
conditioned JJ 0 1 UNK O
place NN 0 1 12 O
preference NN 0 1 1 O
procedure NN 0 1 1 O
. . 0 0 12 O

glycolysis NN 0 1 UNK O
inhibition NN 0 1 13 O
by IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
agents NNS 1 1 1 O
was VBD 1 0 12 O
additive JJ 0 1 16 O
. . 0 0 12 O

Zinc NNP 0 1 2 B-Drug
inhibited VBD 1 1 13 O
glycolysis NN 0 1 UNK O
and CC 0 0 12 O
protease NN 0 1 13 O
to TO 0 0 12 O
a DT 0 0 12 O
greater JJR 1 1 1 O
degree NN 0 1 1 O
than IN 0 0 12 O
o SYM 0 1 2 B-Drug_n
- : 0 0 2 O
cymen NNS 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
ol NN 0 0 UNK I-Drug_n
; : 0 0 2 O

o SYM 0 1 2 B-Drug_n
- : 0 0 2 O
Cymen NNP 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
ol NN 0 0 UNK I-Drug_n
MIC NNP 0 1 13 O
was VBD 1 0 12 O
between IN 0 0 12 O
9 CD 0 0 2 O
mM NNS 0 0 UNK O
to TO 0 0 12 O
9 CD 0 0 2 O
mM NNS 0 0 UNK O
; : 0 0 2 O

coli NNS 0 0 14 O
. . 0 0 12 O

Zinc NNP 0 1 2 B-Drug
gluconate NN 0 1 14 I-Drug
MIC NNP 0 1 13 O
was VBD 1 0 12 O
9 CD 0 0 2 O
mM NN 0 0 UNK O
to TO 0 0 12 O
9 CD 0 0 2 O
mM NNS 0 0 UNK O
; : 0 0 2 O

MBC NNP 0 1 UNK O
was VBD 1 0 12 O
9 CD 0 0 2 O
mM NN 0 0 UNK O
to TO 0 0 12 O
9 CD 0 0 2 O
mM NNS 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
two CD 0 1 12 O
agents NNS 1 1 1 O
in IN 0 0 12 O
solution NN 0 1 1 O
showed VBD 1 1 12 O
synergy NN 0 0 1 O
( ( 0 0 2 O
FICI NNP 0 0 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
against IN 0 0 12 O
P NNP 0 1 2 O
. . 0 0 12 O

MBC NNP 0 1 UNK O
was VBD 1 0 12 O
between IN 0 0 12 O
9 CD 0 0 2 O
mM NNS 0 0 UNK O
and CC 0 0 12 O
> $ 0 0 2 O
9 CD 0 0 2 O
mM NN 0 0 UNK O
. . 0 0 12 O

nucleatum NN 0 0 16 O
with IN 0 0 12 O
MIC NNP 0 1 13 O
of IN 0 0 12 O
9 CD 0 0 2 O
mM NNS 0 0 UNK O
/ VBD 0 0 2 O
9 CD 0 0 2 O
mM NN 0 0 UNK O
for IN 0 0 12 O
o JJ 0 1 2 B-Drug_n
- : 0 0 2 O
cymen NNS 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
ol NN 0 0 UNK I-Drug_n
/ NNP 0 0 2 O
zinc NN 0 1 14 B-Drug
gluconate NN 0 1 14 I-Drug
respectively RB 0 0 1 O
. . 0 0 12 O

gingivalis NN 0 0 UNK O
and CC 0 0 12 O
F NNP 0 1 2 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
randomized NN 0 1 6 O
controlled VBD 1 1 1 O
clinical JJ 0 1 6 O
trial NN 0 1 12 O
the DT 0 0 12 O
abstinence NN 0 1 UNK O
rate NN 0 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
year NN 0 1 12 O
for IN 0 0 12 O
patients NNS 1 1 6 O
using VBG 1 1 1 O
varencline NN 0 0 UNK B-Drug
was VBD 1 0 12 O
superior JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
patients NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
group NN 0 1 12 O
using VBG 1 1 1 O
bupropion NN 0 1 16 B-Drug
SR NNP 0 1 2 I-Drug
( ( 0 0 2 O
Zyban NNP 0 1 UNK B-Brand
) ) 0 0 2 O
and CC 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
placebo NN 0 1 13 O
group NN 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Moreover RB 0 0 1 O
these DT 0 0 12 O
targets NNS 1 1 UNK O
that WDT 0 0 12 O
cause VBP 0 1 12 O
similar JJ 0 1 1 O
side NN 0 1 3 O
effects NNS 1 1 1 O
are VBP 1 0 12 O
more RBR 0 1 12 O
often RB 0 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
linear JJ 0 1 1 O
part NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
network NN 0 1 UNK O
having VBG 1 0 12 O
two CD 0 1 12 O
or CC 0 0 12 O
less JJR 0 1 12 O
interactions NNS 1 1 UNK O
than IN 0 0 12 O
drug NN 0 1 1 O
targets NNS 1 1 UNK O
in IN 0 0 12 O
general JJ 0 1 1 O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
the DT 0 0 12 O
examples NNS 1 1 UNK O
we PRP 0 0 12 O
gained VBD 1 1 12 O
novel JJ 0 1 13 O
insight NN 0 1 UNK O
into IN 0 0 12 O
the DT 0 0 12 O
molecular JJ 0 1 1 O
mechanisms NN 1 1 UNK O
of IN 0 0 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
several JJ 0 1 12 O
drug NN 0 1 1 O
targets NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
study NN 0 1 1 O
we PRP 0 0 12 O
investigated VBD 1 1 1 O
the DT 0 0 12 O
proportion NN 0 1 UNK O
of IN 0 0 12 O
side NN 0 1 3 O
- : 0 0 2 O
effect NN 0 1 1 O
similarities NNS 1 1 UNK O
that WDT 0 0 12 O
is VBZ 1 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
targets NNS 1 1 UNK O
that WDT 0 0 12 O
are VBP 1 0 12 O
close RB 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
network NN 0 1 UNK O
compared VBN 1 1 1 O
to TO 0 0 12 O
shared VBN 1 1 12 O
drug NN 0 1 1 O
targets NNS 1 1 UNK O
. . 0 0 12 O

We PRP 0 0 12 O
found VBD 1 1 12 O
that IN 0 0 12 O
only RB 0 1 12 O
a DT 0 0 12 O
minor JJ 0 1 1 O
fraction NN 0 1 1 O
of IN 0 0 12 O
side NN 0 1 3 O
- : 0 0 2 O
effect NN 0 1 1 O
similarities NNS 1 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
are VBP 1 0 12 O
caused VBN 1 1 1 O
by IN 0 0 12 O
drugs NNS 1 1 6 O
targeting VBG 1 1 UNK O
proteins NNS 1 1 14 O
close RB 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
network NN 0 1 UNK O
compared VBN 1 1 1 O
to TO 0 0 12 O
side VB 0 1 3 O
- : 0 0 2 O
effect NN 0 1 1 O
similarities NNS 1 1 UNK O
caused VBN 1 1 1 O
by IN 0 0 12 O
overlapping VBG 1 1 1 O
drug NN 0 1 1 O
targets NNS 1 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

These DT 0 0 1 O
adverse JJ 0 0 1 O
side NN 0 1 3 O
effects NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
infer VB 0 1 13 O
whether IN 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
share NN 0 1 UNK O
a DT 0 0 12 O
target NN 0 1 1 O
protein NN 0 1 14 O
. . 0 0 12 O

However RB 0 0 1 O
side JJ 0 1 3 O
- : 0 0 2 O
effect NN 0 1 1 O
similarity NN 0 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
could MD 0 0 12 O
also RB 0 0 12 O
be VB 0 0 12 O
caused VBN 1 1 1 O
by IN 0 0 12 O
their PRP$ 0 0 12 O
target NN 0 1 1 O
proteins VBZ 0 1 14 O
being VBG 1 0 12 O
close JJ 0 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
molecular JJ 0 1 1 O
network NN 0 1 UNK O
which WDT 0 0 12 O
as IN 1 0 12 O
such JJ 0 0 1 O
could MD 0 0 12 O
cause VB 0 1 12 O
similar JJ 0 1 1 O
downstream NN 0 1 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

Network NNP 0 1 2 O
neighbors NNS 1 1 12 O
of IN 0 0 12 O
drug NN 0 1 1 O
targets NNS 1 1 UNK O
contribute VBP 0 1 UNK O
to TO 0 0 12 O
drug NN 0 1 1 O
side NN 0 1 3 O
- : 0 0 2 O
effect NN 0 1 1 O
similarity NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
pharmacology NN 0 1 UNK O
it PRP 0 0 12 O
is VBZ 1 0 12 O
essential JJ 0 1 13 O
to TO 0 0 12 O
identify VB 0 0 1 O
the DT 0 0 12 O
molecular JJ 0 1 1 O
mechanisms NNS 1 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
action NN 0 1 13 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
understand VB 0 1 12 O
adverse JJ 0 0 1 O
side NN 0 1 3 O
effects NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
case NN 0 1 12 O
study NN 0 1 1 O
explores VBZ 1 0 UNK O
the DT 0 0 12 O
influence NN 0 0 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
cultural JJ 0 1 13 O
social JJ 0 1 1 O
and CC 0 0 12 O
political JJ 0 0 UNK O
factors NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
production NN 0 1 1 O
of IN 0 0 12 O
scientific JJ 0 1 UNK O
knowledge NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
assessment NN 0 1 1 O
of IN 0 0 12 O
benefit NN 0 1 1 O
/ NN 0 0 2 O
risk NN 0 1 1 O
posed VBN 1 0 UNK O
by IN 0 0 12 O
comestibles NNS 1 0 UNK O
. . 0 0 12 O

Though IN 0 0 12 O
the DT 0 0 12 O
science NN 0 1 UNK O
of IN 0 0 12 O
hepatotoxicity NN 0 1 13 O
is VBZ 1 0 12 O
uncertain JJ 0 1 1 O
enough RB 0 0 12 O
to TO 0 0 12 O
allow VB 0 1 1 O
for IN 0 0 12 O
multiple JJ 0 1 1 O
interpretations NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
data VBZ 0 1 1 O
the DT 0 0 12 O
biomedical JJ 0 1 UNK O
/ NNP 0 0 2 O
clinical JJ 0 1 6 O
narrative NN 0 1 UNK O
about IN 0 1 12 O
kava NN 0 1 UNK O
remains VBZ 1 0 12 O
dominant JJ 0 1 1 O
. . 0 0 12 O

Cultural JJ 0 1 UNK O
constructions NNS 1 1 UNK O
and CC 0 0 12 O
social JJ 0 1 1 O
negotiations NNS 1 1 UNK O
of IN 0 0 12 O
risk NN 0 1 1 O
are VBP 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
context JJ 0 1 1 O
- : 0 0 2 O
specific NN 0 1 1 O
and CC 0 0 12 O
are VBP 1 0 12 O
shaped VBN 1 1 3 O
by IN 0 0 12 O
professional JJ 0 1 1 O
disciplinary NN 0 0 UNK O
and CC 0 0 12 O
organizational JJ 0 1 UNK O
factors NNS 1 1 1 O
among IN 0 0 12 O
others NNS 0 1 12 O
. . 0 0 12 O

This DT 0 0 2 O
paper NN 0 1 13 O
focuses VBZ 1 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
responses NNS 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
bans NNS 1 1 UNK O
by IN 0 0 12 O
scientists NNS 1 1 UNK O
involved VBN 1 1 12 O
in IN 0 0 12 O
kava JJ 0 1 UNK O
research NN 0 1 13 O
contrasting VBG 1 1 UNK O
their PRP$ 0 0 12 O
evidential JJ 0 1 UNK O
culture NN 0 1 1 O
with IN 0 0 12 O
that DT 0 0 12 O
employed VBN 1 1 1 O
by IN 0 0 12 O
clinicians NNS 1 1 UNK O
and CC 0 0 12 O
regulatory JJ 0 1 UNK O
officials NNS 1 1 UNK O
. . 0 0 12 O

Kava NNP 0 1 UNK O
became VBD 1 0 12 O
popular JJ 0 1 UNK O
as IN 1 0 12 O
an DT 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
anxiety NN 0 1 6 O
treatment NN 0 1 6 O
in IN 0 0 12 O
Western JJ 0 1 2 O
countries NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
late JJ 0 1 12 O
9s CD 1 1 UNK O
but CC 0 0 12 O
it PRP 0 0 12 O
was VBD 1 0 12 O
subsequently RB 0 0 1 O
banned VBN 1 1 UNK O
in IN 0 0 12 O
many JJ 0 0 12 O
places NNS 1 1 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
adverse JJ 0 0 1 O
reports NNS 1 1 1 O
of IN 0 0 12 O
liver JJ 0 1 6 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Looking VBG 0 1 UNK O
forward RB 0 1 12 O
such JJ 0 0 1 O
analyses NNS 1 1 UNK O
will MD 0 0 12 O
be VB 0 0 12 O
extremely RB 0 1 12 O
useful JJ 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
process NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
development NN 0 1 1 O
to TO 0 0 12 O
better JJR 1 1 12 O
understand JJ 0 1 12 O
adverse JJ 0 0 1 O
side NN 0 1 3 O
effects NNS 1 1 1 O
. . 0 0 12 O

Tradition NN 0 1 UNK O
and CC 0 0 12 O
toxicity NN 0 1 6 O
: : 0 0 2 O
evidential JJ 0 1 UNK O
cultures NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
kava NN 0 1 UNK O
safety NN 0 1 1 O
debate NN 0 1 12 O
. . 0 0 12 O

Evaluation NN 0 1 2 O
of IN 0 0 12 O
antidepressant JJ 0 1 6 O
like IN 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
curcumin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
its PRP$ 1 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
and CC 0 0 12 O
imipramine NN 0 1 0 B-Drug
: : 0 0 2 O
an DT 0 0 12 O
acute NN 0 1 6 O
and CC 0 0 12 O
chronic JJ 0 1 6 O
study NN 0 1 1 O
. . 0 0 12 O

Curcumin NNP 0 1 UNK B-Drug_n
is VBZ 1 0 12 O
the DT 0 0 12 O
active JJ 0 1 1 O
ingredient NN 0 1 UNK O
of IN 0 0 12 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
spice NN 0 1 UNK O
Curuma NNP 0 0 UNK O
longa NN 0 0 UNK O
Linn NNP 0 0 UNK O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
present JJ 0 1 1 O
study NN 0 1 1 O
the DT 0 0 12 O
antidepressant NN 0 1 6 O
like IN 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
curcumin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
its PRP$ 1 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
and CC 0 0 12 O
imipramine NN 0 1 0 B-Drug
was VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
acute JJ 0 1 6 O
model NN 0 1 UNK O
( ( 0 0 2 O
three CD 0 1 12 O
doses VBZ 1 1 6 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
before IN 0 1 12 O
test NN 0 1 1 O
) ) 0 0 2 O
of IN 0 0 12 O
forced VBN 1 1 13 O
swimming VBG 1 1 12 O
test NN 0 1 1 O
( ( 0 0 2 O
FST NNP 0 1 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
glass NN 0 1 3 O
jar NN 0 1 UNK O
and CC 0 0 12 O
tail NN 0 1 3 O
suspension NN 0 1 3 O
test NN 0 1 1 O
( ( 0 0 2 O
TST NNP 0 1 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
mice NN 1 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
chronic JJ 0 1 6 O
model NN 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
day NN 0 1 12 O
study NN 0 1 1 O
) ) 0 0 2 O
of IN 0 0 12 O
FST NNP 0 1 UNK O
with IN 0 0 12 O
water NN 0 1 3 O
wheel NN 0 1 UNK O
in IN 0 0 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

All PDT 0 0 2 O
the DT 0 0 12 O
tests NNS 1 1 1 O
were VBD 1 0 12 O
carried VBN 1 1 12 O
out RP 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
seven CD 0 1 12 O
groups NNS 1 1 1 O
( ( 0 0 2 O
n JJ 0 1 12 O
= NN 0 0 2 O
9 CD 0 0 2 O
in IN 0 0 12 O
each DT 0 0 12 O
group NN 0 1 12 O
) ) 0 0 2 O
drugs NNS 1 1 6 O
being VBG 1 0 12 O
given VBN 1 1 12 O
orally RB 0 1 14 O
( ( 0 0 2 O
doses NNS 1 1 6 O
for IN 0 0 12 O
mice NN 1 1 UNK O
) ) 0 0 2 O
: : 0 0 2 O
Group NNP 0 1 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
vehicle NN 0 1 1 O
) ) 0 0 2 O
group NN 0 1 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
curcumin NN 0 1 UNK B-Drug_n
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
group NN 0 1 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
curcumin NN 0 1 UNK B-Drug_n
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
group NN 0 1 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
fluoxetine JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
group NN 0 1 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
imipramine JJ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
group NN 0 1 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
curcumin NN 0 1 UNK B-Drug_n
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
plus CC 0 1 16 O
fluoxetine JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
and CC 0 0 12 O
group NN 0 1 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
curcumin NN 0 1 UNK B-Drug_n
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
plus CC 0 1 16 O
imipramine JJ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
. . 0 0 12 O

Equivalent JJ 0 1 UNK O
doses NNS 1 1 6 O
for IN 0 0 12 O
rats NNS 1 1 UNK O
were VBD 1 0 12 O
used VBN 1 1 12 O
. . 0 0 12 O

Both DT 0 0 2 O
the DT 0 0 12 O
acute JJ 0 1 6 O
model NN 0 1 UNK O
of IN 0 0 12 O
FST NNP 0 1 UNK O
and CC 0 0 12 O
TST NNP 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
chronic JJ 0 1 6 O
model NN 0 1 UNK O
of IN 0 0 12 O
FST NNP 0 1 UNK O
with IN 0 0 12 O
water NN 0 1 3 O
wheel NN 0 1 UNK O
showed VBD 1 1 12 O
significant JJ 0 1 1 O
antidepressant JJ 0 1 6 O
like IN 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
curcumin NN 0 1 UNK B-Drug_n
in IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg VBP 0 1 18 O
dose RB 0 1 6 O
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
vehicle NN 0 1 1 O
control NN 0 1 1 O
( ( 0 0 2 O
p JJ 0 1 2 O
< NNP 0 0 16 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
curcumin NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
was VBD 1 0 12 O
similar JJ 0 1 1 O
to TO 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
and CC 0 0 12 O
imipramine NN 0 1 0 B-Drug
( ( 0 0 2 O
p JJ 0 1 2 O
> NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
but CC 0 0 12 O
its PRP$ 1 0 12 O
addition NN 0 1 1 O
to TO 0 0 12 O
fluoxetine VB 0 1 16 B-Drug
and CC 0 0 12 O
imipramine VB 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
improve VB 0 0 1 O
their PRP$ 0 0 12 O
antidepressant JJ 0 1 6 O
activity NN 0 1 1 O
( ( 0 0 2 O
p JJ 0 1 2 O
> NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Spontaneous JJ 0 1 7 O
spiking NN 0 0 3 O
and CC 0 0 12 O
synaptic JJ 0 0 UNK O
depression NN 0 1 6 O
underlie IN 0 0 UNK O
noradrenergic JJ 0 1 UNK O
control NN 0 1 1 O
of IN 0 0 12 O
feed NN 0 1 12 O
- : 0 0 2 O
forward NN 0 1 12 O
inhibition NN 0 1 13 O
. . 0 0 12 O

Curcumin NNP 0 1 UNK B-Drug_n
can MD 0 0 12 O
be VB 0 0 12 O
a DT 0 0 12 O
useful JJ 0 1 UNK O
antidepressant NN 0 1 6 B-Group
especially RB 0 0 12 O
in IN 0 0 12 O
cases NNS 1 1 UNK O
which WDT 0 0 12 O
respond VBP 0 0 1 O
to TO 0 0 12 O
drugs NNS 1 1 6 O
having VBG 1 0 12 O
mixed JJ 0 1 3 O
effects NNS 1 1 1 O
on IN 0 0 12 O
serotonin NN 0 1 13 O
and CC 0 0 12 O
catecholamines NNS 1 1 14 O
levels NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
brain NN 0 1 6 O
. . 0 0 12 O

Varenicline NNP 0 1 UNK B-Drug
reduces VBZ 1 0 UNK O
nicotine JJ 0 1 6 B-Drug
withdrawal NN 0 1 1 O
symptoms NNS 1 1 6 O
cigarette NN 0 1 3 O
craving NN 0 1 UNK O
and CC 0 0 12 O
nicotine JJ 0 1 6 B-Drug
satisfaction NN 0 1 UNK O
. . 0 0 12 O

Independent NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
location NN 0 1 1 O
of IN 0 0 12 O
granule NN 0 1 UNK O
cells NNS 1 1 6 O
within IN 0 0 1 O
the DT 0 0 12 O
9 CD 0 0 2 O
m JJ 0 1 2 O
lateral JJ 0 1 3 O
distance NN 0 1 13 O
examined VBD 1 1 1 O
molecular JJ 0 1 1 O
layer NN 0 1 3 O
interneurons NNS 0 1 UNK O
reduced VBD 1 1 1 O
the DT 0 0 12 O
strength NN 0 1 1 O
of IN 0 0 12 O
granule NN 0 1 UNK O
cell NN 0 1 1 O
inputs NNS 1 1 UNK O
to TO 0 0 12 O
Purkinje NNP 0 0 UNK O
cells NNS 1 1 6 O
to TO 0 0 12 O
a DT 0 0 12 O
comparable JJ 0 0 1 O
extent NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
contrast NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
sagittal JJ 0 1 8 O
orientation NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
coronal JJ 0 1 8 O
orientation NN 0 1 1 O
the DT 0 0 12 O
organization NN 0 1 UNK O
of IN 0 0 12 O
Purkinje NNP 0 0 UNK O
cell NN 0 1 1 O
responses NNS 1 1 1 O
with IN 0 0 12 O
granule NN 0 1 UNK O
cell NN 0 1 1 O
activation NN 0 1 13 O
was VBD 1 0 12 O
remarkably RB 0 0 UNK O
different JJ 0 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
highlight VBD 0 0 UNK O
the DT 0 0 12 O
need NN 0 1 12 O
for IN 0 0 12 O
new JJ 0 1 12 O
anticoagulants NNS 1 1 13 B-Group
in IN 0 0 12 O
atrial JJ 0 1 8 O
fibrillation NN 0 1 6 O
. . 0 0 12 O

Medical JJ 0 1 2 O
standards NNS 1 1 UNK O
include VBP 0 1 1 O
four CD 0 1 12 O
contents NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
prescription NN 0 1 0 O
function NN 0 1 1 O
and CC 0 0 12 O
indications NNS 1 1 1 O
usage NN 0 1 UNK O
and CC 0 0 12 O
dosage NN 0 1 0 O
and CC 0 0 12 O
attentions NNS 1 1 UNK O
. . 0 0 12 O

Despite IN 0 0 12 O
recommendations NNS 1 1 1 O
however RB 0 0 12 O
many JJ 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
atrial JJ 0 1 8 O
fibrillation NN 0 1 6 O
do VBP 0 0 12 O
not RB 0 1 12 O
receive VB 0 1 1 O
adequate JJ 0 1 1 O
thromboprophylaxis NN 0 0 UNK O
. . 0 0 12 O

According VBG 0 1 2 O
to TO 0 0 12 O
the DT 0 0 12 O
calculated JJ 0 1 1 O
level NN 0 1 1 O
of IN 0 0 12 O
risk NN 0 1 1 O
guidelines NNS 1 1 13 O
recommend VBP 0 1 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
atrial JJ 0 1 8 O
fibrillation NN 0 1 6 O
receive VBP 0 1 1 O
antithrombotic JJ 0 0 13 B-Group
therapy NN 0 1 6 O
either CC 0 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
antagonist NN 0 1 13 I-Group
or CC 0 0 12 O
aspirin NN 0 1 14 B-Brand
. . 0 0 12 O

Risk NN 0 1 2 O
stratification NN 0 1 6 O
schemes NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
developed VBN 1 0 1 O
that IN 0 0 12 O
categorize NN 0 1 UNK O
patients NNS 1 1 6 O
' POS 0 0 2 O
stroke NN 0 1 6 O
risk NN 0 1 1 O
into IN 0 0 12 O
classes NNS 1 1 UNK O
based VBN 1 1 1 O
on IN 0 0 12 O
a DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
risk NN 0 1 1 O
factors NNS 1 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
stroke NN 0 1 6 O
risk NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
homogeneous JJ 0 1 UNK O
and CC 0 0 12 O
varies NNS 0 1 UNK O
with IN 0 0 12 O
associated JJ 0 1 1 O
morbidities NNS 1 1 UNK O
and CC 0 0 12 O
risk NN 0 1 1 O
factors NNS 1 1 1 O
. . 0 0 12 O

Prevention NN 0 1 UNK O
of IN 0 0 12 O
atrial JJ 0 1 8 O
fibrillation NN 0 1 6 O
- : 0 0 2 O
related JJ 0 1 1 O
stroke NN 0 1 6 O
is VBZ 1 0 12 O
an DT 0 0 12 O
important JJ 0 1 1 O
part NN 0 1 12 O
of IN 0 0 12 O
atrial JJ 0 1 8 O
fibrillation NN 0 1 6 O
management NN 0 1 1 O
. . 0 0 12 O

Stroke NNP 0 1 7 O
prevention NN 0 1 1 O
in IN 0 0 12 O
atrial JJ 0 1 8 O
fibrillation NN 0 1 6 O
: : 0 0 2 O
current JJ 0 1 1 O
status NN 0 1 1 O
and CC 0 0 12 O
near IN 0 1 12 O
- : 0 0 2 O
future JJ 0 1 12 O
directions NNS 1 1 1 O
. . 0 0 12 O

Of IN 0 0 2 O
residents NNS 1 1 12 O
with IN 0 0 12 O
depression NN 0 1 6 O
who WP 0 0 12 O
received VBD 1 1 12 O
antidepressants NNS 1 1 13 B-Group
9 CD 0 0 2 O
% NN 0 0 18 O
had VBD 1 0 12 O
potential JJ 0 1 1 O
inappropriate NN 0 1 1 O
use NN 0 1 1 O
due JJ 0 1 1 O
primarily RB 0 0 1 O
to TO 0 0 12 O
problems NNS 1 1 1 O
seen VBN 1 1 12 O
with IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
and CC 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
disease NN 0 1 6 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Single NNP 0 1 2 O
- : 0 0 2 O
unit NN 0 1 1 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
extracellular JJ 0 1 14 O
recordings NNS 1 0 1 O
performed VBN 1 1 1 O
in IN 0 0 12 O
neurons NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
NAc NNP 0 1 UNK O
confirmed VBD 1 1 12 O
an DT 0 0 12 O
opiate NN 0 1 6 B-Group
- : 0 0 2 O
state NN 0 1 1 O
- : 0 0 2 O
dependent JJ 0 1 1 O
role NN 0 1 1 O
for IN 0 0 12 O
BLA NNP 0 1 UNK O
D9 NNP 0 1 UNK O
/ NNP 0 0 2 O
D9 NNP 0 1 UNK O
transmission NN 0 1 1 O
in IN 0 0 12 O
NAc NNP 0 1 UNK O
neuronal JJ 0 1 13 O
response NN 0 1 1 O
patterns NNS 1 1 1 O
to TO 0 0 12 O
morphine VB 0 1 14 B-Drug
. . 0 0 12 O

Treatment NN 0 1 7 O
of IN 0 0 12 O
nicotine JJ 0 1 6 B-Drug
dependence NN 0 1 1 O
with IN 0 0 12 O
Chantix NNP 0 1 UNK B-Brand
( ( 0 0 2 O
varenicline NN 0 1 13 B-Drug
) ) 0 0 2 O
. . 0 0 12 O

This DT 0 0 2 O
article NN 0 1 UNK O
explores VBZ 1 0 UNK O
the DT 0 0 12 O
issue NN 0 1 12 O
of IN 0 0 12 O
polypharmacy NN 0 1 14 O
in IN 0 0 12 O
older JJR 1 1 12 O
adults NNS 1 1 13 O
. . 0 0 12 O

We PRP 0 0 12 O
conclude VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
cause NN 0 1 12 O
of IN 0 0 12 O
death NN 0 1 12 O
was VBD 1 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
multiple JJ 0 1 1 O
psychotropic NN 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

The DT 0 0 2 O
risks NNS 1 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
reactions NNS 1 1 1 O
and CC 0 0 12 O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
linked VBN 1 1 UNK O
to TO 0 0 12 O
polypharmacy NN 0 1 14 O
are VBP 1 0 12 O
explored VBN 1 0 1 O
. . 0 0 12 O

During IN 0 0 2 O
spontaneous JJ 0 1 1 O
firing VBG 1 0 12 O
glycine NN 0 1 UNK O
release NN 0 1 12 O
was VBD 1 0 12 O
decreased VBN 1 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
strong JJ 0 1 12 O
short JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
depression NN 0 1 6 O
. . 0 0 12 O

Strategies NNS 0 1 UNK O
to TO 0 0 12 O
achieve VB 0 0 1 O
optimal JJ 0 1 1 O
prescribing NN 0 1 UNK O
in IN 0 0 12 O
older JJR 1 1 12 O
people NNS 0 1 12 O
are VBP 1 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

Drug NN 0 1 2 O
standards NNS 1 1 UNK O
are VBP 1 0 12 O
consist JJ 0 1 1 O
of IN 0 0 12 O
two CD 0 1 12 O
parts NNS 1 1 3 O
the DT 0 0 12 O
pharmaceutical JJ 0 1 13 O
standards NNS 1 1 UNK O
and CC 0 0 12 O
medical JJ 0 1 1 O
standards NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
physiological JJ 0 1 13 O
changes NNS 1 1 1 O
in IN 0 0 12 O
organ JJ 0 1 6 O
function NN 0 1 1 O
in IN 0 0 12 O
older JJR 1 1 12 O
people NNS 0 1 12 O
and CC 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
on IN 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
and CC 0 0 12 O
pharmacodynamics NNS 0 1 UNK O
are VBP 1 0 12 O
discussed VBN 1 1 1 O
. . 0 0 12 O

Two CD 0 1 2 O
separate JJ 0 1 1 O
studies NNS 1 1 1 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
bioequivalence NN 0 1 UNK O
of IN 0 0 12 O
fenofibric JJ 0 0 13 B-Drug
acid NNS 0 1 14 I-Drug
relative VBP 0 1 1 O
to TO 0 0 12 O
fenofibrate VB 0 1 16 B-Drug
under IN 0 0 12 O
fasted VBN 1 1 UNK O
and CC 0 0 12 O
fed VBN 1 1 12 O
( ( 0 0 2 O
standard JJ 0 1 1 O
breakfast NN 0 1 12 O
) ) 0 0 2 O
conditions NNS 1 1 1 O
characterize VBP 0 0 1 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
profile NN 0 1 1 O
and CC 0 0 12 O
assess VB 0 1 1 O
the DT 0 0 12 O
safety NN 0 1 1 O
and CC 0 0 12 O
tolerability NN 0 1 UNK O
of IN 0 0 12 O
fenofibric JJ 0 0 13 B-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

In IN 0 0 2 O
study NN 0 1 1 O
9 CD 0 0 2 O
( ( 0 0 2 O
fasted VBN 1 1 UNK O
) ) 0 0 2 O
during IN 0 0 12 O
each DT 0 0 12 O
study NN 0 1 1 O
period NN 0 1 1 O
volunteers NNS 1 1 UNK O
received VBD 1 1 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
fenofibric JJ 0 0 13 B-Drug
acid NN 0 1 14 I-Drug
or CC 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
fenofibrate NN 0 1 16 B-Drug
( ( 0 0 2 O
depending VBG 1 1 1 O
on IN 0 0 12 O
their PRP$ 0 0 12 O
randomization NN 0 1 6 O
scheme NN 0 1 1 O
) ) 0 0 2 O
after IN 0 0 12 O
an DT 0 0 12 O
overnight JJ 0 1 12 O
fast NN 0 1 12 O
( ( 0 0 2 O
a DT 0 0 12 O
minimum NN 0 1 1 O
fast NN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

A DT 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
washout IN 0 1 3 O
period NN 0 1 1 O
followed VBD 1 1 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
treatment NN 0 1 6 O
period NN 0 1 1 O
after IN 0 0 12 O
which WDT 0 0 12 O
the DT 0 0 12 O
volunteers NNS 1 1 UNK O
received VBD 1 1 12 O
the DT 0 0 12 O
alternate NN 0 1 1 O
treatment NN 0 1 6 O
. . 0 0 12 O

Study NNP 0 1 2 O
9 CD 0 0 2 O
followed VBD 1 1 12 O
a DT 0 0 12 O
similar JJ 0 1 1 O
dosing NN 0 0 14 O
scheme NN 0 1 1 O
and CC 0 0 12 O
differed VBD 1 0 UNK O
only RB 0 1 12 O
in IN 0 0 12 O
that DT 0 0 12 O
volunteers NNS 1 1 UNK O
received VBD 1 1 12 O
their PRP$ 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
after IN 0 0 12 O
being VBG 1 0 12 O
fed VBN 1 1 12 O
a DT 0 0 12 O
standard JJ 0 1 1 O
meal NN 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
calories NNS 1 1 3 O
of IN 0 0 12 O
which WDT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
were VBD 1 0 12 O
contributed VBN 1 1 1 O
by IN 0 0 12 O
fat NN 0 1 3 O
) ) 0 0 2 O
. . 0 0 12 O

Single NNP 0 1 2 O
- : 0 0 2 O
dose JJ 0 1 6 O
bioequivalence NN 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
fenofibric JJ 0 0 13 B-Drug
acid JJ 0 1 14 I-Drug
tablets NNS 1 1 3 O
versus VBP 0 0 1 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
fenofibrate JJ 0 1 16 B-Drug
tablets NNS 1 1 3 O
under IN 0 0 12 O
fasting NN 0 1 6 O
and CC 0 0 12 O
fed JJ 0 1 12 O
conditions NNS 1 1 1 O
: : 0 0 2 O
a DT 0 0 12 O
report NN 0 1 1 O
of IN 0 0 12 O
two CD 0 1 12 O
phase NN 0 1 1 O
I PRP 0 1 12 O
open VBP 0 1 12 O
- : 0 0 2 O
label NN 0 1 13 O
single JJ 0 1 12 O
- : 0 0 2 O
dose NN 0 1 6 O
randomized VBN 1 1 6 O
crossover RB 0 1 UNK O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

Fenofibrate NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
primary JJ 0 1 1 O
hypercholesterolemia NN 0 1 14 O
mixed JJ 0 1 3 O
lipidemia NN 0 1 UNK O
and CC 0 0 12 O
hypertriglyceridemia NN 0 1 UNK O
in IN 0 0 12 O
adults NNS 1 1 13 O
who WP 0 0 12 O
do VBP 0 0 12 O
not RB 0 1 12 O
respond VB 0 0 1 O
to TO 0 0 12 O
nonpharmacologic JJ 0 0 UNK O
measures NNS 1 1 1 O
. . 0 0 12 O

Fenofibrate NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
prodrug NN 0 1 UNK O
that WDT 0 0 12 O
is VBZ 1 0 12 O
rapidly RB 0 1 1 O
and CC 0 0 12 O
completely RB 0 1 12 O
hydrolyzed VBN 1 0 UNK O
to TO 0 0 12 O
fenofibric VB 0 0 13 B-Drug_n
acid PDT 0 1 14 I-Drug_n
the DT 0 0 12 O
active JJ 0 1 1 O
moiety NN 0 0 14 O
. . 0 0 12 O

A DT 0 0 2 O
new JJ 0 1 12 O
orally RB 0 1 14 O
administered VBN 1 1 1 O
agent NN 0 1 1 O
fenofibric JJ 0 0 13 B-Drug
acid NN 0 1 14 I-Drug
was VBD 1 0 12 O
developed VBN 1 0 1 O
as IN 1 0 12 O
an DT 0 0 12 O
alternative NN 0 1 1 O
to TO 0 0 12 O
fenofibrate VB 0 1 16 B-Drug
. . 0 0 12 O

Positive JJ 0 1 2 O
shifts NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
GABAA NNP 0 0 UNK O
receptor NN 0 1 14 O
reversal NN 0 1 1 O
potential JJ 0 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
altered JJ 0 1 1 O
chloride NN 0 1 14 O
homeostasis NN 0 1 UNK O
is VBZ 1 0 12 O
widespread JJ 0 1 1 O
after IN 0 0 12 O
status NN 0 1 1 O
epilepticus NN 0 0 8 O
. . 0 0 12 O

- : 0 0 2 O
Aminobutyric NN 0 0 UNK O
acid NN 0 1 14 O
( ( 0 0 2 O
GABA NNP 0 1 UNK O
) ) 0 0 2 O
ergic VBZ 0 1 UNK O
transmission NN 0 1 1 O
plays VBZ 1 1 UNK O
an DT 0 0 12 O
important JJ 0 1 1 O
role NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
epileptic JJ 0 1 13 O
activity NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
generation NN 0 1 UNK O
of IN 0 0 12 O
ictal JJ 0 1 8 O
discharges NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
functional JJ 0 1 1 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
epileptiform NN 0 0 8 O
hippocampus NN 0 1 8 O
critically RB 0 0 1 O
depend VBP 0 1 1 O
on IN 0 0 12 O
GABAergic NNP 0 0 UNK O
mechanisms NNS 1 1 UNK O
and CC 0 0 12 O
cation NN 0 1 UNK O
- : 0 0 2 O
chloride NN 0 1 14 O
cotransporters NNS 0 0 UNK O
. . 0 0 12 O

To TO 0 0 2 O
understand VB 0 1 12 O
the DT 0 0 12 O
cellular JJ 0 1 13 O
basis NN 0 1 1 O
of IN 0 0 12 O
specific JJ 0 1 1 O
functional JJ 0 1 1 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
epileptic JJ 0 1 13 O
hippocampus NN 0 1 8 O
we PRP 0 0 12 O
studied VBD 1 0 1 O
physiologic JJ 0 1 6 O
characteristics NNS 1 1 UNK O
and CC 0 0 12 O
pharmacologically RB 0 0 UNK O
isolated JJ 0 1 1 O
evoked VBD 1 1 13 O
GABA NNP 0 1 UNK O
( ( 0 0 2 O
A NNP 0 0 2 O
) ) 0 0 2 O
receptor NN 0 1 14 O
- : 0 0 2 O
mediated VBN 1 1 13 O
inhibitory JJ 0 1 UNK O
postsynaptic JJ 0 0 UNK O
currents NNS 1 1 UNK O
( ( 0 0 2 O
IPSCs NNP 0 0 UNK O
) ) 0 0 2 O
recorded VBD 1 1 12 O
from IN 0 0 12 O
principal JJ 0 1 1 O
neurons NNS 1 1 UNK O
in IN 0 0 12 O
hippocampal JJ 0 1 8 O
slices NNS 1 1 UNK O
from IN 0 0 12 O
status NN 0 1 1 O
epilepticus NN 0 0 8 O
( ( 0 0 2 O
SE NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
control NN 0 1 1 O
rats NNS 1 1 UNK O
using VBG 1 1 1 O
whole JJ 0 1 12 O
- : 0 0 2 O
cell NN 0 1 1 O
and CC 0 0 12 O
gramicidin NN 0 1 UNK O
perforated VBN 1 1 3 O
patch NN 0 1 3 O
- : 0 0 2 O
clamp NN 0 1 3 O
recordings NNS 1 0 1 O
. . 0 0 12 O

Serial JJ 0 1 2 O
blood NN 0 1 6 O
samples NNS 1 1 UNK O
in IN 0 0 12 O
both DT 0 0 12 O
studies NNS 1 1 1 O
were VBD 1 0 12 O
collected VBN 1 1 1 O
up RB 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
drug NN 0 1 1 O
administration NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
of IN 0 0 12 O
interest NN 0 1 1 O
for IN 0 0 12 O
assessing VBG 1 1 UNK O
bioequivalence NN 0 1 UNK O
were VBD 1 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
t NN 0 1 12 O
) ) 0 0 2 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
C NNP 0 0 2 O
( ( 0 0 2 O
max NN 0 0 3 O
) ) 0 0 2 O
and CC 0 0 12 O
T NNP 0 1 2 O
( ( 0 0 2 O
max NN 0 0 3 O
) ) 0 0 2 O
. . 0 0 12 O

Our PRP$ 0 0 2 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
alterations NNS 1 1 1 O
of IN 0 0 12 O
cation NN 0 1 UNK O
- : 0 0 2 O
chloride NN 0 1 14 O
cotransporter NN 0 0 UNK O
functions NNS 1 1 13 O
comprising VBG 1 1 UNK O
a DT 0 0 12 O
higher JJR 1 1 1 O
NKCC9 NNP 0 0 UNK O
action NN 0 1 13 O
contribute NN 0 1 UNK O
to TO 0 0 12 O
hyperexcitability NN 0 1 UNK O
within IN 0 0 1 O
the DT 0 0 12 O
hippocampus NN 0 1 8 O
following VBG 1 1 1 O
SE NNP 0 1 UNK O
. . 0 0 12 O

A DT 0 0 2 O
significant JJ 0 1 1 O
improvement NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
asthma NN 0 1 6 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
both DT 0 0 12 O
trial NN 0 1 12 O
arms NNS 1 1 3 O
. . 0 0 12 O

Pulmonary JJ 0 1 7 O
tuberculosis NN 0 1 6 O
( ( 0 0 2 O
TB NNP 0 0 13 O
) ) 0 0 2 O
is VBZ 1 0 12 O
a DT 0 0 12 O
common JJ 0 1 1 O
infectious JJ 0 1 6 O
disease NN 0 1 6 O
and CC 0 0 12 O
a DT 0 0 12 O
major JJ 0 1 1 O
cause NN 0 1 12 O
of IN 0 0 12 O
illness NN 0 1 6 O
and CC 0 0 12 O
death NN 0 1 12 O
throughout IN 0 0 12 O
the DT 0 0 12 O
world NN 0 1 12 O
particularly RB 0 0 1 O
in IN 0 0 12 O
developing VBG 1 0 1 O
countries NNS 1 1 UNK O
. . 0 0 12 O

However RB 0 0 1 O
there EX 0 0 12 O
was VBD 1 0 12 O
only RB 0 1 12 O
a DT 0 0 12 O
slight JJ 0 1 3 O
improvement NN 0 1 1 O
regarding VBG 1 0 1 O
inappropriate JJ 0 1 1 O
drug NN 0 1 1 O
combinations NNS 1 1 1 O
. . 0 0 12 O

Some DT 0 0 2 O
works NNS 1 1 12 O
show VBP 0 1 12 O
that IN 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
possible JJ 0 1 1 O
to TO 0 0 12 O
satisfactorily RB 0 0 UNK O
address VB 0 1 1 O
the DT 0 0 12 O
issues NNS 1 1 1 O
of IN 0 0 12 O
polypharmacy NN 0 1 14 O
but CC 0 0 12 O
it PRP 0 0 12 O
requires VBZ 1 0 1 O
great JJ 0 1 12 O
courage NN 0 1 UNK O
and CC 0 0 12 O
an DT 0 0 12 O
interdisciplinary JJ 0 1 UNK O
approach NN 0 1 1 O
involving VBG 1 1 1 O
modern JJ 0 0 UNK O
information NN 0 1 1 O
technology NN 0 1 13 O
. . 0 0 12 O

Varenicline NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
the DT 0 0 12 O
generic JJ 0 1 16 O
name NN 0 1 12 O
for IN 0 0 12 O
Chantix NNP 0 1 UNK B-Brand
the DT 0 0 12 O
newest JJS 1 1 UNK O
drug NN 0 1 1 O
available JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
tobacco NN 0 1 1 O
dependence NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
significant JJ 0 1 1 O
health NN 0 1 1 O
benefits NNS 1 1 1 O
of IN 0 0 12 O
quitting VBG 1 1 12 O
smoking NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
weighed VBN 1 0 12 O
against IN 0 0 12 O
the DT 0 0 12 O
individual NN 0 1 1 O
's POS 0 1 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
varenicline NN 0 1 13 B-Drug
for IN 0 0 12 O
smoking VBG 1 1 12 O
cessation NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
growing VBG 1 0 12 O
consumption NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
other JJ 0 0 12 O
numerous JJ 0 1 1 O
factors NNS 1 1 1 O
relates VBZ 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
increasing VBG 1 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
polypharmacy NN 0 1 14 O
. . 0 0 12 O

[ JJ 0 0 2 O
Polypharmacy NNP 0 1 UNK O
and CC 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
] VBP 0 0 2 O
. . 0 0 12 O

Repeatedly RB 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
proven VBN 1 1 1 O
the DT 0 0 12 O
dependence NN 0 1 1 O
between IN 0 0 12 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
patients NNS 1 1 6 O
requiring VBG 1 0 1 O
hospitalization NN 0 1 6 O
or CC 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
moderate JJ 0 1 1 O
and CC 0 0 12 O
serious JJ 0 1 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
proportion NN 0 1 UNK O
of IN 0 0 12 O
patients NNS 1 1 6 O
currently RB 0 1 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
or CC 0 0 12 O
more JJR 0 1 12 O
medicines NNS 1 1 6 O
at IN 0 0 12 O
the DT 0 0 12 O
elderly JJ 0 1 12 O
population NN 0 1 13 O
in IN 0 0 12 O
particular JJ 0 0 1 O
is VBZ 1 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Future JJ 0 1 2 O
studies NNS 1 1 1 O
are VBP 1 0 12 O
needed VBN 1 1 12 O
to TO 0 0 12 O
examine VB 0 0 1 O
the DT 0 0 12 O
true JJ 0 1 12 O
risks NNS 1 1 1 O
and CC 0 0 12 O
benefits NNS 1 1 1 O
of IN 0 0 12 O
antidepressant JJ 0 1 6 B-Group
use NN 0 1 1 O
in IN 0 0 12 O
CLC NNP 0 1 UNK O
and CC 0 0 12 O
non SYM 0 1 1 O
- : 0 0 2 O
VA JJ 0 1 2 O
nursing NN 0 1 12 O
homes NNS 1 1 12 O
. . 0 0 12 O

veteran NN 0 1 12 O
CLC NNP 0 1 UNK O
residents NNS 1 1 12 O
. . 0 0 12 O

Potential JJ 0 1 UNK O
problems NNS 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
antidepressants NNS 1 1 13 B-Group
were VBD 1 0 12 O
frequently RB 0 1 1 O
observed VBN 1 1 1 O
in IN 0 0 12 O
older JJR 1 1 12 O
U.S NNP 0 1 UNK O
. . 0 0 12 O

Having VBG 0 0 2 O
moderate JJ 0 1 1 O
to TO 0 0 12 O
severe VB 0 1 6 O
pain NN 0 1 6 O
( ( 0 0 2 O
ARRR=9 NNP 0 0 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
CI=9 NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
the DT 0 0 12 O
prescribing NN 0 1 UNK O
of IN 0 0 12 O
an DT 0 0 12 O
anxiolytic JJ 0 1 13 B-Group
or CC 0 0 12 O
hypnotic JJ 0 1 13 B-Group
( ( 0 0 2 O
ARRR=9 NNP 0 0 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
CI=9 NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
increased VBD 1 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
potential JJ 0 1 1 O
inappropriate NN 0 1 1 O
antidepressant NN 0 1 6 B-Group
use NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
only JJ 0 1 12 O
consistent JJ 0 1 1 O
resident NN 0 1 12 O
factor NN 0 1 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
potential JJ 0 1 1 O
underuse NN 0 0 UNK O
and CC 0 0 12 O
overuse NN 0 0 UNK O
use NN 0 1 1 O
was VBD 1 0 12 O
taking VBG 1 0 12 O
an DT 0 0 12 O
antipsychotic JJ 0 1 UNK B-Group
without IN 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
schizophrenia NN 0 1 13 O
( ( 0 0 2 O
underuse IN 0 0 UNK O
: : 0 0 2 O
adjusted VBN 1 1 1 O
relative JJ 0 1 1 O
risk NN 0 1 1 O
ratio NN 0 1 1 O
( ( 0 0 2 O
ARRR NNP 0 0 UNK O
) ) 0 0 2 O
=9 VBD 0 0 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
confidence NN 0 1 UNK O
interval NN 0 1 1 O
( ( 0 0 2 O
CI NNP 0 1 UNK O
) ) 0 0 2 O
=9 VBD 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
; : 0 0 2 O
overuse NN 0 0 UNK O
: : 0 0 2 O
adjusted VBN 1 1 1 O
odds NNS 0 0 UNK O
ratio=9 VBP 0 1 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
CI=9 NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Overall JJ 0 1 2 O
only RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
antidepressant JJ 0 1 6 B-Group
use NN 0 1 1 O
was VBD 1 0 12 O
appropriate JJ 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
/ RB 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

only RB 0 1 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
of IN 0 0 12 O
these DT 0 0 12 O
had VBD 1 0 12 O
a DT 0 0 12 O
Food NNP 0 1 2 O
and CC 0 0 12 O
Drug NNP 0 1 2 O
Administration NNP 0 1 UNK O
- : 0 0 2 O
approved VBD 1 1 1 O
labeled JJ 0 1 1 O
indication NN 0 1 1 O
suggesting VBG 1 1 1 O
potential JJ 0 1 1 O
overuse NN 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
recent JJ 0 1 12 O
determination NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
atomic JJ 0 1 UNK O
- : 0 0 2 O
scale NN 0 1 1 O
structure NN 0 1 1 O
of IN 0 0 12 O
GLIC NNP 0 0 UNK O
a DT 0 0 12 O
prokaryotic JJ 0 1 UNK O
member NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
pentameric JJ 0 0 UNK O
ligand NN 0 1 UNK O
- : 0 0 2 O
gated VBN 1 0 UNK O
ion NN 0 1 13 O
channel NN 0 1 1 O
( ( 0 0 2 O
pLGIC NN 0 0 UNK O
) ) 0 0 2 O
family NN 0 1 12 O
provides VBZ 1 1 UNK O
a DT 0 0 12 O
unique JJ 0 1 UNK O
opportunity NN 0 0 UNK O
to TO 0 0 12 O
characterize VB 0 0 1 O
the DT 0 0 12 O
structural JJ 0 1 1 O
basis NN 0 1 1 O
for IN 0 0 12 O
modulation NN 0 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
channels NNS 1 1 13 O
many JJ 0 0 12 O
of IN 0 0 12 O
which WDT 0 0 12 O
are VBP 1 0 12 O
alcohol JJ 0 1 1 B-Drug
targets NNS 1 1 UNK O
in IN 0 0 12 O
brain NN 0 1 6 O
. . 0 0 12 O

We PRP 0 0 12 O
observed VBD 1 1 1 O
that IN 0 0 12 O
GLIC NNP 0 0 UNK O
recapitulates VBZ 1 0 UNK O
bimodal JJ 0 0 UNK O
modulation NN 0 1 13 O
by IN 0 0 12 O
n JJ 0 1 12 O
- : 0 0 2 O
alcohols NNS 1 1 13 O
similar JJ 0 1 1 O
to TO 0 0 12 O
some DT 0 0 12 O
eukaryotic JJ 0 1 UNK O
pLGICs NNS 0 0 UNK O
: : 0 0 2 O
methanol NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
ethanol JJ 0 1 1 B-Drug
weakly RB 0 0 3 O
potentiated VBN 1 0 UNK O
proton NN 0 1 14 O
- : 0 0 2 O
activated JJ 0 1 1 O
currents NNS 1 1 UNK O
in IN 0 0 12 O
GLIC NNP 0 0 UNK O
whereas VBP 0 0 UNK O
n SYM 0 1 12 O
- : 0 0 2 O
alcohols NNS 1 1 13 O
larger JJR 1 1 1 O
than IN 0 0 12 O
ethanol RB 0 1 1 O
inhibited VBN 1 1 13 O
them PRP 0 0 12 O
. . 0 0 12 O

Structural JJ 0 1 UNK O
basis NN 0 1 1 O
for IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
modulation NN 0 1 13 O
of IN 0 0 12 O
a DT 0 0 12 O
pentameric JJ 0 0 UNK O
ligand NN 0 1 UNK O
- : 0 0 2 O
gated VBN 1 0 UNK O
ion NN 0 1 13 O
channel NN 0 1 1 O
. . 0 0 12 O

Of IN 0 0 2 O
the DT 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
residents NNS 1 1 12 O
who WP 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
have VB 0 0 12 O
depression NN 0 1 6 O
9 CD 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
were VBD 1 0 12 O
prescribed VBN 1 1 1 O
one CD 0 1 12 O
or CC 0 0 12 O
more JJR 0 1 12 O
antidepressants NNS 1 1 13 B-Group
; : 0 0 2 O

Despite IN 0 0 12 O
its PRP$ 1 0 12 O
long JJ 0 1 12 O
history NN 0 1 12 O
of IN 0 0 12 O
use NN 0 1 1 O
and CC 0 0 12 O
abuse NN 0 1 12 O
in IN 0 0 12 O
human JJ 0 1 1 O
culture NN 0 1 1 O
the DT 0 0 12 O
molecular JJ 0 1 1 O
basis NN 0 1 1 O
for IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
action NN 0 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
brain NN 0 1 6 O
is VBZ 1 0 12 O
poorly RB 0 1 1 O
understood JJ 0 1 12 O
. . 0 0 12 O

One CD 0 1 2 O
hundred VBD 0 0 UNK O
thirty NN 0 1 12 O
- : 0 0 2 O
three CD 0 1 12 O
VA NNP 0 1 2 O
CLCs NNP 0 1 UNK O
. . 0 0 12 O

At IN 0 0 2 O
one CD 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potentiation NN 0 1 UNK O
- : 0 0 2 O
enhancing VBG 1 1 1 O
residues NNS 1 1 UNK O
decreased VBN 1 1 1 O
side RB 0 1 3 O
chain NN 0 1 16 O
volume NN 0 1 1 O
converted VBN 1 0 1 O
GLIC NNP 0 0 UNK O
into IN 0 0 12 O
a DT 0 0 12 O
highly RB 0 1 1 O
ethanol JJ 0 1 1 B-Drug
- : 0 0 2 O
sensitive JJ 0 1 1 O
channel NN 0 1 1 O
comparable JJ 0 0 1 O
to TO 0 0 12 O
its PRP$ 1 0 12 O
eukaryotic JJ 0 1 UNK O
relatives NNS 1 1 12 O
. . 0 0 12 O

To TO 0 0 2 O
examine VB 0 0 1 O
prevalence NN 0 1 UNK O
and CC 0 0 12 O
resident JJ 0 1 12 O
- : 0 0 2 O
and CC 0 0 12 O
site NN 0 1 12 O
- : 0 0 2 O
level NN 0 1 1 O
factors NNS 1 1 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
potential JJ 0 1 1 O
underuse NN 0 0 UNK O
overuse NN 0 0 UNK O
and CC 0 0 12 O
inappropriate JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
antidepressants NNS 1 1 13 B-Group
in IN 0 0 12 O
older JJR 1 1 12 O
Veterans NNS 0 1 UNK O
Affairs NNP 0 0 UNK O
( ( 0 0 2 O
VA NNP 0 1 2 O
) ) 0 0 2 O
Community NNP 0 1 2 O
Living NNP 0 1 UNK O
Center NNP 0 1 2 O
( ( 0 0 2 O
CLC NNP 0 1 UNK O
) ) 0 0 2 O
residents NNS 1 1 12 O
. . 0 0 12 O

Potential JJ 0 1 UNK O
underuse NN 0 0 UNK O
overuse NN 0 0 UNK O
and CC 0 0 12 O
inappropriate JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
antidepressants NNS 1 1 13 B-Group
in IN 0 0 12 O
older JJR 1 1 12 O
veteran NN 0 1 12 O
nursing NN 0 1 12 O
home NN 0 1 12 O
residents NNS 1 1 12 O
. . 0 0 12 O

Of IN 0 0 2 O
the DT 0 0 12 O
9 CD 0 0 2 O
residents NNS 1 1 12 O
with IN 0 0 12 O
depression NN 0 1 6 O
9 CD 0 0 2 O
% NN 0 0 18 O
did VBD 1 0 12 O
not RB 0 1 12 O
receive VB 0 1 1 O
an DT 0 0 12 O
antidepressant JJ 0 1 6 B-Group
suggesting VBG 1 1 1 O
potential JJ 0 1 1 O
underuse NN 0 0 UNK O
. . 0 0 12 O

Selective JJ 0 1 7 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
were VBD 1 0 12 O
the DT 0 0 12 O
most RBS 0 0 12 O
commonly RB 0 0 UNK O
prescribed JJ 0 1 1 O
antidepressant NN 0 1 6 B-Group
. . 0 0 12 O

Prevalence NN 0 1 UNK O
of IN 0 0 12 O
potential JJ 0 1 1 O
underuse NN 0 0 UNK O
inappropriate NN 0 1 1 O
use NN 0 1 1 O
and CC 0 0 12 O
overuse NN 0 0 UNK O
of IN 0 0 12 O
antidepressants NNS 1 1 13 B-Group
in IN 0 0 12 O
residents NNS 1 1 12 O
with IN 0 0 12 O
and CC 0 0 12 O
without IN 0 0 12 O
depression NN 0 1 6 O
( ( 0 0 2 O
as IN 1 0 12 O
documented VBN 1 1 1 O
according VBG 1 1 1 O
to TO 0 0 12 O
International NNP 0 1 UNK O
Classification NNP 0 1 UNK O
of IN 0 0 12 O
Diseases NNP 0 1 UNK O
Ninth NNP 0 1 UNK O
Revision NNP 0 1 UNK O
Clinical NNP 0 1 7 O
Modification NNP 0 1 UNK O
codes VBZ 1 1 16 O
or CC 0 0 12 O
Depression NNP 0 1 2 O
Rating NNP 0 1 UNK O
Scale NNP 0 1 2 O
) ) 0 0 2 O
. . 0 0 12 O

Covalent NNP 0 1 UNK O
labeling NN 0 1 UNK O
of IN 0 0 12 O
M9 NNP 0 1 UNK O
positions NNS 1 1 UNK O
with IN 0 0 12 O
an DT 0 0 12 O
alcohol NN 0 1 1 B-Drug
analog NN 0 1 UNK O
a DT 0 0 12 O
methanethiosulfonate NN 0 1 UNK O
reagent NN 0 1 14 O
further RB 1 1 1 O
implicated VBD 1 0 UNK O
residues NNS 1 1 UNK O
at IN 0 0 12 O
the DT 0 0 12 O
extracellular JJ 0 1 14 O
end NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
helix NN 0 1 UNK O
in IN 0 0 12 O
alcohol NN 0 1 1 O
binding NN 0 1 1 O
. . 0 0 12 O

Group NNP 0 1 2 O
9 CD 0 0 2 O
consisted VBD 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
carbamide NN 0 1 16 B-Drug_n
peroxide IN 0 1 16 I-Drug_n
- : 0 0 2 O
based VBN 1 1 1 O
bleaching NN 0 1 UNK O
gel NN 0 1 3 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
manganese JJ 0 1 13 B-Drug_n
gluconate NN 0 1 14 I-Drug_n
. . 0 0 12 O

The DT 0 0 2 O
applicability NN 0 1 UNK O
of IN 0 0 12 O
DDI NNP 0 1 13 O
management NN 0 1 1 O
guidelines NNS 1 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
pretested VBN 0 1 UNK O
before IN 0 1 12 O
publishing NN 0 1 UNK O
. . 0 0 12 O

Total JJ 0 1 2 O
color NN 0 1 3 O
variation NN 0 1 1 O
was VBD 1 0 12 O
calculated VBN 1 1 1 O
by IN 0 0 12 O
E*Lab NNP 0 1 UNK O
. . 0 0 12 O

Data NNS 0 1 2 O
were VBD 1 0 12 O
submitted VBN 1 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
statistical JJ 0 1 UNK O
t NN 0 1 12 O
- : 0 0 2 O
test NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
which WDT 0 0 12 O
showed VBD 1 1 12 O
that IN 0 0 12 O
after IN 0 0 12 O
seven CD 0 1 12 O
days NNS 1 1 12 O
group NN 0 1 12 O
9 CD 0 0 2 O
had VBD 1 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
tooth NN 0 1 3 O
bleaching NN 0 1 UNK O
compared VBN 1 1 1 O
with IN 0 0 12 O
group NN 0 1 12 O
9 CD 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
influence NN 0 0 UNK O
of IN 0 0 12 O
chemical NN 0 1 13 O
activation NN 0 1 13 O
on IN 0 0 12 O
tooth NN 0 1 3 O
bleaching VBG 1 1 UNK O
using VBG 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
carbamide JJ 0 1 16 B-Drug_n
peroxide NN 0 1 16 I-Drug_n
. . 0 0 12 O

Mapping NN 0 1 UNK O
of IN 0 0 12 O
residues NNS 1 1 UNK O
important JJ 0 1 1 O
to TO 0 0 12 O
alcohol VB 0 1 1 B-Drug
modulation NN 0 1 13 O
of IN 0 0 12 O
ionotropic NN 0 0 UNK O
receptors NNS 1 1 13 O
for IN 0 0 12 O
glycine NN 0 1 UNK O
- : 0 0 2 O
aminobutyric JJ 0 0 UNK O
acid NN 0 1 14 O
and CC 0 0 12 O
acetylcholine VB 0 1 14 O
onto IN 0 0 3 O
GLIC NNP 0 0 UNK O
revealed VBD 1 1 12 O
their PRP$ 0 0 12 O
proximity NN 0 1 UNK O
to TO 0 0 12 O
transmembrane VB 0 1 UNK O
cavities NNS 1 1 13 O
that WDT 0 0 12 O
may MD 0 0 1 O
accommodate VB 0 0 UNK O
one CD 0 1 12 O
or CC 0 0 12 O
more JJR 0 1 12 O
alcohol NN 0 1 1 B-Drug
molecules NNS 1 1 UNK O
. . 0 0 12 O

Forty NNP 0 1 2 O
bovine NN 0 1 13 O
incisors NNS 1 1 UNK O
were VBD 1 0 12 O
immersed VBN 1 0 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
instant JJ 0 0 12 O
coffee NN 0 1 12 O
solution NN 0 1 1 O
for IN 0 0 12 O
seven CD 0 1 12 O
days NNS 1 1 12 O
and CC 0 0 12 O
randomly VB 0 0 UNK O
divided VBN 1 1 1 O
into IN 0 0 12 O
two CD 0 1 12 O
groups NNS 1 1 1 O
. . 0 0 12 O

To TO 0 0 2 O
improve VB 0 0 1 O
guideline NN 0 1 13 O
quality NN 0 1 1 O
more JJR 0 1 12 O
attention NN 0 1 12 O
should MD 0 0 12 O
particularly RB 0 0 1 O
be VB 0 0 12 O
paid VBN 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
available JJ 0 1 1 O
tools NNS 1 1 13 O
for IN 0 0 12 O
applications NNS 1 1 UNK O
and CC 0 0 12 O
cost NN 0 1 UNK O
implications NNS 1 0 UNK O
. . 0 0 12 O

Site NNP 0 1 UNK O
- : 0 0 2 O
directed VBD 1 1 1 O
mutations NNS 1 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
pore NN 0 1 UNK O
- : 0 0 2 O
lining NN 0 1 UNK O
M9 NNP 0 1 UNK O
helix NN 0 1 UNK O
allowed VBD 1 1 12 O
the DT 0 0 12 O
identification NN 0 1 1 O
of IN 0 0 12 O
four CD 0 1 12 O
residues NNS 1 1 UNK O
that WDT 0 0 12 O
influence VBP 0 0 UNK O
alcohol DT 0 1 1 B-Drug
potentiation NN 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
direction NN 0 1 1 O
of IN 0 0 12 O
their PRP$ 0 0 12 O
effects NNS 1 1 1 O
reflecting VBG 1 1 1 O
- : 0 0 2 O
helical JJ 0 1 UNK O
structure NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
mean NN 0 1 12 O
values NNS 1 1 1 O
( ( 0 0 2 O
SD NNP 0 1 UNK O
) ) 0 0 2 O
were VBD 1 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
for IN 0 0 12 O
group NN 0 1 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
for IN 0 0 12 O
group NN 0 1 12 O
9 CD 0 0 2 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
results NNS 1 1 1 O
for IN 0 0 12 O
group NN 0 1 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
group NN 0 1 12 O
9 CD 0 0 2 O
were VBD 1 0 12 O
similar JJ 0 1 1 O
after IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Post NNP 0 1 2 O
- : 0 0 2 O
market NN 0 1 UNK O
reports NNS 1 1 1 O
prompted VBD 1 1 12 O
a DT 0 0 12 O
warning NN 0 1 12 O
of IN 0 0 12 O
serious JJ 0 1 12 O
adverse JJ 0 0 1 O
neuropsychiatric JJ 0 0 UNK O
events NNS 1 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
varenicline NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
novel JJ 0 1 13 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
in IN 0 0 12 O
development NN 0 1 1 O
may MD 0 0 1 O
overcome VB 0 1 UNK O
some DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
limitations NNS 1 1 1 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
K NNP 0 1 2 I-Group
antagonists NNS 1 1 13 I-Group
and CC 0 0 12 O
address VB 0 1 1 O
their PRP$ 0 0 12 O
underuse NN 0 0 UNK O
and CC 0 0 12 O
safety NN 0 1 1 O
concerns NNS 1 1 1 O
. . 0 0 12 O

Within IN 0 0 2 O
the DT 0 0 12 O
domain NN 0 1 UNK O
'Clarity NN 0 1 UNK O
and CC 0 0 12 O
presentation NN 0 1 1 O
' '' 0 0 2 O
the DT 0 0 12 O
item NN 0 1 UNK O
'tools VBZ 0 1 UNK O
for IN 0 0 12 O
application NN 0 1 1 O
' '' 0 0 2 O
received VBD 1 1 12 O
the DT 0 0 12 O
lowest JJS 1 1 13 O
scores NNS 1 1 1 O
. . 0 0 12 O

Within IN 0 0 2 O
the DT 0 0 12 O
domain NN 0 1 UNK O
'Applicability NNP 0 1 UNK O
' POS 0 0 2 O
cost NN 0 1 UNK O
implications NNS 1 0 UNK O
organizational JJ 0 1 UNK O
barriers NNS 1 1 UNK O
and CC 0 0 12 O
key JJ 0 0 13 O
review NN 0 1 2 O
criteria NNS 1 1 1 O
were VBD 1 0 12 O
all DT 0 0 12 O
poorly RB 0 1 1 O
documented VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
well NN 0 1 12 O
established VBN 1 1 1 O
anatomy NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
cerebellar JJ 0 1 8 O
cortex NN 0 1 6 O
has VBZ 1 0 12 O
led VBN 1 1 12 O
to TO 0 0 12 O
suggestions NNS 1 1 UNK O
that IN 0 0 12 O
cerebellar JJ 0 1 8 O
molecular JJ 0 1 1 O
layer NN 0 1 3 O
interneurons NNS 0 1 UNK O
laterally RB 0 0 3 O
inhibit VBP 0 1 13 O
Purkinje NNP 0 0 UNK O
cells NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
role NN 0 1 1 O
of IN 0 0 12 O
interneurons NNS 0 1 UNK O
in IN 0 0 12 O
shaping VBG 1 1 UNK O
Purkinje NNP 0 0 UNK O
cell NN 0 1 1 O
responses NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
cerebellar JJ 0 1 8 O
cortex NN 0 1 6 O
. . 0 0 12 O

Patchy NNP 0 1 15 O
excitation NN 0 1 13 O
of IN 0 0 12 O
Purkinje NNP 0 0 UNK O
cells NNS 1 1 6 O
with IN 0 0 12 O
flanking VBG 1 1 UNK O
inhibition NN 0 1 13 O
of IN 0 0 12 O
sagittally RB 0 0 UNK O
oriented VBN 1 1 1 O
Purkinje NNP 0 0 UNK O
cells NNS 1 1 6 O
have VBP 0 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
following VBG 1 1 1 O
peripheral JJ 0 1 6 O
stimulation NN 0 1 6 O
in IN 0 0 12 O
vivo NN 0 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
support NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
anatomical JJ 0 1 6 O
predictions NNS 1 1 UNK O
on IN 0 0 12 O
- : 0 0 2 O
beam NN 0 1 3 O
excitation NN 0 1 13 O
and CC 0 0 12 O
off IN 0 0 12 O
- : 0 0 2 O
beam NN 0 1 3 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
Purkinje NNP 0 0 UNK O
cells NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
occur VB 0 1 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
surface NN 0 1 3 O
of IN 0 0 12 O
the DT 0 0 12 O
cerebellum NN 0 1 8 O
is VBZ 1 0 12 O
electrically RB 0 1 UNK O
excited VBN 1 1 UNK O
. . 0 0 12 O

Patches NNS 0 1 UNK O
of IN 0 0 12 O
granule NN 0 1 UNK O
cells NNS 1 1 6 O
were VBD 1 0 12 O
asynchronously RB 0 0 UNK O
activated VBN 1 1 1 O
by IN 0 0 12 O
photostimulation NN 0 0 UNK O
to TO 0 0 12 O
mimic VB 0 0 UNK O
their PRP$ 0 0 12 O
excitation NN 0 1 13 O
by IN 0 0 12 O
a DT 0 0 12 O
mossy JJ 0 1 UNK O
fiber NN 0 1 3 O
as IN 1 0 12 O
it PRP 0 0 12 O
occurs VBZ 1 1 1 O
in IN 0 0 12 O
vivo NN 0 1 13 O
. . 0 0 12 O

To TO 0 0 2 O
extend VB 0 1 1 O
these DT 0 0 12 O
observations NNS 1 1 1 O
we PRP 0 0 12 O
mapped VBD 1 1 UNK O
the DT 0 0 12 O
functional JJ 0 1 1 O
connectivity NN 0 1 UNK O
between IN 0 0 12 O
granule NN 0 1 UNK O
cells NNS 1 1 6 O
molecular JJ 0 1 1 O
layer NN 0 1 3 O
interneurons NNS 0 1 UNK O
and CC 0 0 12 O
Purkinje NNP 0 0 UNK O
cells NNS 1 1 6 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

Granule NNP 0 1 UNK O
cells NNS 1 1 6 O
immediately RB 0 1 12 O
underneath IN 0 0 3 O
a DT 0 0 12 O
Purkinje NNP 0 0 UNK O
cell NN 0 1 1 O
provide RB 0 1 1 O
pure JJ 0 1 13 O
excitation NN 0 1 13 O
. . 0 0 12 O

We PRP 0 0 12 O
found VBD 1 1 12 O
with IN 0 0 12 O
remarkable JJ 0 0 12 O
consistency NN 0 1 1 O
that WDT 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
sagittal JJ 0 1 8 O
orientation NN 0 1 1 O
granule NN 0 1 UNK O
cells NNS 1 1 6 O
elicit VBP 0 1 1 O
a DT 0 0 12 O
stereotypic NN 0 1 13 O
set NN 0 1 12 O
of IN 0 0 12 O
responses NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
net JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
exciting VBG 1 1 UNK O
granule NN 0 1 UNK O
cells NNS 1 1 6 O
in IN 0 0 12 O
between IN 0 0 12 O
these DT 0 0 12 O
two CD 0 1 12 O
extremes NNS 1 1 1 O
was VBD 1 0 12 O
to TO 0 0 12 O
provide VB 0 1 1 O
a DT 0 0 12 O
systematic JJ 0 1 UNK O
change NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
response NN 0 1 1 O
of IN 0 0 12 O
Purkinje NNP 0 0 UNK O
cells NNS 1 1 6 O
from IN 0 0 12 O
net JJ 0 1 1 O
excitation NN 0 1 13 O
to TO 0 0 12 O
net JJ 0 1 1 O
inhibition NN 0 1 13 O
moving VBG 1 1 12 O
laterally RB 0 0 3 O
from IN 0 0 12 O
the DT 0 0 12 O
Purkinje NNP 0 0 UNK O
cell NN 0 1 1 O
. . 0 0 12 O

Granule NNP 0 1 UNK O
cells NNS 1 1 6 O
positioned VBD 1 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
m NN 0 1 2 O
laterally RB 0 0 3 O
provided VBN 1 1 1 O
pure NN 0 1 13 O
inhibition NN 0 1 13 O
consistent NN 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
lateral JJ 0 1 3 O
inhibition NN 0 1 13 O
proposed VBN 1 1 UNK O
earlier RBR 0 1 12 O
. . 0 0 12 O

More RBR 0 1 UNK O
mRPCs NNS 0 0 UNK O
expressed VBD 1 0 1 O
rhodopsin NN 0 1 UNK O
recoverin NN 0 1 UNK O
and CC 0 0 12 O
synaptophysin NN 0 1 UNK O
after IN 0 0 12 O
transplantation NN 0 1 6 O
into IN 0 0 12 O
Rho NNP 0 0 UNK O
( ( 0 0 2 O
- : 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
mice NN 1 1 UNK O
when WRB 0 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
chondroitinase NN 0 1 UNK O
ABC NNP 0 1 UNK O
and CC 0 0 12 O
growth NN 0 1 1 O
factors NNS 1 1 1 O
. . 0 0 12 O

As IN 0 0 2 O
is VBZ 1 0 12 O
the DT 0 0 12 O
case NN 0 1 12 O
with IN 0 0 12 O
any DT 0 0 12 O
surgical JJ 0 1 6 O
procedure NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
prescription NN 0 1 0 O
medication NN 0 1 6 O
full JJ 0 1 12 O
disclosure NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
risks NNS 1 1 1 O
and CC 0 0 12 O
benefits NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
discussed VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
identification NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
underlying VBG 1 0 1 O
molecular JJ 0 1 1 O
mechanisms NNS 1 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
synergistic JJ 0 1 UNK O
cell NN 0 1 1 O
death NN 0 1 12 O
induction NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
ongoing VBG 0 1 1 O
over IN 0 1 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
years NNS 1 1 12 O
. . 0 0 12 O

Cell NN 0 1 2 O
counts NNS 1 1 1 O
were VBD 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
examine VB 0 0 1 O
the DT 0 0 12 O
migration NN 0 1 13 O
and CC 0 0 12 O
survival JJ 0 1 1 O
rate NN 0 1 1 O
of IN 0 0 12 O
mRPCs NNS 0 0 UNK O
in IN 0 0 12 O
B9 NNP 0 0 UNK O
mice NN 1 1 UNK O
. . 0 0 12 O

however RB 0 0 12 O
sensitivity NN 0 1 1 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
enhanced VBN 1 1 1 O
in IN 0 0 12 O
females NNS 1 1 UNK O
and CC 0 0 12 O
microfilariae NN 0 1 UNK O
. . 0 0 12 O

[ JJ 0 0 2 O
Ticagrelor NN 0 1 UNK B-Drug
: : 0 0 2 O
a DT 0 0 12 O
novel JJ 0 1 13 O
antiplatelet NN 0 0 13 B-Group
agent NN 0 1 1 I-Group
for IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
acute JJ 0 1 6 O
coronary JJ 0 1 6 O
syndrome NN 0 1 6 O
] NN 0 0 2 O
. . 0 0 12 O

Ticagrelor NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
reversible JJ 0 1 3 O
blocker NN 0 0 3 O
of IN 0 0 12 O
the DT 0 0 12 O
P9Y9 NNP 0 0 UNK O
adenosine NN 0 1 14 O
receptor NN 0 1 14 O
. . 0 0 12 O

In IN 0 0 2 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
the DT 0 0 12 O
antiplatelet NN 0 0 13 B-Group
agent NN 0 1 1 I-Group
reduced VBD 1 1 1 O
significantly RB 0 0 1 O
vascular JJ 0 1 6 O
mortality NN 0 1 13 O
and CC 0 0 12 O
death NN 0 1 12 O
from IN 0 0 12 O
any DT 0 0 12 O
cause NN 0 1 12 O
when WRB 0 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
clopidogrel VB 0 1 16 B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
acute JJ 0 1 6 O
coronary JJ 0 1 6 O
syndrome NN 0 1 6 O
. . 0 0 12 O

Immunohistochemistry NN 0 1 UNK O
was VBD 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
differentiation NN 0 1 1 O
and CC 0 0 12 O
integration NN 0 1 13 O
of IN 0 0 12 O
mRPCs NNS 0 0 UNK O
in IN 0 0 12 O
B9 NNP 0 0 UNK O
and CC 0 0 12 O
Rho NNP 0 0 UNK O
( ( 0 0 2 O
- : 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
mice NN 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
pharmacotherapy NN 0 1 UNK O
of IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
and CC 0 0 12 O
liver JJ 0 1 6 O
diseases VBZ 0 1 6 O
a DT 0 0 12 O
significant JJ 0 1 1 O
number NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
that IN 0 0 12 O
occur VBP 0 1 1 O
can MD 0 0 12 O
be VB 0 0 12 O
explained VBN 1 0 12 O
by IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Some DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
are VBP 1 0 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
competitive JJ 0 1 UNK O
inhibition NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
leading VBG 1 1 1 O
to TO 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
concentration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
which WDT 0 0 12 O
was VBD 1 0 12 O
not RB 0 1 12 O
intended VBN 1 1 UNK O
. . 0 0 12 O

A DT 0 0 2 O
fatal JJ 0 1 13 O
poisoning NN 0 1 13 O
case NN 0 1 12 O
involving VBG 1 1 1 O
etizolam JJ 0 1 UNK B-Drug
phenobarbital JJ 0 1 16 B-Drug
promethazine NN 0 1 16 B-Drug
and CC 0 0 12 O
chlorpromazine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
presented VBN 1 1 1 O
. . 0 0 12 O

An DT 0 0 2 O
autopsy JJ 0 1 6 O
case NN 0 1 12 O
of IN 0 0 12 O
multiple JJ 0 1 1 O
psychotropic JJ 0 1 13 B-Group
drug NN 0 1 1 I-Group
poisoning NN 0 1 13 O
. . 0 0 12 O

Such JJ 0 0 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
are VBP 1 0 12 O
termed VBN 1 1 UNK O
idiosyncratic JJ 0 1 13 O
and CC 0 0 12 O
are VBP 1 0 12 O
often RB 0 1 12 O
initiated VBN 1 1 1 O
by IN 0 0 12 O
metabolites NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
parent NN 0 1 13 O
drug NN 0 1 1 O
or CC 0 0 12 O
by IN 0 0 12 O
other JJ 0 0 12 O
indirect JJ 0 1 1 O
mechanisms NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
detailed JJ 0 1 1 O
understanding NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
events NNS 1 1 12 O
has VBZ 1 0 12 O
become VBN 0 0 12 O
a DT 0 0 12 O
major JJ 0 1 1 O
focus NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
regulatory JJ 0 1 UNK O
agencies NNS 1 1 UNK O
throughout IN 0 0 12 O
the DT 0 0 12 O
world NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacotherapy NN 0 1 UNK O
of IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
and CC 0 0 12 O
liver JJ 0 1 6 O
disorders NNS 1 1 6 O
is VBZ 1 0 12 O
becoming VBG 1 0 12 O
increasingly RB 0 0 1 O
complex JJ 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
recent JJ 0 1 12 O
years NNS 1 1 12 O
with IN 0 0 12 O
the DT 0 0 12 O
advent NN 0 0 UNK O
of IN 0 0 12 O
novel JJ 0 1 13 O
therapeutic JJ 0 1 6 O
agents NNS 1 1 1 O
to TO 0 0 12 O
treat VB 0 1 12 O
a DT 0 0 12 O
host NN 0 1 12 O
of IN 0 0 12 O
disorders NNS 1 1 6 O
including VBG 1 1 1 O
viral JJ 0 1 6 O
hepatitis NN 0 1 6 O
gastrointestinal JJ 0 1 6 O
motility NN 0 1 6 O
disorders NNS 1 1 6 O
inflammatory JJ 0 1 6 O
bowel JJ 0 1 6 O
disease NN 0 1 6 O
and CC 0 0 12 O
others NNS 0 1 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
drug NN 0 1 1 O
reactions NNS 1 1 1 O
has VBZ 1 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

Mechanisms NNP 0 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
toxicity NN 0 1 6 O
or CC 0 0 12 O
intolerance NN 0 1 6 O
. . 0 0 12 O

Classically RB 0 0 UNK O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
reactions NNS 1 1 1 O
had VBD 1 0 12 O
been VBN 1 0 12 O
considered VBN 1 1 1 O
as IN 1 0 12 O
type NN 0 1 1 O
A NNP 0 0 2 O
reactions NNS 1 1 1 O
which WDT 0 0 12 O
are VBP 1 0 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
main JJ 0 1 12 O
pharmacological JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
and CC 0 0 12 O
therefore NN 0 0 1 O
are VBP 1 0 12 O
predictable JJ 0 1 UNK O
. . 0 0 12 O

Such JJ 0 0 1 O
reactions NNS 1 1 1 O
are VBP 1 0 12 O
predictable JJ 0 1 UNK O
reversible JJ 0 1 3 O
and CC 0 0 12 O
usually RB 0 1 12 O
can MD 0 0 12 O
be VB 0 0 12 O
managed VBN 1 1 12 O
by IN 0 0 12 O
lowering VBG 1 1 UNK O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
offending JJ 0 0 UNK O
drug NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
other JJ 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
can MD 0 0 12 O
occur VB 0 1 1 O
which WDT 0 0 12 O
are VBP 1 0 12 O
unrelated JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
main JJ 0 1 12 O
pharmacological JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
type NN 0 1 1 O
B NNP 0 0 2 O
reactions NNS 1 1 1 O
. . 0 0 12 O

Volunteers NNS 0 1 UNK O
in IN 0 0 12 O
study NN 0 1 1 O
9 CD 0 0 2 O
( ( 0 0 2 O
fed VBN 1 1 12 O
; : 0 0 2 O
n CC 0 1 12 O
= VB 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
were VBD 1 0 12 O
aged VBN 1 1 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
; : 0 0 2 O

9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
were VBD 1 0 12 O
men NNS 0 1 13 O
and CC 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
were VBD 1 0 12 O
women NNS 1 1 UNK O
; : 0 0 2 O

mean JJ 0 1 12 O
weight NN 0 1 3 O
was VBD 1 0 12 O
9 CD 0 0 2 O
pounds NNS 1 1 3 O
( ( 0 0 2 O
range NN 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
pounds NNS 1 1 3 O
) ) 0 0 2 O
; : 0 0 2 O

and CC 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
were VBD 1 0 12 O
white JJ 0 1 3 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
was VBD 1 0 12 O
black JJ 0 1 3 O
and CC 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
were VBD 1 0 12 O
white JJ 0 1 3 O
/ JJ 0 0 2 O
American JJ 0 1 2 O
Indian JJ 0 1 UNK O
/ NNP 0 0 2 O
Alaskan NNP 0 1 UNK O
native JJ 0 1 12 O
/ NN 0 0 2 O
Asian NNP 0 1 2 O
. . 0 0 12 O

Volunteers NNS 0 1 UNK O
in IN 0 0 12 O
study NN 0 1 1 O
9 CD 0 0 2 O
( ( 0 0 2 O
fasted VBN 1 1 UNK O
; : 0 0 2 O
n CC 0 1 12 O
= VB 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
were VBD 1 0 12 O
aged VBN 1 1 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
; : 0 0 2 O

9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
were VBD 1 0 12 O
men NNS 0 1 13 O
and CC 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
were VBD 1 0 12 O
women NNS 1 1 UNK O
; : 0 0 2 O

The DT 0 0 2 O
criterion NN 0 1 UNK O
for IN 0 0 12 O
a DT 0 0 12 O
lack NN 0 1 1 O
of IN 0 0 12 O
difference NN 0 1 UNK O
between IN 0 0 12 O
products NNS 1 1 1 O
was VBD 1 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
between IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
for IN 0 0 12 O
the DT 0 0 12 O
fenofibric JJ 0 0 13 B-Drug
acid NN 0 1 14 I-Drug
: : 0 0 2 O
fenofibrate JJ 0 1 16 B-Drug
ratios NNS 1 1 UNK O
for IN 0 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
t NN 0 1 12 O
) ) 0 0 2 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
C NNP 0 0 2 O
( ( 0 0 2 O
max FW 0 0 3 O
. . 0 0 12 O
) ) 0 0 2 O

Tolerability NN 0 1 UNK O
was VBD 1 0 12 O
assessed VBN 1 1 1 O
by IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
( ( 0 0 2 O
AEs NNP 0 1 UNK O
) ) 0 0 2 O
laboratory NN 0 1 1 O
parameters NNS 1 1 1 O
vital JJ 0 1 1 O
signs NNS 1 1 12 O
and CC 0 0 12 O
physical JJ 0 1 1 O
examinations NNS 1 1 1 O
. . 0 0 12 O

Molecular JJ 0 1 UNK O
dynamics NNS 1 1 UNK O
simulations NNS 1 1 UNK O
elucidated VBD 1 0 UNK O
the DT 0 0 12 O
structural JJ 0 1 1 O
consequences NNS 1 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
potentiation NN 0 1 UNK O
- : 0 0 2 O
enhancing VBG 1 1 1 O
mutation NN 0 1 13 O
and CC 0 0 12 O
suggested VBD 1 1 12 O
a DT 0 0 12 O
structural JJ 0 1 1 O
mechanism NN 0 1 13 O
for IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
potentiation NN 0 1 UNK O
via IN 0 0 1 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
transmembrane NN 0 1 UNK O
cavity NN 0 1 3 O
previously RB 0 0 1 O
termed VBD 1 1 UNK O
the DT 0 0 12 O
`` `` 0 0 13 O
linking JJ 0 1 UNK O
tunnel NN 0 1 3 O
. . 0 0 12 O
'' '' 0 0 13 O

These DT 0 0 1 O
results NNS 1 1 1 O
provide VBP 0 1 1 O
a DT 0 0 12 O
unique JJ 0 1 UNK O
structural JJ 0 1 1 O
model NN 0 1 UNK O
for IN 0 0 12 O
independent JJ 0 1 1 O
potentiating NN 0 0 UNK O
and CC 0 0 12 O
inhibitory JJ 0 1 UNK O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
n JJ 0 1 12 O
- : 0 0 2 O
alcohols NNS 1 1 13 O
with IN 0 0 12 O
a DT 0 0 12 O
pLGIC JJ 0 0 UNK O
family NN 0 1 12 O
member NN 0 1 12 O
. . 0 0 12 O

mean JJ 0 1 12 O
weight NN 0 1 3 O
was VBD 1 0 12 O
9 CD 0 0 2 O
pounds NNS 1 1 3 O
( ( 0 0 2 O
range NN 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
pounds NNS 1 1 3 O
) ) 0 0 2 O
; : 0 0 2 O

and CC 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
were VBD 1 0 12 O
white JJ 0 1 3 O
( ( 0 0 2 O
including VBG 1 1 1 O
9 CD 0 0 2 O
Hispanic NNP 0 1 2 O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
were VBD 1 0 12 O
black JJ 0 1 3 O
. . 0 0 12 O

Pulmonary JJ 0 1 7 O
tuberculosis NN 0 1 6 O
: : 0 0 2 O
clinical JJ 0 1 6 O
features NNS 1 1 1 O
and CC 0 0 12 O
patient JJ 0 1 6 O
management NN 0 1 1 O
. . 0 0 12 O

Whereas IN 0 0 UNK O
the DT 0 0 12 O
resting VBG 1 1 3 O
membrane NN 0 1 3 O
potential NN 0 1 1 O
and CC 0 0 12 O
input NN 0 1 13 O
resistance NN 0 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
different JJ 0 1 1 O
between IN 0 0 12 O
control NN 0 1 1 O
and CC 0 0 12 O
epileptic JJ 0 1 13 O
tissue NN 0 1 6 O
the DT 0 0 12 O
reversal NN 0 1 1 O
potential NN 0 1 1 O
( ( 0 0 2 O
E NNP 0 0 2 O
( ( 0 0 2 O
GABA NNP 0 1 UNK O
) ) 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
IPSCs NNP 0 0 UNK O
was VBD 1 0 12 O
significantly RB 0 0 1 O
shifted VBN 1 1 1 O
to TO 0 0 12 O
more RBR 0 1 12 O
positive JJ 0 1 1 O
values NNS 1 1 1 O
in IN 0 0 12 O
SE NNP 0 1 UNK O
rats NNS 1 1 UNK O
with IN 0 0 12 O
regard NN 0 0 1 O
to TO 0 0 12 O
the DT 0 0 12 O
resting VBG 1 1 3 O
membrane NN 0 1 3 O
potential NN 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
article NN 0 1 UNK O
explores VBZ 1 0 UNK O
the DT 0 0 12 O
difference NN 0 1 UNK O
between IN 0 0 12 O
latent JJ 0 1 13 O
TB NNP 0 0 13 O
infection NN 0 1 6 O
and CC 0 0 12 O
active JJ 0 1 1 O
TB NNP 0 0 13 O
disease NN 0 1 6 O
and CC 0 0 12 O
discusses VBZ 1 1 UNK O
the DT 0 0 12 O
pharmacological JJ 0 1 14 O
management NN 0 1 1 O
of IN 0 0 12 O
TB NNP 0 0 13 O
and CC 0 0 12 O
issues NNS 1 1 1 O
around IN 0 0 12 O
adherence NN 0 1 UNK O
to TO 0 0 12 O
medication NN 0 1 6 O
. . 0 0 12 O

Although IN 0 0 12 O
TB NNP 0 0 13 O
is VBZ 1 0 12 O
usually RB 0 1 12 O
managed VBN 1 1 12 O
by IN 0 0 12 O
specialist JJ 0 1 1 O
teams NNS 1 1 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
essential JJ 0 1 13 O
that IN 0 0 12 O
all DT 0 0 12 O
practitioners NNS 1 1 UNK O
have VBP 0 0 12 O
an DT 0 0 12 O
understanding NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
signs NNS 1 1 12 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
disease NN 0 1 6 O
to TO 0 0 12 O
ensure VB 0 1 1 O
early JJ 0 1 12 O
referral NN 0 1 1 O
and CC 0 0 12 O
accurate JJ 0 1 1 O
diagnosis NN 0 1 6 O
. . 0 0 12 O

Pharmacologic JJ 0 1 UNK O
experiments NNS 1 1 UNK O
and CC 0 0 12 O
quantitative JJ 0 1 1 O
reverse NN 0 1 1 O
transcriptase NN 0 1 UNK O
polymerase NN 0 1 UNK O
chain NN 0 1 16 O
reaction NN 0 1 1 O
( ( 0 0 2 O
RT NNP 0 1 UNK O
- : 0 0 2 O
PCR NN 0 1 14 O
) ) 0 0 2 O
showed VBD 1 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
observed JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
epileptic JJ 0 1 13 O
tissue NN 0 1 6 O
were VBD 1 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
decreased VBN 1 1 1 O
ratio NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
main JJ 0 1 12 O
Cl NNP 0 1 13 O
( ( 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
extrusion NN 0 1 UNK O
transporter NN 0 1 UNK O
( ( 0 0 2 O
K NNP 0 1 2 O
( ( 0 0 2 O
+ NNP 0 0 2 O
) ) 0 0 2 O
- : 0 0 2 O
Cl NN 0 1 13 O
( ( 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
cotransporter NN 0 0 UNK O
KCC9 NNP 0 0 UNK O
) ) 0 0 2 O
to TO 0 0 12 O
the DT 0 0 12 O
main JJ 0 1 12 O
Cl NNP 0 1 13 O
( ( 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
uptake VBP 0 1 14 O
transporter NN 0 1 UNK O
( ( 0 0 2 O
Na NNP 0 1 13 O
( ( 0 0 2 O
+ NNP 0 0 2 O
) ) 0 0 2 O
- : 0 0 2 O
K NNP 0 1 2 O
( ( 0 0 2 O
+ NNP 0 0 2 O
) ) 0 0 2 O
- : 0 0 2 O
9Cl CD 0 0 UNK O
( ( 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
cotransporter NN 0 0 UNK O
NKCC9 NNP 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

DDI NNP 0 1 13 O
management NN 0 1 1 O
guidelines NNS 1 1 13 O
are VBP 1 0 12 O
often RB 0 1 12 O
inadequate JJ 0 1 1 O
and CC 0 0 12 O
clear JJ 0 1 12 O
management NN 0 1 1 O
options NNS 1 1 1 O
are VBP 1 0 12 O
lacking VBG 1 1 13 O
which WDT 0 0 12 O
attributes VBZ 1 1 UNK O
to TO 0 0 12 O
overriding VBG 1 1 UNK O
of IN 0 0 12 O
DDI NNP 0 1 13 O
signals NNS 1 1 1 O
. . 0 0 12 O

EGGB NNP 0 0 UNK B-Drug
showed VBD 1 1 12 O
beneficial JJ 0 0 UNK O
neuroprotective JJ 0 1 13 O
effects NNS 1 1 1 O
against IN 0 0 12 O
neuronal JJ 0 1 13 O
apoptosis NN 0 1 UNK O
which WDT 0 0 12 O
might MD 0 0 12 O
be VB 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
improving VBG 1 1 1 O
the DT 0 0 12 O
structures NNS 1 1 1 O
of IN 0 0 12 O
neuron NN 0 1 13 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
subcellular JJ 0 0 UNK O
organelles NNS 1 1 UNK O
enhancing VBG 1 1 1 O
cellular JJ 0 1 13 O
proliferative JJ 0 1 13 O
activity NN 0 1 1 O
and CC 0 0 12 O
inhibiting VBG 1 1 UNK O
caspase NN 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
overexpression NN 0 1 UNK O
in IN 0 0 12 O
neurons NNS 1 1 UNK O
. . 0 0 12 O

Clarity NN 0 1 UNK O
and CC 0 0 12 O
applicability NN 0 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
management NN 0 1 1 O
guidelines NNS 1 1 13 O
: : 0 0 2 O
a DT 0 0 12 O
systematic JJ 0 1 UNK O
appraisal NN 0 0 UNK O
by IN 0 0 12 O
general JJ 0 1 1 O
practitioners NNS 1 1 UNK O
and CC 0 0 12 O
community NN 0 1 12 O
pharmacists NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
Netherlands NNP 0 1 UNK O
. . 0 0 12 O

Despite IN 0 0 12 O
the DT 0 0 12 O
availability NN 0 1 UNK O
and CC 0 0 12 O
daily JJ 0 1 12 O
use NN 0 1 1 O
of IN 0 0 12 O
computerized JJ 0 0 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
surveillance NN 0 1 1 O
systems NNS 1 1 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
potentially RB 0 0 1 O
relevant JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
( ( 0 0 2 O
DDIs NNP 0 1 UNK O
) ) 0 0 2 O
continues VBZ 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
clarity NN 0 1 UNK O
and CC 0 0 12 O
applicability NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
management NN 0 1 1 O
guidelines NNS 1 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
DDIs NNP 0 1 UNK O
were VBD 1 0 12 O
appraised VBN 1 0 UNK O
using VBG 1 1 1 O
the DT 0 0 12 O
appropriate JJ 0 1 1 O
two CD 0 1 12 O
domains NNS 1 1 UNK O
- : 0 0 2 O
'Clarity NN 0 1 UNK O
and CC 0 0 12 O
presentation NN 0 1 1 O
' '' 0 0 2 O
and CC 0 0 12 O
'Applicability NNP 0 1 UNK O
' '' 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
validated JJ 0 0 UNK O
Appraisal NNP 0 0 UNK O
of IN 0 0 12 O
Guidelines NNP 0 1 UNK O
for IN 0 0 12 O
Research NNP 0 1 UNK O
and CC 0 0 12 O
Evaluation NNP 0 1 2 O
( ( 0 0 2 O
AGREE NNP 0 1 UNK O
) ) 0 0 2 O
Instrument NNP 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
appraisal NN 0 0 UNK O
was VBD 1 0 12 O
performed VBN 1 1 1 O
by IN 0 0 12 O
9 CD 0 0 2 O
community NN 0 1 12 O
pharmacists NNS 1 1 UNK O
and CC 0 0 12 O
9 CD 0 0 2 O
general JJ 0 1 1 O
practitioners NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
aim NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
to TO 0 0 12 O
assess VB 0 1 1 O
the DT 0 0 12 O
clarity NN 0 1 UNK O
and CC 0 0 12 O
applicability NN 0 1 UNK O
of IN 0 0 12 O
guidelines NNS 1 1 13 O
for IN 0 0 12 O
the DT 0 0 12 O
management NN 0 1 1 O
of IN 0 0 12 O
potentially RB 0 0 1 O
harmful JJ 0 0 13 O
DDIs NNP 0 1 UNK O
. . 0 0 12 O

We PRP 0 0 12 O
selected VBD 1 1 UNK O
9 CD 0 0 2 O
DDIs NNP 0 1 UNK O
that WDT 0 0 12 O
are VBP 1 0 12 O
potentially RB 0 0 1 O
harmful JJ 0 0 13 O
for IN 0 0 12 O
patients NNS 1 1 6 O
and CC 0 0 12 O
frequently RB 0 1 1 O
occur VBP 0 1 1 O
in IN 0 0 12 O
community NN 0 1 12 O
pharmacy NN 0 1 1 O
practice NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
Netherlands NNP 0 1 UNK O
. . 0 0 12 O

[ JJ 0 0 2 O
Protective NNP 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
ginseng NN 0 1 14 B-Drug
- : 0 0 2 O
ginko NN 0 1 UNK B-Drug
extracts VBZ 1 1 UNK O
combination NN 0 1 1 O
on IN 0 0 12 O
rat NN 0 1 13 O
primary NN 0 1 1 O
cultured VBD 1 0 14 O
neurons NNS 1 1 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
Abeta NNP 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
) ) 0 0 2 O
] NN 0 0 2 O
. . 0 0 12 O

To TO 0 0 2 O
observe VB 0 1 1 O
the DT 0 0 12 O
injury NN 0 1 6 O
in IN 0 0 12 O
rat NN 0 1 13 O
primary NN 0 1 1 O
cultured VBD 1 0 14 O
neurons NNS 1 1 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
Abeta NNP 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
) ) 0 0 2 O
and CC 0 0 12 O
the DT 0 0 12 O
protective JJ 0 0 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
ginseng NN 0 1 14 B-Drug
and CC 0 0 12 O
ginko NN 0 1 UNK B-Drug
extracts NNS 1 1 UNK O
. . 0 0 12 O

Primary JJ 0 1 2 O
neurons NNS 1 1 UNK O
were VBD 1 0 12 O
induced VBN 1 1 6 O
by IN 0 0 12 O
Abeta NNP 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
) ) 0 0 2 O
to TO 0 0 12 O
establish VB 0 1 UNK O
the DT 0 0 12 O
cell NN 0 1 1 O
model NN 0 1 UNK O
of IN 0 0 12 O
toxic JJ 0 1 1 O
injury NN 0 1 6 O
. . 0 0 12 O

Using VBG 0 1 2 O
flow JJ 0 1 1 O
cytometry NN 0 1 UNK O
with IN 0 0 12 O
Annexin NNP 0 1 UNK O
V NNP 0 0 2 O
- : 0 0 2 O
FITC NNP 0 1 UNK O
/ NNP 0 0 2 O
PI NNP 0 1 UNK O
double JJ 0 1 3 O
staining VBG 1 1 13 O
MTP NNP 0 1 13 O
assay VBP 0 1 14 O
transmission NN 0 1 1 O
electron NN 0 1 13 O
microscopy NN 0 1 16 O
and CC 0 0 12 O
Western JJ 0 1 2 O
blot NN 0 0 UNK O
the DT 0 0 12 O
appropriate JJ 0 1 1 O
concentration NN 0 1 1 O
and CC 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
AP NNP 0 1 2 O
for IN 0 0 12 O
cell NN 0 1 1 O
model NN 0 1 UNK O
establishment NN 0 0 13 O
were VBD 1 0 12 O
determined VBN 1 1 1 O
. . 0 0 12 O

Whether NNP 0 0 12 O
determination NN 0 1 13 O
of IN 0 0 12 O
cannabinoid JJ 0 1 UNK B-Drug_n
conjugates NNS 1 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
useful JJ 0 1 UNK O
is VBZ 1 0 12 O
a DT 0 0 12 O
matter NN 0 0 12 O
of IN 0 0 12 O
further JJ 0 1 1 O
consideration NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
apoptotic JJ 0 1 UNK O
rate NN 0 1 1 O
was VBD 1 0 12 O
increased VBN 1 1 1 O
significantly RB 0 0 1 O
after IN 0 0 12 O
neurons NNS 1 1 UNK O
were VBD 1 0 12 O
induced VBN 1 1 6 O
by IN 0 0 12 O
9 CD 0 0 2 O
micromol NNS 0 1 UNK O
x JJ 0 0 10 O
L NNP 0 1 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
Abeta NNP 0 1 UNK B-Drug_n
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
( ( 0 0 2 O
P NNP 0 1 2 O
< NNP 0 0 16 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

EGGB NNP 0 0 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
L NNP 0 1 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
significantly RB 0 0 1 O
enhanced VBD 1 1 1 O
the DT 0 0 12 O
proliferative JJ 0 1 13 O
activity NN 0 1 1 O
( ( 0 0 2 O
P NNP 0 1 2 O
< NNP 0 0 16 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Meanwhile RB 0 0 12 O
EGGB NNP 0 0 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
L NNP 0 1 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
inhibited VBD 1 1 13 O
neuronal JJ 0 1 13 O
apoptosis NN 0 1 UNK O
and CC 0 0 12 O
caspase NN 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
overexpression NN 0 1 UNK O
and CC 0 0 12 O
improved VBN 1 1 1 O
cellular JJ 0 1 13 O
ultrastructure NN 0 1 UNK O
remarkably RB 0 0 UNK O
( ( 0 0 2 O
P NNP 0 1 2 O
< VBZ 0 0 16 O
9 CD 0 0 2 O
P NNP 0 1 2 O
< NNP 0 0 16 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

o SYM 0 1 2 B-Drug_n
- : 0 0 2 O
Cymen NNP 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
ol NN 0 0 UNK I-Drug_n
/ NNP 0 0 2 O
zinc NNP 0 1 14 B-Drug
chloride NN 0 1 14 I-Drug
in IN 0 0 12 O
toothpaste NN 0 1 UNK O
showed VBD 1 1 12 O
greater JJR 1 1 1 O
effects NNS 1 1 1 O
than IN 0 0 12 O
placebo NN 0 1 13 O
( ( 0 0 2 O
9s CD 1 1 UNK O
log9 NN 0 0 UNK O
kill=9 NN 0 1 UNK O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
respectively RB 0 0 1 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
zinc NN 0 1 14 B-Drug
/ NNP 0 0 2 O
o SYM 0 1 2 B-Drug_n
- : 0 0 2 O
cymen NNS 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
ol NN 0 0 UNK I-Drug_n
system NN 0 1 1 O
has VBZ 1 0 12 O
direct JJ 0 1 1 O
antimicrobial JJ 0 1 14 O
effects NNS 1 1 1 O
and CC 0 0 12 O
inhibits VBZ 1 1 UNK O
oral JJ 0 1 6 O
disease NN 0 1 6 O
- : 0 0 2 O
related JJ 0 1 1 O
processes NNS 1 1 1 O
. . 0 0 12 O

Synergistic JJ 0 1 UNK O
effects NNS 1 1 1 O
were VBD 1 0 12 O
seen VBN 1 1 12 O
against IN 0 0 12 O
anaerobes NNS 1 1 13 O
. . 0 0 12 O

A DT 0 0 2 O
system NN 0 1 1 O
combining VBG 1 1 UNK O
o SYM 0 1 2 B-Drug_n
- : 0 0 2 O
cymen NNS 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
ol NN 0 0 UNK I-Drug_n
and CC 0 0 12 O
zinc NN 0 1 14 B-Drug
shows NNS 1 1 12 O
properties NNS 1 1 UNK O
desirable JJ 0 0 UNK O
for IN 0 0 12 O
incorporation NN 0 1 UNK O
in IN 0 0 12 O
toothpastes NNS 1 1 UNK O
. . 0 0 12 O

However RB 0 0 1 O
antibacterial JJ 0 1 UNK O
activity NN 0 1 1 O
changed VBD 1 1 12 O
also RB 0 0 12 O
by IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
these DT 0 0 12 O
standard JJ 0 1 1 O
antibiotics NNS 1 1 6 B-Group
and CC 0 0 12 O
essential JJ 0 1 13 O
oils NNS 1 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
plants NNS 1 1 13 O
. . 0 0 12 O

Improvement NN 0 1 2 O
of IN 0 0 12 O
colchicine JJ 0 1 0 B-Drug
oral JJ 0 1 6 O
bioavailability NN 0 1 UNK O
by IN 0 0 12 O
incorporating VBG 1 0 UNK O
eugenol NN 0 1 UNK B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
nanoemulsion NN 0 1 UNK O
as IN 1 0 12 O
an DT 0 0 12 O
oil NN 0 1 3 O
excipient NN 0 1 UNK O
and CC 0 0 12 O
enhancer NN 0 1 UNK O
. . 0 0 12 O

mutans NNS 0 0 13 O
and CC 0 0 12 O
E NNP 0 0 2 O
. . 0 0 12 O

Slurried NNP 0 1 UNK O
toothpastes VBZ 0 1 UNK O
containing VBG 1 1 1 O
the DT 0 0 12 O
system NN 0 1 1 O
were VBD 1 0 12 O
assessed VBN 1 1 1 O
in IN 0 0 12 O
kill NN 0 1 12 O
time NN 0 1 12 O
assays NNS 1 1 13 O
against IN 0 0 12 O
S NNP 0 1 2 O
. . 0 0 12 O

inhibition NN 0 1 13 O
of IN 0 0 12 O
P NNP 0 1 2 O
. . 0 0 12 O

Synergy NNP 0 0 UNK O
was VBD 1 0 12 O
investigated VBN 1 1 1 O
by IN 0 0 12 O
checkerboard JJ 0 0 UNK O
MIC NNP 0 1 13 O
/ NNP 0 0 2 O
MBC NNP 0 1 UNK O
; : 0 0 2 O

mutans NNS 0 0 13 O
glycolysis NN 0 1 UNK O
were VBD 1 0 12 O
investigated VBN 1 1 1 O
. . 0 0 12 O

gingivalis JJ 0 0 UNK O
protease NN 0 1 13 O
activity NN 0 1 1 O
and CC 0 0 12 O
S NNP 0 1 2 O
. . 0 0 12 O

in IN 0 0 12 O
combination NN 0 1 1 O
in IN 0 0 12 O
simple JJ 0 1 1 O
solutions NNS 1 1 UNK O
and CC 0 0 12 O
toothpaste NN 0 1 UNK O
formulations NNS 1 1 UNK O
. . 0 0 12 O

Antimicrobial JJ 0 1 7 O
effects NNS 1 1 1 O
of IN 0 0 12 O
o JJ 0 1 2 B-Drug_n
- : 0 0 2 O
cymen NNS 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
ol NN 0 0 UNK I-Drug_n
and CC 0 0 12 O
zinc NNP 0 1 14 B-Drug
alone RB 0 1 12 O
& CC 0 0 2 O

o SYM 0 1 2 B-Drug_n
- : 0 0 2 O
Cymen NNP 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
ol NN 0 0 UNK I-Drug_n
and CC 0 0 12 O
zinc NN 0 1 14 B-Drug
gluconate NN 0 1 14 I-Drug
minimum JJ 0 1 1 O
inhibitory JJ 0 1 UNK O
concentration NN 0 1 1 O
( ( 0 0 2 O
MIC NNP 0 1 13 O
) ) 0 0 2 O
and CC 0 0 12 O
minimum JJ 0 1 1 O
bactericidal JJ 0 1 UNK O
concentration NN 0 1 1 O
( ( 0 0 2 O
MBC NNP 0 1 UNK O
) ) 0 0 2 O
were VBD 1 0 12 O
determined VBN 1 1 1 O
against IN 0 0 12 O
Streptococcus NNP 0 1 14 O
mutans NNS 0 0 13 O
Actinomyces NNP 0 1 UNK O
viscosus NN 0 0 UNK O
Porphyromonas NNP 0 1 UNK O
gingivalis NN 0 0 UNK O
Fusobacterium NNP 0 1 UNK O
nucleatum NN 0 0 16 O
and CC 0 0 12 O
Candida NNP 0 1 6 O
albicans NNS 0 0 14 O
. . 0 0 12 O

This DT 0 0 2 O
study NN 0 1 1 O
aimed VBD 1 1 UNK O
to TO 0 0 12 O
evaluate VB 0 1 1 O
antimicrobial JJ 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
o JJ 0 1 2 B-Drug_n
- : 0 0 2 O
cymen NNS 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
ol NN 0 0 UNK I-Drug_n
/ NNP 0 0 2 O
zinc NN 0 1 14 B-Drug
system NN 0 1 1 O
. . 0 0 12 O

Abeta NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
) ) 0 0 2 O
could MD 0 0 12 O
significantly RB 0 0 1 O
induce VB 0 1 6 O
primary JJ 0 1 1 O
cultured JJ 0 0 14 O
neurons NNS 1 1 UNK O
to TO 0 0 12 O
apoptosis VB 0 1 UNK O
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

Aromatherapy NNP 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
claims NNS 1 0 1 O
made VBN 1 1 12 O
for IN 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
the DT 0 0 12 O
subject NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
second JJ 0 1 12 O
article NN 0 1 UNK O
in IN 0 0 12 O
our PRP$ 0 0 12 O
six CD 0 1 12 O
- : 0 0 2 O
part NN 0 1 12 O
series NN 0 1 12 O
on IN 0 0 12 O
alternative JJ 0 1 1 O
and CC 0 0 12 O
complementary JJ 0 0 UNK O
therapies NNS 1 1 6 O
. . 0 0 12 O

It PRP 0 0 12 O
makes VBZ 1 1 12 O
scents NNS 1 1 UNK O
. . 0 0 12 O

Although IN 0 0 12 O
general JJ 0 1 1 O
criteria NNS 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
and CC 0 0 12 O
reporting NN 0 1 1 O
of IN 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
quality NN 0 1 1 O
clinical JJ 0 1 6 O
practice NN 0 1 UNK O
guidelines NNS 1 1 13 O
have VBP 0 0 12 O
been VBN 1 0 12 O
identified VBN 1 1 1 O
it PRP 0 0 12 O
appears VBZ 1 1 12 O
these DT 0 0 12 O
have VBP 0 0 12 O
not RB 0 1 12 O
yet RB 0 0 12 O
been VBN 1 0 12 O
applied VBN 1 1 1 O
to TO 0 0 12 O
DDI NNP 0 1 13 O
management NN 0 1 1 O
guidelines NNS 1 1 13 O
. . 0 0 12 O

Standard NNP 0 1 2 O
antibiotic JJ 0 1 6 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
Gentamicin NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
microg NN 0 0 UNK O
) ) 0 0 2 O
Cephalothin NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
microg NN 0 0 UNK O
) ) 0 0 2 O
Ceftriaxone NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
microg NN 0 0 UNK O
) ) 0 0 2 O
Nystatin NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
U NNP 0 0 2 O
) ) 0 0 2 O
discs NN 1 1 3 O
were VBD 1 0 12 O
used VBN 1 1 12 O
for IN 0 0 12 O
comparison NN 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
antimicrobial JJ 0 1 14 O
activities NNS 1 1 1 O
of IN 0 0 12 O
essential JJ 0 1 13 O
oils NNS 1 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
plants NNS 1 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
antibacterial JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
essential JJ 0 1 13 O
oils NNS 1 1 13 O
of IN 0 0 12 O
these DT 0 0 12 O
plants NNS 1 1 13 O
was VBD 1 0 12 O
researched VBN 1 1 UNK O
by IN 0 0 12 O
effects NNS 1 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
was VBD 1 0 12 O
used VBN 1 1 12 O
together RB 0 1 12 O
with IN 0 0 12 O
these DT 0 0 12 O
standard JJ 0 1 1 O
antibiotics NNS 1 1 6 B-Group
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

Davis NNP 0 0 19 O
Cumium NNP 0 0 UNK O
cyminum NN 0 0 UNK O
L. NNP 0 1 19 O
Mentha NNP 0 1 UNK O
piperita NN 0 0 UNK O
L NNP 0 1 2 O
. . 0 0 12 O

The DT 0 0 2 O
treatment NN 0 1 6 O
of IN 0 0 12 O
coinfected JJ 0 0 UNK O
patients NNS 1 1 6 O
requires VBZ 1 0 1 O
antituberculosis NN 0 1 UNK B-Group
and CC 0 0 12 O
antiretroviral JJ 0 0 UNK B-Group
drugs NNS 1 1 6 I-Group
to TO 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concomittantly RB 0 0 UNK O
; : 0 0 2 O

were VBD 1 0 12 O
shown VBN 1 1 1 O
antimicrobial JJ 0 1 14 O
activity NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
range NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mm NN 0 0 18 O
9 CD 0 0 2 O
microl NN 0 0 UNK O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
inhibition NN 0 1 13 O
zone NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
microorganisms NNS 1 1 13 O
tested VBD 1 1 1 O
using VBG 1 1 1 O
disc JJ 0 1 3 O
diffusion NN 0 1 1 O
method NN 0 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
other JJ 0 0 12 O
examples NNS 1 1 UNK O
the DT 0 0 12 O
interaction NN 0 1 UNK O
can MD 0 0 12 O
be VB 0 0 12 O
mechanistic JJ 0 1 UNK O
in IN 0 0 12 O
which WDT 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
more JJR 0 1 12 O
drugs NNS 1 1 6 O
when WRB 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered JJ 0 1 1 O
potentiate NN 0 0 UNK O
each DT 0 0 12 O
other JJ 0 0 12 O
's POS 0 1 12 O
actions NNS 1 1 UNK O
without IN 0 0 12 O
any DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
drug NN 0 1 1 O
levels NNS 1 1 1 O
termed VBN 1 1 UNK O
pharmacodynamic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Further JJ 0 1 2 O
research NN 0 1 13 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
to TO 0 0 12 O
provide VB 0 1 1 O
a DT 0 0 12 O
scientifically RB 0 0 UNK O
supported VBN 1 1 1 O
recommendation NN 0 1 1 O
for IN 0 0 12 O
other JJ 0 0 12 O
clinical JJ 0 1 6 O
applications NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
human JJ 0 1 1 O
immunodeficiency NN 0 1 14 O
virus NN 0 1 6 O
( ( 0 0 2 O
HIV NNP 0 1 6 O
) ) 0 0 2 O
epidemic NN 0 1 13 O
has VBZ 1 0 12 O
allowed VBN 1 1 12 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
tuberculosis NN 0 1 6 O
to TO 0 0 12 O
rise VB 0 0 1 O
globally RB 0 0 UNK O
and CC 0 0 12 O
particularly RB 0 0 1 O
in IN 0 0 12 O
sub JJ 0 1 1 O
- : 0 0 2 O
Saharan NN 0 1 UNK O
Africa NNP 0 1 UNK O
. . 0 0 12 O

Optimizing VBG 0 0 UNK O
the DT 0 0 12 O
utility NN 0 1 1 O
of IN 0 0 12 O
PHAs NNP 0 1 UNK O
requires VBZ 1 0 1 O
a DT 0 0 12 O
thorough JJ 0 0 1 O
understanding NN 0 1 1 O
of IN 0 0 12 O
older JJR 1 1 12 O
adults NNS 1 1 13 O
' POS 0 0 2 O
needs NNS 1 1 12 O
preferences NNS 1 1 1 O
and CC 0 0 12 O
practices NNS 1 1 UNK O
. . 0 0 12 O

Personal JJ 0 1 UNK O
health NN 0 1 1 O
applications NNS 1 1 UNK O
( ( 0 0 2 O
PHAs NNP 0 1 UNK O
) ) 0 0 2 O
show VBP 0 1 12 O
promise JJ 0 1 UNK O
assisting NN 0 1 13 O
in IN 0 0 12 O
medication NN 0 1 6 O
self PRP 0 1 12 O
- : 0 0 2 O
management NN 0 1 1 O
but CC 0 0 12 O
adoption NN 0 1 UNK O
of IN 0 0 12 O
new JJ 0 1 12 O
computer NN 0 1 1 O
technologies NNS 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
population NN 0 1 13 O
is VBZ 1 0 12 O
challenging VBG 1 1 UNK O
. . 0 0 12 O

Older JJR 0 1 UNK O
adults NNS 1 1 13 O
often RB 0 1 12 O
have VBP 0 0 12 O
multiple JJ 0 1 1 O
chronic JJ 0 1 6 O
problems NNS 1 1 1 O
requiring VBG 1 0 1 O
them PRP 0 0 12 O
to TO 0 0 12 O
manage VB 0 0 1 O
complex JJ 0 1 1 O
medication NN 0 1 6 O
regimens NNS 1 1 UNK O
overseen JJ 0 0 UNK O
by IN 0 0 12 O
various JJ 0 1 1 O
clinicians NNS 1 1 UNK O
. . 0 0 12 O

Older JJR 0 1 UNK O
adults NNS 1 1 13 O
with IN 0 0 12 O
multi JJ 0 1 16 O
- : 0 0 2 O
morbidity NN 0 1 13 O
: : 0 0 2 O
medication NN 0 1 6 O
management NN 0 1 1 O
processes NNS 1 1 1 O
and CC 0 0 12 O
design NN 0 1 UNK O
implications NNS 1 0 UNK O
for IN 0 0 12 O
personal JJ 0 1 12 O
health NN 0 1 1 O
applications NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
casein NN 0 1 UNK O
derivatives NNS 1 1 13 O
specifically RB 0 0 1 O
CCP NNP 0 1 UNK B-Drug_n
- : 0 0 2 O
ACP NN 0 0 UNK I-Drug_n
in IN 0 0 12 O
caries NNS 0 1 13 O
prevention NN 0 1 1 O
and CC 0 0 12 O
lesion NN 0 1 6 O
reversal NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
supported VBN 1 1 1 O
by IN 0 0 12 O
many JJ 0 0 12 O
controlled VBN 1 1 1 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
. . 0 0 12 O

Hydrolysis NN 0 1 UNK O
of IN 0 0 12 O
cannabis NN 0 1 13 O
conjugates NNS 1 1 UNK O
may MD 0 0 1 O
occur VB 0 1 1 O
during IN 0 0 12 O
storage NN 0 1 UNK O
of IN 0 0 12 O
blood NN 0 1 6 O
samples NNS 1 1 UNK O
and CC 0 0 12 O
processing NN 0 1 13 O
of IN 0 0 12 O
specimens NNS 1 1 1 O
for IN 0 0 12 O
analysis NN 0 1 1 O
; : 0 0 2 O

knowledge NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
stability NN 0 1 1 O
of IN 0 0 12 O
cannabinoids NNS 0 1 UNK B-Drug_n
in IN 0 0 12 O
forensic JJ 0 1 UNK O
specimens NNS 1 1 1 O
is VBZ 1 0 12 O
still RB 0 0 12 O
poor JJ 0 1 12 O
. . 0 0 12 O

challenges NNS 1 1 UNK O
include VBP 0 1 1 O
pill NN 0 1 6 O
burden NN 0 1 1 O
and CC 0 0 12 O
patient JJ 0 1 6 O
compliance NN 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
overlapping VBG 1 1 1 O
toxic JJ 0 1 1 O
effects NNS 1 1 1 O
and CC 0 0 12 O
immune JJ 0 1 6 O
reconstitution NN 0 0 UNK O
inflammatory JJ 0 1 6 O
syndrome NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
panorama NN 0 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
induced JJ 0 1 6 O
side NN 0 1 3 O
effects NNS 1 1 1 O
causing VBG 1 1 1 O
ototoxicity NN 0 1 UNK O
or CC 0 0 12 O
symptoms NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
tinnitus NN 0 1 13 O
or CC 0 0 12 O
dizziness NN 0 1 6 O
and CC 0 0 12 O
vertigo NN 0 1 6 O
has VBZ 1 0 12 O
enlarged VBN 1 1 3 O
in IN 0 0 12 O
recent JJ 0 1 12 O
years NNS 1 1 12 O
thanks NNS 0 1 UNK O
to TO 0 0 12 O
a DT 0 0 12 O
better JJR 1 1 12 O
knowledge NN 0 1 1 O
and CC 0 0 12 O
a DT 0 0 12 O
more RBR 0 1 12 O
specific JJ 0 1 1 O
attention NN 0 1 12 O
of IN 0 0 12 O
pharmaceutical JJ 0 1 13 O
firms NNS 1 1 UNK O
and CC 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
control NN 0 1 1 O
institutions NNS 1 1 UNK O
. . 0 0 12 O

today NN 0 1 12 O
cannabis NN 0 1 13 O
is VBZ 1 0 12 O
the DT 0 0 12 O
most RBS 0 0 12 O
widely RB 0 0 1 O
used JJ 0 1 12 O
illegal JJ 0 1 UNK O
drug NN 0 1 1 O
all DT 0 0 12 O
over IN 0 1 12 O
the DT 0 0 12 O
world NN 0 1 12 O
. . 0 0 12 O

Nevertheless RB 0 0 1 O
the DT 0 0 12 O
interpretation NN 0 1 1 O
of IN 0 0 12 O
cannabis JJ 0 1 13 O
findings NNS 1 1 1 O
in IN 0 0 12 O
blood NN 0 1 6 O
with IN 0 0 12 O
regard NN 0 0 1 O
to TO 0 0 12 O
consumption VB 0 1 1 O
behaviour NN 0 1 UNK O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
estimating VBG 1 1 UNK O
the DT 0 0 12 O
elapsed JJ 0 1 UNK O
time NN 0 1 12 O
since IN 0 1 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
cannabis NN 0 1 13 O
use NN 0 1 1 O
is VBZ 1 0 12 O
still RB 0 0 12 O
a DT 0 0 12 O
very RB 0 1 12 O
challenging JJ 0 1 UNK O
task NN 0 1 16 O
. . 0 0 12 O

[ JJ 0 0 2 O
Variability NNP 0 1 UNK O
of IN 0 0 12 O
cannabinoid JJ 0 1 UNK B-Drug_n
findings NNS 1 1 1 O
in IN 0 0 12 O
blood NN 0 1 6 O
] NN 0 0 2 O
. . 0 0 12 O

Cannabis NN 0 1 UNK O
products NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
administered VBN 1 1 1 O
for IN 0 0 12 O
many JJ 0 0 12 O
centuries NNS 1 1 UNK O
; : 0 0 2 O

Polymorphic JJ 0 1 UNK O
enzymes NNS 1 1 14 O
are VBP 1 0 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
phase NN 0 1 1 O
- : 0 0 2 O
I PRP 0 1 12 O
- : 0 0 2 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
THC NNP 0 1 UNK B-Drug_n
. . 0 0 12 O

The DT 0 0 2 O
standardized JJ 0 0 UNK O
domain NN 0 1 UNK O
scores NNS 1 1 1 O
and CC 0 0 12 O
mean JJ 0 1 12 O
item NN 0 1 UNK O
scores NNS 1 1 1 O
for IN 0 0 12 O
'Clarity NN 0 1 UNK O
and CC 0 0 12 O
presentation NN 0 1 1 O
' '' 0 0 2 O
and CC 0 0 12 O
'Applicability NNP 0 1 UNK O
' POS 0 0 2 O
were VBD 1 0 12 O
compared VBN 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
wide JJ 0 1 3 O
variation NN 0 1 1 O
of IN 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
even RB 0 0 12 O
in IN 0 0 12 O
experimental JJ 0 1 UNK O
studies NNS 1 1 1 O
. . 0 0 12 O

Different JJ 0 1 UNK O
chemical JJ 0 1 13 O
structures NNS 1 1 1 O
of IN 0 0 12 O
precursors NNS 1 1 UNK O
smoking VBG 1 1 12 O
dynamics NNS 1 1 UNK O
pyrolysis NN 0 0 UNK O
of IN 0 0 12 O
phytocannabinoids NNS 0 0 UNK B-Drug_n
and CC 0 0 12 O
frequency NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
use NN 0 1 1 O
affect VBP 0 1 1 O
the DT 0 0 12 O
amount NN 0 1 1 O
of IN 0 0 12 O
THC NNP 0 1 UNK B-Drug_n
absorbed VBD 1 0 3 O
. . 0 0 12 O

Our PRP$ 0 0 2 O
findings NNS 1 1 1 O
illustrate VBP 0 0 UNK O
a DT 0 0 12 O
simple JJ 0 1 1 O
yet RB 0 0 12 O
powerful JJ 0 1 UNK O
neuromodulatory JJ 0 0 UNK O
mechanism NN 0 1 13 O
to TO 0 0 12 O
shift VB 0 1 1 O
the DT 0 0 12 O
balance NN 0 1 1 O
between IN 0 0 12 O
background NN 0 1 12 O
and CC 0 0 12 O
stimulus JJ 0 1 1 O
- : 0 0 2 O
evoked JJ 0 1 13 O
signals NNS 1 1 1 O
. . 0 0 12 O

All DT 0 0 2 O
DDI NNP 0 1 13 O
management NN 0 1 1 O
guidelines NNS 1 1 13 O
were VBD 1 0 12 O
generally RB 0 0 1 O
found VBN 1 1 12 O
to TO 0 0 12 O
score RB 0 1 12 O
well RB 0 1 12 O
on IN 0 0 12 O
'Clarity NN 0 1 UNK O
and CC 0 0 12 O
presentation NN 0 1 1 O
' '' 0 0 2 O
but CC 0 0 12 O
poorly RB 0 1 1 O
with IN 0 0 12 O
respect NN 0 1 1 O
to TO 0 0 12 O
'Applicability NNP 0 1 UNK O
' POS 0 0 2 O
( ( 0 0 2 O
standardized JJ 0 0 UNK O
domain NN 0 1 UNK O
scores NNS 1 1 1 O
9 CD 0 0 2 O
vs RB 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

CPP NNP 0 1 UNK B-Drug_n
- : 0 0 2 O
ACP NNP 0 0 UNK I-Drug_n
complex NN 0 1 1 I-Drug_n
as IN 1 0 12 O
a DT 0 0 12 O
new JJ 0 1 12 O
adjunctive JJ 0 1 13 O
agent NN 0 1 1 O
for IN 0 0 12 O
remineralisation NN 0 1 UNK O
: : 0 0 2 O
a DT 0 0 12 O
review NN 0 1 2 O
. . 0 0 12 O

The DT 0 0 2 O
dosage NN 0 1 0 O
regimen NNS 0 1 6 O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
need VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
into IN 0 0 12 O
consideration NN 0 1 1 O
when WRB 0 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
neferine NN 0 1 UNK B-Drug_n
. . 0 0 12 O

Inhibitory JJ 0 1 UNK O
interneurons NNS 0 1 UNK O
across IN 0 0 12 O
diverse NN 0 1 UNK O
brain NN 0 1 6 O
regions NNS 1 1 1 O
commonly RB 0 0 UNK O
exhibit VBP 0 1 1 O
spontaneous JJ 0 1 1 O
spiking NN 0 0 3 O
activity NN 0 1 1 O
even RB 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
external JJ 0 1 1 O
stimuli NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
extracts NNS 1 1 UNK O
of IN 0 0 12 O
ginseng NN 0 1 14 B-Drug
and CC 0 0 12 O
ginko NN 0 1 UNK B-Drug
( ( 0 0 2 O
EGGB NNP 0 0 UNK B-Drug
) ) 0 0 2 O
on IN 0 0 12 O
cellular JJ 0 1 13 O
proliferative JJ 0 1 13 O
activity NN 0 1 1 O
apoptotic JJ 0 1 UNK O
rate NN 0 1 1 O
ultrastructure NN 0 1 UNK O
and CC 0 0 12 O
caspase NN 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
expression NN 0 1 1 O
were VBD 1 0 12 O
detected VBN 1 1 1 O
. . 0 0 12 O

We PRP 0 0 12 O
found VBD 1 1 12 O
that IN 0 0 12 O
noradrenaline NN 0 1 UNK O
simultaneously RB 0 1 13 O
reduced VBD 1 1 1 O
spontaneous JJ 0 1 1 O
inhibitory NN 0 1 UNK O
inputs NNS 1 1 UNK O
and CC 0 0 12 O
enhanced VBD 1 1 1 O
evoked JJ 0 1 13 O
inhibitory NN 0 1 UNK O
currents NNS 1 1 UNK O
recorded VBN 1 1 12 O
from IN 0 0 12 O
principal JJ 0 1 1 O
neurons NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
mouse NN 0 1 UNK O
dorsal NN 0 1 8 O
cochlear JJ 0 1 13 O
nucleus NN 0 1 UNK O
( ( 0 0 2 O
DCN NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
well RB 0 1 12 O
understood VB 1 1 12 O
how WRB 0 0 12 O
stimulus JJ 0 1 1 O
- : 0 0 2 O
evoked JJ 0 1 13 O
inhibition NN 0 1 13 O
can MD 0 0 12 O
be VB 0 0 12 O
distinguished VBN 1 0 UNK O
from IN 0 0 12 O
background NN 0 1 12 O
inhibition NN 0 1 13 O
arising VBG 1 1 1 O
from IN 0 0 12 O
spontaneous JJ 0 1 1 O
firing NN 0 0 12 O
. . 0 0 12 O

Surprisingly RB 0 0 UNK O
the DT 0 0 12 O
opposing NN 0 0 UNK O
effects NNS 1 1 1 O
on IN 0 0 12 O
background NN 0 1 12 O
and CC 0 0 12 O
evoked VBD 1 1 13 O
currents NNS 1 1 UNK O
could MD 0 0 12 O
both DT 0 0 12 O
be VB 0 0 12 O
attributed VBN 1 1 1 O
to TO 0 0 12 O
noradrenergic JJ 0 1 UNK O
silencing NN 0 1 UNK O
of IN 0 0 12 O
spontaneous JJ 0 1 1 O
spiking VBG 1 0 3 O
in IN 0 0 12 O
glycinergic JJ 0 0 UNK O
interneurons NNS 0 1 UNK O
. . 0 0 12 O

Together RB 0 1 2 O
these DT 0 0 12 O
effects NNS 1 1 1 O
produced VBD 1 0 1 O
a DT 0 0 12 O
large JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
signal JJ 0 1 1 O
- : 0 0 2 O
to TO 0 0 12 O
- : 0 0 2 O
noise NN 0 1 3 O
ratio NN 0 1 1 O
for IN 0 0 12 O
stimulus JJ 0 1 1 O
- : 0 0 2 O
evoked JJ 0 1 13 O
inhibition NN 0 1 13 O
. . 0 0 12 O

Elimination NN 0 1 UNK O
of IN 0 0 12 O
background NN 0 1 12 O
spiking VBG 1 0 3 O
relieved VBD 1 1 12 O
inhibitory JJ 0 1 UNK O
synapses NNS 1 1 UNK O
from IN 0 0 12 O
depression NN 0 1 6 O
and CC 0 0 12 O
thereby RB 0 0 UNK O
enhanced VBD 1 1 1 O
stimulus JJ 0 1 1 O
- : 0 0 2 O
evoked JJ 0 1 13 O
inhibition NN 0 1 13 O
. . 0 0 12 O

At IN 0 0 2 O
present JJ 0 1 1 O
the DT 0 0 12 O
broad JJ 0 1 1 O
variation NN 0 1 1 O
of IN 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
limiting JJ 0 1 1 O
factors NNS 1 1 1 O
discussed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
present JJ 0 1 1 O
paper NN 0 1 13 O
should MD 0 0 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
into IN 0 0 12 O
account NN 0 1 1 O
when WRB 0 0 12 O
using VBG 1 1 1 O
data NNS 0 1 1 O
from IN 0 0 12 O
experimental JJ 0 1 UNK O
studies NNS 1 1 1 O
for IN 0 0 12 O
interpretation NN 0 1 1 O
of IN 0 0 12 O
analytical JJ 0 1 UNK O
results NNS 1 1 1 O
in IN 0 0 12 O
forensic JJ 0 1 UNK O
case NN 0 1 12 O
work NN 0 1 12 O
. . 0 0 12 O

Current JJ 0 1 2 O
guidelines NNS 1 1 13 O
recommend VBP 0 1 12 O
starting VBG 1 1 12 O
antiretroviral JJ 0 0 UNK B-Group
treatment NN 0 1 6 O
within IN 0 0 1 O
a DT 0 0 12 O
few JJ 0 1 12 O
weeks NNS 1 1 12 O
of IN 0 0 12 O
antituberculosis NN 0 1 UNK B-Group
therapy NN 0 1 6 O
for IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
CD9 NNP 0 0 UNK O
cell NN 0 1 1 O
counts NNS 1 1 1 O

In IN 0 0 2 O
contrast NN 0 1 1 O
forelimb NN 0 1 UNK O
locomotion NN 0 1 UNK O
was VBD 1 0 12 O
mostly RB 0 1 12 O
unresponsive JJ 0 1 6 O
to TO 0 0 12 O
these DT 0 0 12 O
agonists NNS 1 1 UNK O
. . 0 0 12 O

Injections NNS 0 1 UNK O
of IN 0 0 12 O
specific JJ 0 1 1 O
serotonergic NN 0 0 UNK O
and CC 0 0 12 O
noradrenergic JJ 0 1 UNK O
agonists NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
chronic JJ 0 1 6 O
phase NN 0 1 1 O
after IN 0 0 12 O
the DT 0 0 12 O
spinal JJ 0 1 6 O
cord NN 0 1 3 O
lesion NN 0 1 6 O
revealed VBD 1 1 12 O
remarkable JJ 0 0 12 O
although IN 0 0 12 O
mostly RB 0 1 12 O
functionally RB 0 0 UNK O
negative JJ 0 1 1 O
modulations NNS 1 1 UNK O
of IN 0 0 12 O
particular JJ 0 0 1 O
parameters NNS 1 1 1 O
of IN 0 0 12 O
hindlimb NN 0 1 UNK O
locomotion NN 0 1 UNK O
. . 0 0 12 O

Understanding VBG 0 1 UNK O
these DT 0 0 12 O
differences NNS 1 1 UNK O
may MD 0 0 1 O
help VB 0 1 12 O
to TO 0 0 12 O
develop VB 0 0 1 O
future JJ 0 1 12 O
therapeutic JJ 0 1 6 O
strategies NNS 1 1 UNK O
to TO 0 0 12 O
improve VB 0 0 1 O
upper NN 0 1 3 O
and CC 0 0 12 O
lower JJR 1 1 1 O
limb NN 0 1 6 O
function NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
incomplete JJ 0 1 1 O
cervical JJ 0 1 6 O
spinal NN 0 1 6 O
cord NN 0 1 3 O
injuries NNS 1 1 6 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
therefore VBD 0 0 1 O
show JJ 0 1 12 O
fundamental JJ 0 0 UNK O
differences NNS 1 1 UNK O
between IN 0 0 12 O
fore NN 0 1 UNK O
- : 0 0 2 O
and CC 0 0 12 O
hindlimb JJ 0 1 UNK O
spinal JJ 0 1 6 O
motor NN 0 1 3 O
circuitries NNS 1 0 UNK O
and CC 0 0 12 O
their PRP$ 0 0 12 O
functional JJ 0 1 1 O
dependence NN 0 1 1 O
on IN 0 0 12 O
remaining VBG 1 1 1 O
descending VBG 1 1 3 O
inputs NNS 1 1 UNK O
and CC 0 0 12 O
exogenous JJ 0 1 UNK O
spinal JJ 0 1 6 O
excitation NN 0 1 13 O
. . 0 0 12 O

in IN 0 0 12 O
both DT 0 0 12 O
cases NNS 1 1 UNK O
discussions NNS 1 1 1 O
were VBD 1 0 12 O
guided VBN 1 1 1 O
by IN 0 0 12 O
a DT 0 0 12 O
trained JJ 0 1 12 O
moderator NN 0 0 UNK O
. . 0 0 12 O

Outcome NNP 0 1 UNK O
measures NNS 1 1 1 O
included VBD 1 1 1 O
health NN 0 1 1 O
- : 0 0 2 O
related JJ 0 1 1 O
quality NN 0 1 1 O
of IN 0 0 12 O
life NN 0 1 12 O
and CC 0 0 12 O
patient JJ 0 1 6 O
satisfaction NN 0 1 UNK O
with IN 0 0 12 O
treatment NN 0 1 6 O
asthma NN 0 1 6 O
severity NN 0 1 6 O
and CC 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
potentially RB 0 0 1 O
inappropriate JJ 0 1 1 O
drug NN 0 1 1 O
combinations NNS 1 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
the DT 0 0 12 O
general JJ 0 1 1 O
practitioners NNS 1 1 UNK O
' POS 0 0 2 O
satisfaction NN 0 1 UNK O
in IN 0 0 12 O
relation NN 0 1 13 O
to TO 0 0 12 O
the DT 0 0 12 O
performance NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
QC NNP 0 1 UNK O
. . 0 0 12 O

Two CD 0 1 2 O
QC JJ 0 1 UNK O
meetings NNS 1 1 12 O
supported VBN 1 1 1 O
with IN 0 0 12 O
feedback NN 0 1 UNK O
reports NNS 1 1 1 O
were VBD 1 0 12 O
held VBN 1 1 12 O
covering VBG 1 1 1 O
the DT 0 0 12 O
topics NNS 1 1 UNK O
`` `` 0 0 13 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
'' '' 0 0 13 O

and CC 0 0 12 O
`` `` 0 0 13 O
asthma JJ 0 1 6 O
'' '' 0 0 13 O
; : 0 0 2 O

Twelve NNP 0 1 UNK O
QCs NNP 0 0 UNK O
involving VBG 1 1 1 O
9 CD 0 0 2 O
general JJ 0 1 1 O
practitioners NNS 1 1 UNK O
from IN 0 0 12 O
9 CD 0 0 2 O
practices NNS 1 1 UNK O
were VBD 1 0 12 O
randomised VBN 1 0 UNK O
. . 0 0 12 O

Six NNP 0 1 2 O
QCs NNP 0 0 UNK O
worked VBD 1 1 12 O
with IN 0 0 12 O
traditional JJ 0 1 UNK O
anonymous JJ 0 1 13 O
feedback NN 0 1 UNK O
and CC 0 0 12 O
six CD 0 1 12 O
with IN 0 0 12 O
an DT 0 0 12 O
open JJ 0 1 12 O
benchmark NN 0 1 UNK O
. . 0 0 12 O

[ NN 0 0 2 O
Does NNP 0 0 2 O
implementation NN 0 1 UNK O
of IN 0 0 12 O
benchmarking VBG 0 1 UNK O
in IN 0 0 12 O
quality NN 0 1 1 O
circles NNS 1 1 UNK O
improve VBP 0 0 1 O
the DT 0 0 12 O
quality NN 0 1 1 O
of IN 0 0 12 O
care NN 0 1 12 O
of IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
asthma JJ 0 1 6 O
and CC 0 0 12 O
reduce VB 0 0 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
] NN 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
purpose NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
cluster NN 0 1 13 O
- : 0 0 2 O
randomised VBN 1 0 UNK O
controlled JJ 0 1 1 O
trial NN 0 1 12 O
was VBD 1 0 12 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
quality NN 0 1 1 O
circles NNS 1 1 UNK O
( ( 0 0 2 O
QCs NNP 0 0 UNK O
) ) 0 0 2 O
working VBG 1 1 12 O
either CC 0 1 12 O
with IN 0 0 12 O
general JJ 0 1 1 O
data NNS 0 1 1 O
- : 0 0 2 O
based VBN 1 1 1 O
feedback NN 0 1 UNK O
or CC 0 0 12 O
with IN 0 0 12 O
an DT 0 0 12 O
open JJ 0 1 12 O
benchmark NN 0 1 UNK O
within IN 0 0 1 O
the DT 0 0 12 O
field NN 0 1 1 O
of IN 0 0 12 O
asthma JJ 0 1 6 O
care NN 0 1 12 O
and CC 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

We PRP 0 0 12 O
sought VBD 1 0 UNK O
to TO 0 0 12 O
determine VB 0 0 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
the DT 0 0 12 O
frequency NN 0 1 1 O
of IN 0 0 12 O
colchicine JJ 0 1 0 B-Drug
toxicity NN 0 1 6 O
among IN 0 0 12 O
hospitalized JJ 0 1 6 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
colchicine NN 0 1 0 B-Drug
who WP 0 0 12 O
died VBD 1 1 12 O
during IN 0 0 12 O
an DT 0 0 12 O
admission NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
the DT 0 0 12 O
likelihood NN 0 1 1 O
that WDT 0 0 12 O
colchicine NN 0 1 0 B-Drug
contributed VBD 1 1 1 O
to TO 0 0 12 O
death NN 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
whether IN 0 0 12 O
patients NNS 1 1 6 O
were VBD 1 0 12 O
taking VBG 1 0 12 O
interacting VBG 1 0 1 O
medications NNS 1 1 6 O
that WDT 0 0 12 O
could MD 0 0 12 O
have VB 0 0 12 O
contributed VBN 1 1 1 O
to TO 0 0 12 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
whether IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
dosing NN 0 0 14 O
among IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
adhered VBD 1 1 1 O
to TO 0 0 12 O
established VBN 1 1 1 O
guidelines NNS 1 1 13 O
. . 0 0 12 O

It PRP 0 0 12 O
has VBZ 1 0 12 O
a DT 0 0 12 O
narrow JJ 0 1 3 O
therapeutic JJ 0 1 6 O
index NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
severe JJ 0 1 6 O
or CC 0 0 12 O
fatal JJ 0 1 13 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Colchicine NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
for IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
gout NN 0 1 6 O
and CC 0 0 12 O
occasionally RB 0 1 12 O
for IN 0 0 12 O
other JJ 0 0 12 O
inflammatory JJ 0 1 6 O
diseases NNS 1 1 6 O
. . 0 0 12 O

Unrecognized VBN 0 0 UNK O
fatalities NNS 1 1 UNK O
related VBN 1 1 1 O
to TO 0 0 12 O
colchicine VB 0 1 0 B-Drug
in IN 0 0 12 O
hospitalized JJ 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

An DT 0 0 2 O
expert JJ 0 0 13 O
panel NN 0 1 1 O
reviewed VBD 1 1 1 O
each DT 0 0 12 O
case NN 0 1 12 O
and CC 0 0 12 O
classified VBD 1 1 13 O
the DT 0 0 12 O
likelihood NN 0 1 1 O
of IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
toxicity NN 0 1 6 O
the DT 0 0 12 O
likelihood NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
causal JJ 0 1 UNK O
role NN 0 1 1 O
of IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
death NN 0 1 12 O
using VBG 1 1 1 O
the DT 0 0 12 O
WHO NNP 0 0 11 O
classification NN 0 1 13 O
system NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
appropriateness NN 0 1 UNK O
of IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
dosing NN 0 0 14 O
. . 0 0 12 O

We PRP 0 0 12 O
reviewed VBD 1 1 1 O
charts NNS 1 1 UNK O
for IN 0 0 12 O
signs NNS 1 1 12 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
colchicine JJ 0 1 0 B-Drug
toxicity NN 0 1 6 O
. . 0 0 12 O

Only RB 0 1 2 O
a DT 0 0 12 O
few JJ 0 1 12 O
mRPCs NNS 0 0 UNK O
expressed VBD 1 0 1 O
recoverin NN 0 1 UNK O
in IN 0 0 12 O
B9 NNP 0 0 UNK O
mice NN 1 1 UNK O
. . 0 0 12 O

Developers NNS 0 1 UNK O
of IN 0 0 12 O
DDI NNP 0 1 13 O
management NN 0 1 1 O
guidelines NNS 1 1 13 O
should MD 0 0 12 O
take VB 0 1 12 O
the DT 0 0 12 O
appropriate JJ 0 1 1 O
domains NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
AGREE NNP 0 1 UNK O
Instrument NNP 0 1 UNK O
into IN 0 0 12 O
consideration NN 0 1 1 O
in IN 0 0 12 O
their PRP$ 0 0 12 O
development NN 0 1 1 O
processes NNS 1 1 1 O
. . 0 0 12 O

Our PRP$ 0 0 2 O
results NNS 1 1 1 O
show VBP 0 1 12 O
that IN 0 0 12 O
substantial JJ 0 0 1 O
numbers NNS 1 1 1 O
of IN 0 0 12 O
mRPCs NNS 0 0 UNK O
migrated VBN 1 1 UNK O
and CC 0 0 12 O
survived VBN 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
retina NN 0 1 13 O
when WRB 0 0 12 O
transplanted VBN 1 1 13 O
with IN 0 0 12 O
chondroitinase NN 0 1 UNK O
ABC NNP 0 1 UNK O
into IN 0 0 12 O
B9 NNP 0 0 UNK O
and CC 0 0 12 O
Rho NNP 0 0 UNK O
( ( 0 0 2 O
- : 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
mice NN 1 1 UNK O
. . 0 0 12 O

Chondroitinase NNP 0 1 UNK O
ABC NNP 0 1 UNK O
disrupted VBD 1 1 UNK O
the DT 0 0 12 O
glial JJ 0 1 UNK O
scar NN 0 1 6 O
around IN 0 0 12 O
the DT 0 0 12 O
mRPCs NN 0 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
subretinal JJ 0 1 UNK O
space NN 0 1 1 O
. . 0 0 12 O

Toxicity NN 0 1 UNK O
was VBD 1 0 12 O
unlikely JJ 0 1 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
/ NNS 0 0 2 O
9 CD 0 0 2 O
possible JJ 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
/ NN 0 0 2 O
9 CD 0 0 2 O
likely JJ 0 1 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
certain JJ 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

Thirty NNP 0 1 2 O
- : 0 0 2 O
seven CD 0 1 12 O
hospitalized JJ 0 1 6 O
patients NNS 1 1 6 O
who WP 0 0 12 O
died VBD 1 1 12 O
during IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
month NN 0 1 12 O
study NN 0 1 1 O
period NN 0 1 1 O
received VBD 1 1 12 O
colchicine NN 0 1 0 B-Drug
. . 0 0 12 O

mRPCs NNS 0 0 UNK O
from IN 0 0 12 O
P9 NNP 0 1 UNK O
green JJ 0 1 3 O
fluorescent NN 0 1 UNK O
protein NN 0 1 14 O
- : 0 0 2 O
transgenic JJ 0 1 UNK O
mice NNS 1 1 UNK O
were VBD 1 0 12 O
isolated VBN 1 1 1 O
and CC 0 0 12 O
expanded VBN 1 1 1 O
for IN 0 0 12 O
transplantation NN 0 1 6 O
. . 0 0 12 O

All DT 0 0 2 O
mRPCs NNS 0 0 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
passages NNS 1 1 13 O
or CC 0 0 12 O
less JJR 0 1 12 O
were VBD 1 0 12 O
transplanted VBN 1 1 13 O
into IN 0 0 12 O
the DT 0 0 12 O
subretinal JJ 0 1 UNK O
space NN 0 1 1 O
of IN 0 0 12 O
B9 NNP 0 0 UNK O
mice FW 1 1 UNK O
together RB 0 1 12 O
with IN 0 0 12 O
chondroitinase NN 0 1 UNK O
ABC NNP 0 1 UNK O
and CC 0 0 12 O
into IN 0 0 12 O
Rho NNP 0 0 UNK O
( ( 0 0 2 O
- : 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
mice NN 1 1 UNK O
combined VBN 1 1 1 O
with IN 0 0 12 O
chondroitinase NN 0 1 UNK O
ABC NNP 0 1 UNK O
N NNP 0 1 2 B-Drug_n
- : 0 0 2 O
[ NN 0 0 2 O
N NNP 0 1 2 I-Drug_n
- : 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
Difluorophenacetyl NN 0 0 UNK I-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
L SYM 0 1 2 I-Drug_n
- : 0 0 2 O
alanyl NN 0 0 UNK I-Drug_n
] SYM 0 0 2 O
- : 0 0 2 O
S NNP 0 1 2 I-Drug_n
- : 0 0 2 O
phenylglycine NN 0 0 UNK I-Drug_n
t SYM 0 1 12 I-Drug_n
- : 0 0 2 O
butyl NN 0 0 UNK I-Drug_n
ester NN 0 1 UNK I-Drug_n
( ( 0 0 2 O
DAPT NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
and CC 0 0 12 O
insulin JJ 0 1 14 B-Drug_n
growth NN 0 1 1 I-Drug_n
factor NN 0 1 1 I-Drug_n
( ( 0 0 2 O
IGF NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
. . 0 0 12 O

Combining VBG 0 1 UNK O
chondroitinase NN 0 1 UNK O
ABC NNP 0 1 UNK O
and CC 0 0 12 O
growth NN 0 1 1 O
factors NNS 1 1 1 O
promotes VBZ 1 1 UNK O
the DT 0 0 12 O
integration NN 0 1 13 O
of IN 0 0 12 O
murine JJ 0 1 13 O
retinal JJ 0 1 6 O
progenitor NN 0 1 UNK O
cells NNS 1 1 6 O
transplanted VBD 1 1 13 O
into IN 0 0 12 O
Rho NNP 0 0 UNK O
( ( 0 0 2 O
- : 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
mice NN 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
aim NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
is VBZ 1 0 12 O
to TO 0 0 12 O
investigate VB 0 1 1 O
the DT 0 0 12 O
synergistic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
chondroitinase NN 0 1 UNK O
ABC NNP 0 1 UNK O
and CC 0 0 12 O
growth NN 0 1 1 O
factors NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
integration NN 0 1 13 O
of IN 0 0 12 O
murine JJ 0 1 13 O
retinal JJ 0 1 6 O
progenitor NN 0 1 UNK O
cells NNS 1 1 6 O
( ( 0 0 2 O
mRPCs NNS 0 0 UNK O
) ) 0 0 2 O
transplanted VBD 1 1 13 O
into IN 0 0 12 O
Rho NNP 0 0 UNK O
( ( 0 0 2 O
- : 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
mice NN 1 1 UNK O
. . 0 0 12 O

9 CD 0 0 2 O
cells NNS 1 1 6 O
/ JJ 0 0 2 O
ul NN 0 1 13 O
. . 0 0 12 O

Subjects NNS 0 1 UNK O
included VBD 1 1 1 O
hospitalized JJ 0 1 6 O
patients NNS 1 1 6 O
who WP 0 0 12 O
received VBD 1 1 12 O
colchicine NN 0 1 0 B-Drug
and CC 0 0 12 O
died VBD 1 1 12 O
in IN 0 0 12 O
hospital NN 0 1 12 O
between IN 0 0 12 O
9 CD 0 0 2 O
January NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
February NNP 0 1 2 O
9 CD 0 0 2 O
. . 0 0 12 O

We PRP 0 0 12 O
found VBD 1 1 12 O
that IN 0 0 12 O
eugenol NN 0 1 UNK B-Drug
increased VBD 1 1 1 O
the DT 0 0 12 O
absorptive JJ 0 1 UNK O
transport NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
efficiently RB 0 0 UNK O
. . 0 0 12 O

Globally RB 0 0 UNK O
tuberculosis NN 0 1 6 O
( ( 0 0 2 O
TB NNP 0 0 13 O
) ) 0 0 2 O
and CC 0 0 12 O
HIV NNP 0 1 6 O
interact NN 0 0 UNK O
in IN 0 0 12 O
deadly JJ 0 0 UNK O
synergy NN 0 0 1 O
. . 0 0 12 O

Tuberculosis NN 0 1 7 O
and CC 0 0 12 O
HIV NNP 0 1 6 O
co VBP 0 1 12 O
- : 0 0 2 O
infection NN 0 1 6 O
: : 0 0 2 O
screening NN 0 1 1 O
and CC 0 0 12 O
treatment NN 0 1 6 O
strategies NNS 1 1 UNK O
. . 0 0 12 O

Despite IN 0 0 12 O
expanding VBG 1 1 1 O
access NN 0 1 1 O
to TO 0 0 12 O
antiretroviral JJ 0 0 UNK B-Group
therapy NN 0 1 6 O
( ( 0 0 2 O
ART NNP 0 1 11 O
) ) 0 0 2 O
to TO 0 0 12 O
treat VB 0 1 12 O
HIV NNP 0 1 6 O
infection NN 0 1 6 O
in IN 0 0 12 O
resource NN 0 1 13 O
- : 0 0 2 O
limited JJ 0 1 1 O
settings NNS 1 1 1 O
many JJ 0 0 12 O
individuals NNS 1 1 1 O
in IN 0 0 12 O
need NN 0 1 12 O
of IN 0 0 12 O
therapy NN 0 1 6 O
initiate JJ 0 1 1 O
ART NNP 0 1 11 O
too RB 0 0 12 O
late RB 0 1 12 O
and CC 0 0 12 O
have VBP 0 0 12 O
already RB 0 0 12 O
developed VBN 1 0 1 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
TB NN 0 0 13 O
by IN 0 0 12 O
the DT 0 0 12 O
time NN 0 1 12 O
they PRP 0 0 12 O
present VBP 0 1 1 O
for IN 0 0 12 O
care NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
high JJ 0 1 1 O
burden NN 0 1 1 O
of IN 0 0 12 O
TB NNP 0 0 13 O
among IN 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
infected JJ 0 1 6 O
individuals NNS 1 1 1 O
underlies VBZ 1 0 UNK O
the DT 0 0 12 O
importance NN 0 1 1 O
of IN 0 0 12 O
TB NNP 0 0 13 O
diagnosis NN 0 1 6 O
treatment NN 0 1 6 O
and CC 0 0 12 O
prevention NN 0 1 1 O
for IN 0 0 12 O
clinicians NNS 1 1 UNK O
involved VBN 1 1 12 O
in IN 0 0 12 O
HIV NNP 0 1 6 O
care NN 0 1 12 O
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
the DT 0 0 12 O
survival JJ 0 1 1 O
benefits NNS 1 1 1 O
of IN 0 0 12 O
promptly RB 0 0 12 O
initiating VBG 1 1 1 O
ART NNP 0 1 11 O
among IN 0 0 12 O
all DT 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
infected JJ 0 1 6 O
individuals NNS 1 1 1 O
including VBG 1 1 1 O
those DT 0 0 12 O
with IN 0 0 12 O
TB NNP 0 0 13 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
infected JJ 0 1 6 O
individuals NNS 1 1 1 O
receive VBP 0 1 1 O
treatment NN 0 1 6 O
for IN 0 0 12 O
both DT 0 0 12 O
diseases NNS 1 1 6 O
regardless RB 0 1 UNK O
of IN 0 0 12 O
CD9+ NNP 0 0 UNK O
cell NN 0 1 1 O
count NN 0 1 12 O
. . 0 0 12 O

Many JJ 0 0 UNK O
co SYM 0 1 12 O
- : 0 0 2 O
infected JJ 0 1 6 O
individuals NNS 1 1 1 O
are VBP 1 0 12 O
in IN 0 0 12 O
need NN 0 1 12 O
of IN 0 0 12 O
concurrent JJ 0 1 1 O
ART NNP 0 1 11 O
and CC 0 0 12 O
anti SYM 0 0 3 O
- : 0 0 2 O
TB NN 0 0 13 O
therapy NN 0 1 6 O
which WDT 0 0 12 O
dramatically RB 0 0 1 O
improves VBZ 1 1 1 O
survival NN 0 1 1 O
but CC 0 0 12 O
also RB 0 0 12 O
raises VBZ 1 0 1 O
several JJ 0 1 12 O
management NN 0 1 1 O
challenges NNS 1 1 UNK O
including VBG 1 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
shared VBN 1 1 12 O
drug NN 0 1 1 O
toxicities NNS 1 1 UNK O
and CC 0 0 12 O
TB NNP 0 0 13 O
immune JJ 0 1 6 O
reconstitution NN 0 0 UNK O
inflammatory NN 0 1 6 O
syndrome NN 0 1 6 O
( ( 0 0 2 O
IRIS NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Recent JJ 0 1 2 O
findings NNS 1 1 1 O
and CC 0 0 12 O
ongoing VBG 0 1 1 O
studies NNS 1 1 1 O
will MD 0 0 12 O
assist VB 0 1 1 O
clinicians NNS 1 1 UNK O
in IN 0 0 12 O
managing VBG 1 1 1 O
the DT 0 0 12 O
prevention NN 0 1 1 O
and CC 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
TB NNP 0 0 13 O
and CC 0 0 12 O
HIV NNP 0 1 6 O
co VBP 0 1 12 O
- : 0 0 2 O
infection NN 0 1 6 O
which WDT 0 0 12 O
remains VBZ 1 0 12 O
a DT 0 0 12 O
major JJ 0 1 1 O
global JJ 0 1 1 O
health NN 0 1 1 O
challenge NN 0 1 12 O
. . 0 0 12 O

We PRP 0 0 12 O
review VBP 0 1 2 O
current JJ 0 1 1 O
screening NN 0 1 1 O
and CC 0 0 12 O
treatment NN 0 1 6 O
strategies NNS 1 1 UNK O
for IN 0 0 12 O
TB NNP 0 0 13 O
and CC 0 0 12 O
HIV NNP 0 1 6 O
co VBP 0 1 12 O
- : 0 0 2 O
infection NN 0 1 6 O
. . 0 0 12 O

Identification NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
dopamine NN 0 1 14 O
receptor NN 0 1 14 O
- : 0 0 2 O
mediated VBN 1 1 13 O
opiate JJ 0 1 6 B-Group
reward NN 0 1 UNK O
memory NN 0 1 1 O
switch NN 0 1 3 O
in IN 0 0 12 O
the DT 0 0 12 O
basolateral JJ 0 0 UNK O
amygdala NN 0 1 UNK O
- : 0 0 2 O
nucleus NN 0 1 UNK O
accumbens VBZ 0 0 UNK O
circuit NN 0 0 13 O
. . 0 0 12 O

The DT 0 0 2 O
basolateral JJ 0 0 UNK O
amygdala NN 0 1 UNK O
( ( 0 0 2 O
BLA NNP 0 1 UNK O
) ) 0 0 2 O
ventral JJ 0 1 8 O
tegmental JJ 0 1 UNK O
area NN 0 1 12 O
( ( 0 0 2 O
VTA NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
nucleus JJ 0 1 UNK O
accumbens NNS 0 0 UNK O
( ( 0 0 2 O
NAc NNP 0 1 UNK O
) ) 0 0 2 O
play VBP 0 1 13 O
central JJ 0 1 1 O
roles NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
processing NN 0 1 13 O
of IN 0 0 12 O
opiate JJ 0 1 6 B-Group
- : 0 0 2 O
related JJ 0 1 1 O
associative JJ 0 1 UNK O
reward NN 0 1 UNK O
learning NN 0 1 13 O
and CC 0 0 12 O
memory NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
BLA NNP 0 1 UNK O
receives VBZ 1 1 1 O
innervation NN 0 1 13 O
from IN 0 0 12 O
dopaminergic JJ 0 1 UNK O
fibers NNS 1 1 3 O
originating VBG 1 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
VTA NNP 0 1 UNK O
and CC 0 0 12 O
both DT 0 0 12 O
dopamine NN 0 1 14 O
( ( 0 0 2 O
DA NNP 0 1 11 O
) ) 0 0 2 O
D9 NNP 0 1 UNK O
and CC 0 0 12 O
D9 NNP 0 1 UNK O
receptors NNS 1 1 13 O
are VBP 1 0 12 O
expressed VBN 1 0 1 O
in IN 0 0 12 O
this DT 0 0 12 O
region NN 0 1 1 O
. . 0 0 12 O

Using VBG 0 1 2 O
a DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
single JJ 0 1 12 O
- : 0 0 2 O
unit NN 0 1 1 O
extracellular JJ 0 1 14 O
recording NN 0 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
NAc NNP 0 1 UNK O
combined VBN 1 1 1 O
with IN 0 0 12 O
behavioral JJ 0 1 13 O
pharmacology NN 0 1 UNK O
studies NNS 1 1 1 O
we PRP 0 0 12 O
have VBP 0 0 12 O
identified VBN 1 1 1 O
a DT 0 0 12 O
double JJ 0 1 3 O
dissociation NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
functional JJ 0 1 1 O
roles NNS 1 1 UNK O
of IN 0 0 12 O
DA NNP 0 1 11 O
D9 NNP 0 1 UNK O
versus NN 0 0 1 O
D9 NNP 0 1 UNK O
receptor NN 0 1 14 O
transmission NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
BLA NNP 0 1 UNK O
which WDT 0 0 12 O
depends VBZ 1 1 UNK O
on IN 0 0 12 O
opiate JJ 0 1 6 B-Group
exposure NN 0 1 1 O
state NN 0 1 1 O
; : 0 0 2 O

The DT 0 0 2 O
Casein NNP 0 1 UNK B-Drug_n
phosphopeptide IN 0 1 UNK I-Drug_n
- : 0 0 2 O
amorphous JJ 0 1 13 I-Drug_n
calcium NN 0 1 14 I-Drug_n
phosphate NN 0 1 14 I-Drug_n
CPP NNP 0 1 UNK I-Drug_n
- : 0 0 2 O
ACP NNP 0 0 UNK I-Drug_n
complex NN 0 1 1 I-Drug_n
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
remineralise VB 0 0 UNK O
tooth DT 0 1 3 O
surfaces NNS 1 1 3 O
in IN 0 0 12 O
situ NN 0 0 1 O
when WRB 0 0 12 O
delivered VBN 1 1 12 O
in IN 0 0 12 O
oral JJ 0 1 6 O
care NN 0 1 12 O
products NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
direct JJ 0 1 1 O
contrast NN 0 1 1 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
made VBN 1 1 12 O
opiate JJ 0 1 6 B-Group
dependent NN 0 1 1 O
and CC 0 0 12 O
conditioned VBN 1 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
state NN 0 1 1 O
of IN 0 0 12 O
withdrawal NN 0 1 1 O
intra JJ 0 1 6 O
- : 0 0 2 O
BLA NNP 0 1 UNK O
D9 NNP 0 1 UNK O
but CC 0 0 12 O
not RB 0 1 12 O
D9 NNP 0 1 UNK O
receptor NN 0 1 14 O
blockade NN 0 1 1 O
blocked VBD 1 1 13 O
opiate JJ 0 1 6 B-Group
reward NN 0 1 UNK O
encoding NN 0 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
functional JJ 0 1 1 O
switch NN 0 1 3 O
was VBD 1 0 12 O
dependent JJ 0 1 1 O
on IN 0 0 12 O
cAMP NN 0 1 UNK O
signaling VBG 1 1 UNK O
as IN 1 0 12 O
comodulation NN 0 0 UNK O
of IN 0 0 12 O
intra JJ 0 1 6 O
- : 0 0 2 O
BLA NNP 0 1 UNK O
cAMP NN 0 1 UNK O
levels NNS 1 1 1 O
reversed VBD 1 1 1 O
or CC 0 0 12 O
replicated VBD 1 1 UNK O
the DT 0 0 12 O
functional JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
intra JJ 0 1 6 O
- : 0 0 2 O
BLA NNP 0 1 UNK O
D9 NNP 0 1 UNK O
or CC 0 0 12 O
D9 NNP 0 1 UNK O
transmission NN 0 1 1 O
during IN 0 0 12 O
opiate JJ 0 1 6 B-Group
reward NN 0 1 UNK O
processing NN 0 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
to TO 0 0 12 O
regular JJ 0 1 12 O
professional JJ 0 1 1 O
oral JJ 0 1 6 O
hygiene NN 0 1 1 O
visits NNS 1 1 12 O
and CC 0 0 12 O
the DT 0 0 12 O
application NN 0 1 1 O
of IN 0 0 12 O
appropriate JJ 0 1 1 O
preventive JJ 0 1 13 O
medications NNS 1 1 6 O
successful JJ 0 1 12 O
preventive JJ 0 1 13 O
strategies NNS 1 1 UNK O
involve VBP 0 0 1 O
oral JJ 0 1 6 O
health NN 0 1 1 O
promotion NN 0 1 UNK O
patient JJ 0 1 6 O
education NN 0 1 1 O
and CC 0 0 12 O
patient JJ 0 1 6 O
compliance NN 0 1 1 O
. . 0 0 12 O

Our PRP$ 0 0 2 O
results NNS 1 1 1 O
characterize VB 0 0 1 O
and CC 0 0 12 O
identify VB 0 0 1 O
a DT 0 0 12 O
novel JJ 0 1 13 O
opiate NN 0 1 6 B-Group
addiction NN 0 1 12 O
switching VBG 1 1 UNK O
mechanism NN 0 1 13 O
directly RB 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
BLA NNP 0 1 UNK O
that WDT 0 0 12 O
can MD 0 0 12 O
control VB 0 1 1 O
the DT 0 0 12 O
processing NN 0 1 13 O
of IN 0 0 12 O
opiate JJ 0 1 6 B-Group
reward NN 0 1 UNK O
information NN 0 1 1 O
as IN 1 0 12 O
a DT 0 0 12 O
direct JJ 0 1 1 O
function NN 0 1 1 O
of IN 0 0 12 O
opiate NN 0 1 6 B-Group
exposure NN 0 1 1 O
state NN 0 1 1 O
via IN 0 0 1 O
D9 NNP 0 1 UNK O
or CC 0 0 12 O
D9 NNP 0 1 UNK O
receptor NN 0 1 14 O
signaling VBG 1 1 UNK O
substrates NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
eugenol NN 0 1 UNK B-Drug
on IN 0 0 12 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
in IN 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
administrative JJ 0 1 13 O
nanoemulsion NN 0 1 UNK O
formulation NN 0 1 13 O
was VBD 1 0 12 O
also RB 0 0 12 O
demonstrated VBN 1 0 1 O
in IN 0 0 12 O
vivo NN 0 1 13 O
. . 0 0 12 O

Further JJ 0 1 2 O
promotion NN 0 1 UNK O
and CC 0 0 12 O
integration NN 0 1 13 O
of IN 0 0 12 O
laboratory NN 0 1 1 O
and CC 0 0 12 O
clinical JJ 0 1 6 O
research NN 0 1 13 O
are VBP 1 0 12 O
encouraged VBN 1 0 12 O
to TO 0 0 12 O
advance VB 0 1 1 O
the DT 0 0 12 O
understanding NN 0 1 1 O
of IN 0 0 12 O
placebo NN 0 1 13 O
mechanisms NNS 1 1 UNK O
in IN 0 0 12 O
IBS NNP 0 1 UNK O
patients NNS 1 1 6 O
. . 0 0 12 O

Emerging VBG 0 0 UNK O
literature NN 0 1 UNK O
using VBG 1 1 1 O
functional JJ 0 1 1 O
brain NN 0 1 6 O
imaging NN 0 1 1 O
has VBZ 1 0 12 O
started VBN 1 1 12 O
to TO 0 0 12 O
document VB 0 1 1 O
the DT 0 0 12 O
neuronal JJ 0 1 13 O
changes NNS 1 1 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
placebo NN 0 1 13 O
phenomenon NN 0 1 1 O
in IN 0 0 12 O
IBS NNP 0 1 UNK O
patients NNS 1 1 6 O
showing VBG 1 1 12 O
aberrant JJ 0 1 6 O
neural JJ 0 1 6 O
network NN 0 1 UNK O
during IN 0 0 12 O
visceral JJ 0 1 13 O
placebo NN 0 1 13 O
analgesia NN 0 1 6 O
when WRB 0 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
controls NNS 1 1 UNK O
. . 0 0 12 O

Irritable JJ 0 1 UNK O
bowel NN 0 1 6 O
syndrome NN 0 1 6 O
( ( 0 0 2 O
IBS NNP 0 1 UNK O
) ) 0 0 2 O
is VBZ 1 0 12 O
a DT 0 0 12 O
functional JJ 0 1 1 O
disorder NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
gastrointestinal JJ 0 1 6 O
tract NN 0 1 6 O
that WDT 0 0 12 O
shows VBZ 1 1 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
placebo NN 0 1 13 O
response NN 0 1 1 O
of IN 0 0 12 O
around IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
among IN 0 0 12 O
different JJ 0 1 1 O
clinical JJ 0 1 6 O
trials.A NN 0 1 UNK O
positive JJ 0 1 1 O
patient NN 0 1 6 O
- : 0 0 2 O
practitioner NN 0 1 1 O
relationship NN 0 1 12 O
can MD 0 0 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
placebo NN 0 1 13 O
effect NN 0 1 1 O
in IN 0 0 12 O
IBS NNP 0 1 UNK O
patients NNS 1 1 6 O
. . 0 0 12 O

New NNP 0 1 2 O
research NN 0 1 13 O
findings NNS 1 1 1 O
show VBP 0 1 12 O
that IN 0 0 12 O
a DT 0 0 12 O
placebo NN 0 1 13 O
has VBZ 1 0 12 O
real JJ 0 1 12 O
psychobiological JJ 0 1 UNK O
and CC 0 0 12 O
biological JJ 0 1 13 O
effects NNS 1 1 1 O
that WDT 0 0 12 O
are VBP 1 0 12 O
attributable JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
overall JJ 0 1 1 O
therapeutic JJ 0 1 6 O
context NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
placebo NN 0 1 13 O
effect NN 0 1 1 O
has VBZ 1 0 12 O
evolved VBN 1 1 UNK O
from IN 0 0 12 O
being VBG 1 0 12 O
considered VBN 1 1 1 O
a DT 0 0 12 O
nuisance JJ 0 0 UNK O
factor NN 0 1 1 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
research NN 0 1 13 O
to TO 0 0 12 O
a DT 0 0 12 O
hot JJ 0 1 3 O
topic NN 0 1 13 O
of IN 0 0 12 O
scientific JJ 0 1 UNK O
investigation NN 0 1 1 O
. . 0 0 12 O

Placebo NNP 0 1 UNK O
effect NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
irritable JJ 0 1 6 O
bowel NN 0 1 6 O
syndrome NN 0 1 6 O
. . 0 0 12 O

We PRP 0 0 12 O
conducted VBD 1 1 1 O
an DT 0 0 12 O
IRB NNP 0 1 UNK O
- : 0 0 2 O
approved VBD 1 1 1 O
retrospective JJ 0 1 UNK O
chart NN 0 1 1 O
review NN 0 1 2 O
at IN 0 0 12 O
an DT 0 0 12 O
urban JJ 0 1 13 O
tertiary JJ 0 1 13 O
care NN 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
bed NN 0 1 3 O
university NN 0 1 UNK O
hospital NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
work NN 0 1 12 O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
ABC NNP 0 1 UNK O
transporters NNS 1 1 UNK O
influence VBP 0 0 UNK O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
moxidectin VB 0 1 UNK B-Drug_n
and CC 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
potential JJ 0 1 1 O
role NN 0 1 1 O
in IN 0 0 12 O
drug NN 0 1 1 O
resistance NN 0 1 1 O
. . 0 0 12 O

ABC NNP 0 1 UNK O
transporters NNS 1 1 UNK O
influence VBP 0 0 UNK O
sensitivity NN 0 1 1 O
of IN 0 0 12 O
Brugia NNP 0 1 UNK O
malayi NN 0 0 UNK O
to TO 0 0 12 O
moxidectin VB 0 1 UNK B-Drug_n
and CC 0 0 12 O
have VB 0 0 12 O
potential JJ 0 1 1 O
roles NNS 1 1 UNK O
in IN 0 0 12 O
drug NN 0 1 1 O
resistance NN 0 1 1 O
. . 0 0 12 O

Some DT 0 0 2 O
ABC NNP 0 1 UNK O
transporters NNS 1 1 UNK O
play VBP 0 1 13 O
a DT 0 0 12 O
significant JJ 0 1 1 O
role NN 0 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
health NN 0 1 1 O
and CC 0 0 12 O
illness NN 0 1 6 O
because IN 0 0 12 O
they PRP 0 0 12 O
confer VBP 0 0 UNK O
multidrug JJ 0 0 UNK O
resistance NN 0 1 1 O
( ( 0 0 2 O
MDR NNP 0 0 13 O
) ) 0 0 2 O
through IN 0 0 12 O
their PRP$ 0 0 12 O
overexpression NN 0 1 UNK O
. . 0 0 12 O

Compounds NNS 0 1 UNK O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
the DT 0 0 12 O
drug NN 0 1 1 O
efflux VBZ 0 0 UNK O
mechanism NN 0 1 13 O
can MD 0 0 12 O
improve VB 0 0 1 O
efficacy NN 0 1 UNK O
or CC 0 0 12 O
reverse NN 0 1 1 O
resistance NN 0 1 1 O
. . 0 0 12 O

Of IN 0 0 2 O
the DT 0 0 12 O
eight CD 0 1 12 O
described NNS 0 1 1 O
ABC NNP 0 1 UNK O
transporter NN 0 1 UNK O
subfamilies NNS 1 1 UNK O
those DT 0 0 12 O
proteins NNS 1 1 14 O
conferring VBG 1 0 1 O
MDR NNP 0 0 13 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
are VBP 1 0 12 O
in IN 0 0 12 O
subfamilies NNS 1 1 UNK O
A NNP 0 0 2 O
B NNP 0 0 2 O
C NNP 0 0 2 O
and CC 0 0 12 O
G NNP 0 1 2 O
. . 0 0 12 O

In IN 0 0 2 O
nematodes JJ 0 1 UNK O
transporters NNS 1 1 UNK O
in IN 0 0 12 O
subfamilies NNS 1 1 UNK O
B NNP 0 0 2 O
and CC 0 0 12 O
C NNP 0 0 2 O
are VBP 1 0 12 O
suggested VBN 1 1 12 O
to TO 0 0 12 O
confer VB 0 0 UNK O
resistance NN 0 1 1 O
to TO 0 0 12 O
ivermectin VB 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
Brugia NNP 0 1 UNK O
malayi NN 0 0 UNK O
ABC NNP 0 1 UNK O
transporter NN 0 1 UNK O
superfamily RB 0 1 UNK O
was VBD 1 0 12 O
examined VBN 1 1 1 O
to TO 0 0 12 O
assess VB 0 1 1 O
their PRP$ 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
influence VB 0 0 UNK O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
moxidectin VB 0 1 UNK B-Drug_n
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
expression NN 0 1 1 O
of IN 0 0 12 O
ABC NNP 0 1 UNK O
transporters NNS 1 1 UNK O
in IN 0 0 12 O
subfamilies NNS 1 1 UNK O
A NNP 0 0 2 O
B NNP 0 0 2 O
C NNP 0 0 2 O
and CC 0 0 12 O
G NNP 0 1 2 O
following VBG 1 1 1 O
treatment NN 0 1 6 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
moxidectin NN 0 1 UNK B-Drug_n
with IN 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
ABC NNP 0 1 UNK O
transporter NN 0 1 UNK O
function NN 0 1 1 O
did VBD 1 0 12 O
not RB 0 1 12 O
enhance VB 0 1 UNK O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
moxidectin VB 0 1 UNK B-Drug_n
in IN 0 0 12 O
males NNS 1 1 UNK O
; : 0 0 2 O

In IN 0 0 2 O
an DT 0 0 12 O
attempt NN 0 1 12 O
to TO 0 0 12 O
facilitate VB 0 0 1 O
locomotion NN 0 1 UNK O
different JJ 0 1 1 O
monoaminergic JJ 0 0 UNK O
agonists NNS 1 1 UNK O
were VBD 1 0 12 O
injected VBN 1 1 3 O
intrathecally RB 0 0 UNK O
. . 0 0 12 O

On IN 0 0 2 O
the DT 0 0 12 O
lesioned JJ 0 1 UNK O
side NN 0 1 3 O
cortico SYM 0 0 UNK O
- : 0 0 2 O
rubro NN 0 0 UNK O
- : 0 0 2 O
vestibulo NN 0 0 UNK O
- : 0 0 2 O
and CC 0 0 12 O
reticulospinal JJ 0 0 UNK O
tracts NNS 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
important JJ 0 1 1 O
modulatory NN 0 0 UNK O
serotonergic JJ 0 0 UNK O
dopaminergic NN 0 1 UNK O
and CC 0 0 12 O
noradrenergic JJ 0 1 UNK O
fibre NN 0 1 13 O
systems NNS 1 1 1 O
were VBD 1 0 12 O
interrupted VBN 1 1 12 O
by IN 0 0 12 O
the DT 0 0 12 O
lesion NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
physicians NNS 1 1 6 O
' POS 0 0 2 O
satisfaction NN 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
QC NNP 0 1 UNK O
performance NN 0 1 13 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
higher JJR 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
T NNP 0 1 2 O
- : 0 0 2 O
QCs NN 0 0 UNK O
. . 0 0 12 O

Cervical JJ 0 1 7 O
incomplete JJ 0 1 1 O
spinal JJ 0 1 6 O
cord NN 0 1 3 O
injuries NNS 1 1 6 O
often RB 0 1 12 O
lead VBP 0 1 12 O
to TO 0 0 12 O
severe VB 0 1 6 O
and CC 0 0 12 O
persistent JJ 0 1 1 O
impairments NNS 1 1 UNK O
of IN 0 0 12 O
sensorimotor NN 0 0 13 O
functions NNS 1 1 13 O
and CC 0 0 12 O
are VBP 1 0 12 O
clinically RB 0 0 6 O
the DT 0 0 12 O
most RBS 0 0 12 O
frequent JJ 0 1 1 O
type NN 0 1 1 O
of IN 0 0 12 O
spinal JJ 0 1 6 O
cord NN 0 1 3 O
injury NN 0 1 6 O
. . 0 0 12 O

Motor NNP 0 1 2 O
deficits NNS 1 1 1 O
and CC 0 0 12 O
recovery NN 0 1 1 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
with IN 0 0 12 O
unilateral JJ 0 1 13 O
spinal JJ 0 1 6 O
cord NN 0 1 3 O
hemisection NN 0 0 UNK O
mimic VBD 0 0 UNK O
the DT 0 0 12 O
Brown NNP 0 1 19 O
- : 0 0 2 O
Sequard NNP 0 0 UNK O
syndrome NN 0 1 6 O
. . 0 0 12 O

Animal NNP 0 1 UNK O
models NNS 1 1 UNK O
investigating VBG 1 1 UNK O
motor NN 0 1 3 O
dysfunction NN 0 1 6 O
following VBG 1 1 1 O
cervical JJ 0 1 6 O
spinal JJ 0 1 6 O
cord NN 0 1 3 O
injury NN 0 1 6 O
are VBP 1 0 12 O
rare JJ 0 1 12 O
. . 0 0 12 O

Understanding VBG 0 1 UNK O
the DT 0 0 12 O
motor NN 0 1 3 O
impairments NNS 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
possible JJ 0 1 1 O
functional JJ 0 1 1 O
recovery NN 0 1 1 O
of IN 0 0 12 O
upper JJ 0 1 3 O
and CC 0 0 12 O
lower JJR 1 1 1 O
extremities NNS 1 1 6 O
is VBZ 1 0 12 O
of IN 0 0 12 O
great JJ 0 1 12 O
importance NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
showed VBD 1 1 12 O
disproportionately RB 0 0 UNK O
better RBR 1 1 12 O
performance NN 0 1 13 O
of IN 0 0 12 O
hindlimb NN 0 1 UNK O
compared VBN 1 1 1 O
with IN 0 0 12 O
forelimb JJ 0 1 UNK O
locomotion NN 0 1 UNK O
; : 0 0 2 O

We PRP 0 0 12 O
analysed VBD 1 0 UNK O
the DT 0 0 12 O
differential JJ 0 1 1 O
spontaneous JJ 0 1 1 O
recovery NN 0 1 1 O
of IN 0 0 12 O
fore NN 0 1 UNK O
- : 0 0 2 O
and CC 0 0 12 O
hindlimb JJ 0 1 UNK O
locomotion NN 0 1 UNK O
by IN 0 0 12 O
detailed JJ 0 1 1 O
kinematic JJ 0 1 UNK O
analysis NN 0 1 1 O
in IN 0 0 12 O
adult NN 0 1 12 O
rats NNS 1 1 UNK O
with IN 0 0 12 O
unilateral JJ 0 1 13 O
C9 NNP 0 1 UNK O
/ NNP 0 0 2 O
C9 NNP 0 1 UNK O
hemisection NN 0 0 UNK O
a DT 0 0 12 O
lesion NN 0 1 6 O
that WDT 0 0 12 O
leads VBZ 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
Brown NNP 0 1 19 O
- : 0 0 2 O
S NNP 0 1 2 O
quard RB 0 0 UNK O
syndrome VBZ 0 1 6 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
. . 0 0 12 O

Such JJ 0 0 1 O
a DT 0 0 12 O
differential JJ 0 1 1 O
motor NN 0 1 3 O
recovery NN 0 1 1 O
pattern NN 0 1 3 O
is VBZ 1 0 12 O
also RB 0 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
occur VB 0 1 1 O
in IN 0 0 12 O
monkeys NNS 1 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
after IN 0 0 12 O
similar JJ 0 1 1 O
spinal JJ 0 1 6 O
cord NN 0 1 3 O
lesions NNS 1 1 6 O
. . 0 0 12 O

hindlimb NN 0 1 UNK O
locomotion NN 0 1 UNK O
showed VBD 1 1 12 O
substantial JJ 0 0 1 O
recovery NN 0 1 1 O
whereas IN 0 0 UNK O
the DT 0 0 12 O
ipsilesional JJ 0 0 UNK O
forelimb NN 0 1 UNK O
remained VBD 1 0 12 O
in IN 0 0 12 O
a DT 0 0 12 O
very RB 0 1 12 O
poor JJ 0 1 12 O
functional JJ 0 1 1 O
state NN 0 1 1 O
. . 0 0 12 O

Attention NN 0 1 2 O
is VBZ 1 0 12 O
paid VBN 1 1 12 O
to TO 0 0 12 O
calcium VB 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
diuretics NNS 1 1 14 B-Group
and CC 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
risk NN 0 1 1 O
of IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
bleeding NN 0 1 6 O
during IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
antiagregants NNS 0 0 UNK B-Group
and CC 0 0 12 O
anticoagulants VBZ 0 1 13 B-Group
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
bradycardia NN 0 1 8 O
in IN 0 0 12 O
beta NN 0 1 16 O
- : 0 0 2 O
blockade NN 0 1 1 O
possible JJ 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
lowering VBG 1 1 UNK O
the DT 0 0 12 O
heart NN 0 1 12 O
rate NN 0 1 1 O
are VBP 1 0 12 O
discussed VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
table NN 0 1 3 O
containing VBG 1 1 1 O
possible JJ 0 1 1 O
clinical JJ 0 1 6 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
unwanted JJ 0 0 13 O
side NN 0 1 3 O
effect NN 0 1 1 O
of IN 0 0 12 O
most JJS 0 0 12 O
frequently RB 0 1 1 O
used VBN 1 1 12 O
cardiovascular JJ 0 1 6 O
medications NNS 1 1 6 O
in IN 0 0 12 O
elderly JJ 0 1 12 O
is VBZ 1 0 12 O
added VBN 1 1 12 O
as IN 1 0 12 O
the DT 0 0 12 O
conclusion NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
article NN 0 1 UNK O
. . 0 0 12 O

Authors NNS 0 1 UNK O
analyze VBP 0 0 UNK O
the DT 0 0 12 O
situation NN 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
therapy NN 0 1 6 O
of IN 0 0 12 O
cardiovascular JJ 0 1 6 O
diseases NNS 1 1 6 O
- : 0 0 2 O
- : 0 0 2 O
unsatisfactory JJ 0 1 13 O
situation NN 0 0 12 O
especially RB 0 0 12 O
from IN 0 0 12 O
the DT 0 0 12 O
dyslipidaemia NN 0 1 UNK O
point NN 0 1 12 O
of IN 0 0 12 O
view NN 0 1 12 O
. . 0 0 12 O

[ JJ 0 0 2 O
Seniors NNS 0 1 UNK O
and CC 0 0 12 O
cardiovascular JJ 0 1 6 O
medications NNS 1 1 6 O
] VBP 0 0 2 O
. . 0 0 12 O

Colchicine NN 0 1 0 B-Drug
doses NNS 1 1 6 O
( ( 0 0 2 O
based VBN 1 1 1 O
on IN 0 0 12 O
creatinine JJ 0 1 14 O
clearance NN 0 1 16 O
) ) 0 0 2 O
exceeded VBD 1 0 UNK O
the DT 0 0 12 O
accepted JJ 0 1 12 O
range NN 0 1 1 O
for IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
including VBG 1 1 1 O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
death NN 0 1 12 O
classified VBN 1 1 13 O
as IN 1 0 12 O
possible JJ 0 1 1 O
or CC 0 0 12 O
higher JJR 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
contributing JJ 0 1 1 O
role NN 0 1 1 O
for IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
in IN 0 0 12 O
causing VBG 1 1 1 O
death NN 0 1 12 O
was VBD 1 0 12 O
unlikely JJ 0 1 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
/ NNS 0 0 2 O
9 CD 0 0 2 O
possible JJ 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
/ NN 0 0 2 O
9 CD 0 0 2 O
likely JJ 0 1 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
certain JJ 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

This DT 0 0 2 O
paper NN 0 1 13 O
summarized VBD 1 0 1 O
the DT 0 0 12 O
revised JJ 0 1 16 O
contents NNS 1 1 1 O
of IN 0 0 12 O
medical JJ 0 1 1 O
standards NNS 1 1 UNK O
and CC 0 0 12 O
suggested VBD 1 1 12 O
some DT 0 0 12 O
propositions NNS 1 0 UNK O
. . 0 0 12 O

Adding VBG 0 1 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
manganese JJ 0 1 13 B-Drug_n
gluconate NN 0 1 14 I-Drug_n
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
carbamide JJ 0 1 16 B-Drug_n
peroxide IN 0 1 16 I-Drug_n
bleaching VBG 1 1 UNK O
gel NN 0 1 3 O
increased VBD 1 1 1 O
the DT 0 0 12 O
degree NN 0 1 1 O
of IN 0 0 12 O
tooth NN 0 1 3 O
bleaching NN 0 1 UNK O
after IN 0 0 12 O
a DT 0 0 12 O
seven CD 0 1 12 O
- : 0 0 2 O
day NN 0 1 12 O
treatment NN 0 1 6 O
and CC 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
resulting VBG 1 1 1 O
shade NN 0 1 UNK O
after IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

Diagnostics NNS 0 1 UNK O
of IN 0 0 12 O
HIV NNP 0 1 6 O
infection NN 0 1 6 O
is VBZ 1 0 12 O
based VBN 1 1 1 O
upon IN 0 0 12 O
the DT 0 0 12 O
proof NN 0 1 1 O
of IN 0 0 12 O
specific JJ 0 1 1 O
antibodies NNS 1 1 14 O
. . 0 0 12 O

Before IN 0 1 2 O
and CC 0 0 12 O
during IN 0 0 12 O
antiretroviral JJ 0 0 UNK B-Group
treatment NN 0 1 6 O
antiretroviral JJ 0 0 UNK B-Group
drug NN 0 1 1 O
resistances NNS 1 1 UNK O
individual JJ 0 1 1 O
tolerance NN 0 1 1 O
profiles NNS 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
needs NNS 1 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
individual JJ 0 1 1 O
patient NN 0 1 6 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
several JJ 0 1 12 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
considered VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
most JJS 0 0 12 O
cases NNS 1 1 UNK O
the DT 0 0 12 O
application NN 0 1 1 O
of IN 0 0 12 O
two CD 0 1 12 O
nucleoside NN 0 1 UNK B-Group
or CC 0 0 12 I-Group
nucleotide JJ 0 1 UNK I-Group
reverse NN 0 1 1 I-Group
transcriptase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
NRTI NNP 0 1 UNK B-Group
) ) 0 0 2 O
together RB 0 1 12 O
with IN 0 0 12 O
a DT 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
nucleoside JJ 0 1 UNK I-Group
reverse NN 0 1 1 I-Group
transcriptase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
( ( 0 0 2 O
NNRTI NNP 0 1 UNK B-Group
) ) 0 0 2 O
a DT 0 0 12 O
protease NN 0 1 13 B-Group
inhibitor NN 0 1 14 I-Group
( ( 0 0 2 O
PI NNP 0 1 UNK B-Group
) ) 0 0 2 O
or CC 0 0 12 O
an DT 0 0 12 O
integrase JJ 0 1 UNK B-Group
inhibitor NN 0 1 14 I-Group
( ( 0 0 2 O
II NNP 0 0 2 B-Group
) ) 0 0 2 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
. . 0 0 12 O

Type NNP 0 1 2 O
- : 0 0 2 O
I PRP 0 1 12 O
insulin VBP 0 1 14 O
- : 0 0 2 O
like IN 0 0 12 O
growth NN 0 1 1 O
factor NN 0 1 1 O
receptor NN 0 1 14 O
( ( 0 0 2 O
IGF9R NNP 0 0 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
signaling VBG 1 1 UNK O
play NN 0 1 13 O
an DT 0 0 12 O
important JJ 0 1 1 O
role NN 0 1 1 O
in IN 0 0 12 O
osteosarcomagenesis JJ 0 0 UNK O
tumor NN 0 1 6 O
progression NN 0 1 1 O
and CC 0 0 12 O
chemoresistance NN 0 0 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
therapeutic JJ 0 1 6 O
drug NN 0 1 1 O
monitoring NN 0 1 1 O
requires VBZ 1 0 1 O
the DT 0 0 12 O
application NN 0 1 1 O
of IN 0 0 12 O
reliable JJ 0 1 UNK O
and CC 0 0 12 O
effective JJ 0 1 1 O
methods NNS 1 1 1 O
to TO 0 0 12 O
study VB 0 1 1 O
the DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
variability NN 0 1 UNK O
by IN 0 0 12 O
direct JJ 0 1 1 O
measurements NNS 1 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
immune NN 0 1 6 O
cell NN 0 1 1 O
functions NNS 1 1 13 O
. . 0 0 12 O

Flow NNP 0 1 2 O
cytometry NN 0 1 UNK O
offers VBZ 1 0 1 O
a DT 0 0 12 O
multiplicity NN 0 1 UNK O
of IN 0 0 12 O
quantitative JJ 0 1 1 O
analysis NN 0 1 1 O
possibilities NNS 1 1 1 O
from IN 0 0 12 O
detection NN 0 1 1 O
of IN 0 0 12 O
phosphorylated JJ 0 0 UNK O
molecules NNS 1 1 UNK O
up RB 0 0 12 O
to TO 0 0 12 O
complex VB 0 1 1 O
multicolor NN 0 0 UNK O
analysis NN 0 1 1 O
of IN 0 0 12 O
whole JJ 0 1 12 O
blood NN 0 1 6 O
samples NNS 1 1 UNK O
. . 0 0 12 O

A DT 0 0 2 O
large JJ 0 1 3 O
spectrum NN 0 1 1 O
of IN 0 0 12 O
flow JJ 0 1 1 O
cytometry NN 0 1 UNK O
- : 0 0 2 O
based VBN 1 1 1 O
applications NNS 1 1 UNK O
for IN 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
monitoring NN 0 1 1 O
is VBZ 1 0 12 O
available JJ 0 1 1 O
and CC 0 0 12 O
allows VBZ 1 1 UNK O
detection NN 0 1 1 O
and CC 0 0 12 O
analysis NN 0 1 1 O
of IN 0 0 12 O
diverse JJ 0 1 UNK O
function NN 0 1 1 O
of IN 0 0 12 O
T NNP 0 1 2 O
cells NNS 1 1 6 O
and CC 0 0 12 O
dendritic JJ 0 1 13 O
cell NN 0 1 1 O
subsets NNS 1 1 UNK O
. . 0 0 12 O

For IN 0 0 2 O
the DT 0 0 12 O
initial JJ 0 1 1 O
treatment NN 0 1 6 O
of IN 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
9 CD 0 0 2 O
infection NN 0 1 6 O
an DT 0 0 12 O
adjunction NN 0 1 UNK O
with IN 0 0 12 O
three CD 0 1 12 O
antiretroviral JJ 0 0 UNK B-Group
agents NNS 1 1 1 I-Group
is VBZ 1 0 12 O
generally RB 0 0 1 O
used VBN 1 1 12 O
. . 0 0 12 O

Flow NNP 0 1 2 O
cytometry NN 0 1 UNK O
- : 0 0 2 O
based VBN 1 1 1 O
pharmacodynamic JJ 0 1 UNK O
monitoring NN 0 1 1 O
after IN 0 0 12 O
organ JJ 0 1 6 O
transplantation NN 0 1 6 O
. . 0 0 12 O

Conventional JJ 0 1 UNK O
therapeutic JJ 0 1 6 O
drug NN 0 1 1 O
monitoring NN 0 1 1 O
based VBN 1 1 1 O
on IN 0 0 12 O
measuring VBG 1 1 1 O
immunosupressive JJ 0 0 UNK B-Group
drug NN 0 1 1 I-Group
concentrations NNS 1 1 13 O
in IN 0 0 12 O
blood NN 0 1 6 O
is VBZ 1 0 12 O
important JJ 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
management NN 0 1 1 O
of IN 0 0 12 O
immunosuppressive JJ 0 1 14 B-Group
therapy NN 0 1 6 O
in IN 0 0 12 O
transplantation NN 0 1 6 O
medicine NN 0 1 6 O
. . 0 0 12 O

Since IN 0 1 2 O
rejection NN 0 1 1 O
or CC 0 0 12 O
infection NN 0 1 6 O
occurs NNS 0 1 1 O
at IN 0 0 12 O
irregular JJ 0 1 3 O
drug NN 0 1 1 O
concentrations NNS 1 1 13 O
immunosuppressive JJ 0 1 14 B-Group
drug NN 0 1 1 I-Group
therapy NN 0 1 6 O
is VBZ 1 0 12 O
often RB 0 1 12 O
empiric JJ 0 1 14 O
and CC 0 0 12 O
prophylactic JJ 0 1 6 O
in IN 0 0 12 O
nature NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
blood NN 0 1 6 O
immunosuppressant NN 0 1 14 B-Group
levels NNS 1 1 1 O
are VBP 1 0 12 O
only RB 0 1 12 O
indirect JJ 0 1 1 O
predictors NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
pharmacologic JJ 0 1 14 O
effects NNS 1 1 1 O
on IN 0 0 12 O
immune NN 0 1 6 O
cells NNS 1 1 6 O
because IN 0 0 12 O
the DT 0 0 12 O
genetic JJ 0 1 13 O
heterogeneity NN 0 1 UNK O
the DT 0 0 12 O
immune JJ 0 1 6 O
systems NNS 1 1 1 O
of IN 0 0 12 O
transplant JJ 0 1 6 O
recipients NNS 1 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
equally RB 0 0 12 O
sensitive JJ 0 1 1 O
to TO 0 0 12 O
drug NN 0 1 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Life NNP 0 1 2 O
expectancy NN 0 1 UNK O
of IN 0 0 12 O
antiretrovirally RB 0 0 UNK O
treated VBN 1 1 1 O
HIV NNP 0 1 6 O
- : 0 0 2 O
infected JJ 0 1 6 O
people NNS 0 1 12 O
applying VBG 1 1 1 O
HAART NNP 0 1 14 O
could MD 0 0 12 O
be VB 0 0 12 O
considerably RB 0 0 1 O
extended VBN 1 1 1 O
and CC 0 0 12 O
now RB 0 1 12 O
resembles VBZ 1 0 UNK O
that IN 0 0 12 O
of IN 0 0 12 O
several JJ 0 1 12 O
other JJ 0 0 12 O
chronic JJ 0 1 6 O
diseases NNS 1 1 6 O
. . 0 0 12 O

Furthermore IN 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
even RB 0 0 12 O
possible JJ 0 1 1 O
to TO 0 0 12 O
differentiate VB 0 1 UNK O
between IN 0 0 12 O
synergistic JJ 0 1 UNK O
and CC 0 0 12 O
antagonistic JJ 0 1 UNK O
pharmacodynamic JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
immunosuppressive JJ 0 1 14 B-Group
drug NN 0 1 1 I-Group
combination NN 0 1 1 O
therapy NN 0 1 6 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
to TO 0 0 12 O
predict VB 0 0 UNK O
the DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
drug NN 0 1 1 O
effects NNS 1 1 1 O
in IN 0 0 12 O
transplanted JJ 0 1 13 O
recipients NNS 1 1 UNK O
. . 0 0 12 O

Such JJ 0 0 1 O
a DT 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
drug NN 0 1 1 O
monitoring NN 0 1 1 O
may MD 0 0 1 O
offer VB 0 0 12 O
the DT 0 0 12 O
opportunity NN 0 0 UNK O
to TO 0 0 12 O
complete VB 0 1 1 O
conventional JJ 0 1 1 O
therapeutic JJ 0 1 6 O
drug NN 0 1 1 O
monitoring NN 0 1 1 O
and CC 0 0 12 O
therefore RB 0 0 1 O
to TO 0 0 12 O
tailor VB 0 1 UNK O
immunosuppressive JJ 0 1 14 B-Group
therapy NN 0 1 6 O
more RBR 0 1 12 O
individually RB 0 0 13 O
. . 0 0 12 O

Since IN 0 1 2 O
the DT 0 0 12 O
introduction NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
highly RB 0 1 1 B-Group
active JJ 0 1 1 I-Group
antiretroviral JJ 0 0 UNK I-Group
therapy NN 0 1 6 O
( ( 0 0 2 O
HAART NNP 0 1 14 O
) ) 0 0 2 O
into IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
HIV NNP 0 1 6 O
infections NNS 1 1 6 O
in IN 0 0 12 O
many JJ 0 0 12 O
cases NNS 1 1 UNK O
a DT 0 0 12 O
delayed JJ 0 1 1 O
appearance NN 0 1 12 O
of IN 0 0 12 O
AIDS NNP 0 1 6 O
- : 0 0 2 O
defining NN 0 0 UNK O
diseases NNS 1 1 6 O
is VBZ 1 0 12 O
achievable JJ 0 0 UNK O
. . 0 0 12 O

Infections NNS 0 1 7 O
with IN 0 0 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
immunodeficiency NN 0 1 14 O
virus NN 0 1 6 O
9 CD 0 0 2 O
( ( 0 0 2 O
HIV NNP 0 1 6 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
lead NN 0 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
acquired VBN 1 1 1 O
immunodeficiency NN 0 1 14 O
syndrome NN 0 1 6 O
( ( 0 0 2 O
AIDS NNP 0 1 6 O
) ) 0 0 2 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
establishment NN 0 0 13 O
of IN 0 0 12 O
a DT 0 0 12 O
wide JJ 0 1 3 O
range NN 0 1 1 O
of IN 0 0 12 O
severe JJ 0 1 6 O
opportunistic JJ 0 0 1 O
infections NNS 1 1 6 O
. . 0 0 12 O

[ JJ 0 0 2 O
Infections NNS 0 1 7 O
with IN 0 0 12 O
human JJ 0 1 1 O
immunodeficiency NN 0 1 14 O
viruses NNS 1 1 13 O
. . 0 0 12 O
Part NNP 0 1 2 O
II NNP 0 0 2 O
: : 0 0 2 O
Antiretroviral JJ 0 0 UNK B-Group
drugs NNS 1 1 6 I-Group
therapeutic JJ 0 1 6 O
options NNS 1 1 1 O
and CC 0 0 12 O
diagnostics NNS 0 1 UNK O
] VBP 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
geometric JJ 0 1 UNK O
mean NN 0 1 12 O
ratio NN 0 1 1 O
for IN 0 0 12 O
C NNP 0 0 2 O
( ( 0 0 2 O
max NN 0 0 3 O
) ) 0 0 2 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
was VBD 1 0 12 O
calculated VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
hepatic JJ 0 1 14 O
clearance NN 0 1 16 O
and CC 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
luteolin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
apigenin NN 0 1 UNK B-Drug_n
were VBD 1 0 12 O
studied VBN 1 0 1 O
by IN 0 0 12 O
using VBG 1 1 1 O
primary JJ 0 1 1 O
cultured JJ 0 0 14 O
rat NN 0 1 13 O
hepatocytes NNS 0 1 UNK O
. . 0 0 12 O

We PRP 0 0 12 O
found VBD 1 1 12 O
that IN 0 0 12 O
oligophrenin JJ 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
interacts NNS 0 0 UNK O
with IN 0 0 12 O
Rev NNP 0 1 UNK O
- : 0 0 2 O
erb NN 0 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
mouse NN 0 1 UNK O
brain NN 0 1 6 O
causing VBG 1 1 1 O
it PRP 0 0 12 O
to TO 0 0 12 O
locate VB 0 0 UNK O
to TO 0 0 12 O
dendrites NNS 1 1 UNK O
reducing VBG 1 1 1 O
its PRP$ 1 0 12 O
repressor NN 0 1 UNK O
activity NN 0 1 1 O
and CC 0 0 12 O
protecting VBG 1 0 UNK O
it PRP 0 0 12 O
from IN 0 0 12 O
degradation NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
teaching NN 0 1 12 O
case NN 0 1 12 O
we PRP 0 0 12 O
present VBP 0 1 1 O
a DT 0 0 12 O
systematic JJ 0 1 UNK O
approach NN 0 1 1 O
to TO 0 0 12 O
diagnosing VBG 1 1 UNK O
high JJ 0 1 1 O
serum NN 0 1 14 O
osmolality NN 0 1 14 O
and CC 0 0 12 O
increased VBD 1 1 1 O
serum NN 0 1 14 O
osmolal NN 0 1 UNK O
gap NN 0 1 1 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
anion NN 0 1 14 O
- : 0 0 2 O
gap NN 0 1 1 O
metabolic JJ 0 1 6 O
acidosis NN 0 1 14 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
essential JJ 0 1 13 O
for IN 0 0 12 O
clinicians NNS 1 1 UNK O
to TO 0 0 12 O
understand VB 0 1 12 O
the DT 0 0 12 O
value NN 0 1 1 O
and CC 0 0 12 O
limitations NNS 1 1 1 O
of IN 0 0 12 O
osmolal NN 0 1 UNK O
gap NN 0 1 1 O
to TO 0 0 12 O
assist VB 0 1 1 O
in IN 0 0 12 O
reaching VBG 1 1 12 O
the DT 0 0 12 O
correct JJ 0 1 1 O
diagnosis NN 0 1 6 O
and CC 0 0 12 O
initiating VBG 1 1 1 O
appropriate JJ 0 1 1 O
treatment NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
other JJ 0 0 12 O
disorders NNS 1 1 6 O
including VBG 1 1 1 O
diabetic JJ 0 1 6 O
or CC 0 0 12 O
alcoholic JJ 0 1 12 O
ketoacidosis NN 0 1 6 O
acute NN 0 1 6 O
kidney NN 0 1 6 O
injury NN 0 1 6 O
chronic JJ 0 1 6 O
kidney NN 0 1 6 O
disease NN 0 1 6 O
and CC 0 0 12 O
lactic JJ 0 1 14 O
acidosis NN 0 1 14 O
can MD 0 0 12 O
cause VB 0 1 12 O
high JJ 0 1 1 O
- : 0 0 2 O
anion NN 0 1 14 O
- : 0 0 2 O
gap NN 0 1 1 O
metabolic JJ 0 1 6 O
acidosis NN 0 1 14 O
associated VBN 1 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
serum NN 0 1 14 O
osmolal NN 0 1 UNK O
gap NN 0 1 1 O
and CC 0 0 12 O
therefore NN 0 0 1 O
should MD 0 0 12 O
be VB 0 0 12 O
explored VBN 1 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
differential JJ 0 1 1 O
diagnosis NN 0 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
osmolal NN 0 1 UNK O
gap NN 0 1 1 O
and CC 0 0 12 O
metabolic JJ 0 1 6 O
acidosis NN 0 1 14 O
can MD 0 0 12 O
occur VB 0 1 1 O
either CC 0 1 12 O
together RB 0 1 12 O
or CC 0 0 12 O
alone RB 0 1 12 O
depending VBG 1 1 1 O
on IN 0 0 12 O
several JJ 0 1 12 O
factors NNS 1 1 1 O
including VBG 1 1 1 O
baseline NN 0 1 1 O
serum NN 0 1 14 O
osmolal VBP 0 1 UNK O
gap NN 0 1 1 O
molecular JJ 0 1 1 O
weight NN 0 1 3 O
of IN 0 0 12 O
the DT 0 0 12 O
alcohol NN 0 1 1 O
and CC 0 0 12 O
stage NN 0 1 12 O
of IN 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
the DT 0 0 12 O
alcohol NN 0 1 1 O
. . 0 0 12 O

An DT 0 0 2 O
increase NN 0 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
osmolality NN 0 1 14 O
and CC 0 0 12 O
serum NN 0 1 14 O
osmolal NNS 0 1 UNK O
gap NN 0 1 1 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
anion NN 0 1 14 O
- : 0 0 2 O
gap NN 0 1 1 O
metabolic JJ 0 1 6 O
acidosis NN 0 1 14 O
is VBZ 1 0 12 O
an DT 0 0 12 O
important JJ 0 1 1 O
clue NN 0 0 UNK O
to TO 0 0 12 O
exposure VB 0 1 1 O
to TO 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
toxic NN 0 1 1 O
alcohols VBZ 0 1 13 O
which WDT 0 0 12 O
include VBP 0 1 1 O
methanol JJ 0 1 UNK B-Drug_n
ethylene JJ 0 1 13 B-Drug_n
glycol NN 0 1 16 I-Drug_n
diethylene NN 0 0 UNK B-Drug_n
glycol NN 0 1 16 I-Drug_n
propylene NN 0 1 UNK B-Drug_n
glycol NN 0 1 16 I-Drug_n
or CC 0 0 12 O
isopropanol NN 0 1 UNK B-Drug
. . 0 0 12 O

Approach NN 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
evaluation NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
with IN 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
serum NN 0 1 14 O
osmolal NN 0 1 UNK O
gap NN 0 1 1 O
and CC 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
anion NN 0 1 14 O
- : 0 0 2 O
gap NN 0 1 1 O
metabolic JJ 0 1 6 O
acidosis NN 0 1 14 O
. . 0 0 12 O

So IN 0 1 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
important JJ 0 1 1 O
for IN 0 0 12 O
clinical JJ 0 1 6 O
drug NN 0 1 1 O
use NN 0 1 1 O
by IN 0 0 12 O
rational JJ 0 0 UNK O
utilization NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
herb NN 0 1 UNK O
and CC 0 0 12 O
western JJ 0 1 13 O
drug NN 0 1 1 O
which WDT 0 0 12 O
medicated VBN 1 1 UNK O
by IN 0 0 12 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
between IN 0 0 12 O
herb NN 0 1 UNK O
and CC 0 0 12 O
western JJ 0 1 13 O
drug NN 0 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
by IN 0 0 12 O
inducing VBG 1 1 6 O
or CC 0 0 12 O
inhibiting VBG 1 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
resulting VBG 1 1 1 O
in IN 0 0 12 O
either DT 0 1 12 O
efficacy NN 0 1 UNK O
enhancement NN 0 1 1 O
or CC 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

As IN 0 0 2 O
an DT 0 0 12 O
efflux NN 0 0 UNK O
transporter NN 0 1 UNK O
protein NN 0 1 14 O
widely RB 0 0 1 O
distributed VBN 1 1 13 O
in IN 0 0 12 O
various JJ 0 1 1 O
tissues NNS 1 1 6 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
plays VBZ 1 1 UNK O
an DT 0 0 12 O
important JJ 0 1 1 O
role NN 0 1 1 O
in IN 0 0 12 O
many JJ 0 0 12 O
drugs NNS 1 1 6 O
interactions NNS 1 1 UNK O
via IN 0 0 1 O
affecting VBG 1 1 1 O
the DT 0 0 12 O
metabolic JJ 0 1 6 O
process NN 0 1 1 O
to TO 0 0 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
in IN 0 0 12 O
plasma NN 0 1 14 O
and CC 0 0 12 O
tissue NN 0 1 6 O
. . 0 0 12 O

Potential JJ 0 1 UNK O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
on IN 0 0 12 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
transport NN 0 1 1 O
level NN 0 1 1 O
were VBD 1 0 12 O
discussed VBN 1 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
article NN 0 1 UNK O
. . 0 0 12 O

[ JJ 0 0 2 O
Drug NNP 0 1 2 O
interactions NNS 1 1 UNK O
on IN 0 0 12 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
transport NN 0 1 1 O
level NN 0 1 1 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
application NN 0 1 1 O
] NN 0 0 2 O
. . 0 0 12 O

We PRP 0 0 12 O
discovered VBD 1 1 12 O
a DT 0 0 12 O
previously RB 0 0 1 O
unknown JJ 0 1 12 O
partner NN 0 1 12 O
of IN 0 0 12 O
oligophrenin JJ 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
Rev NNP 0 1 UNK O
- : 0 0 2 O
erb NN 0 0 UNK O
a DT 0 0 12 O
nuclear JJ 0 1 1 O
receptor NN 0 1 14 O
that WDT 0 0 12 O
represses VBZ 1 0 UNK O
the DT 0 0 12 O
transcription NN 0 1 UNK O
of IN 0 0 12 O
circadian JJ 0 0 13 O
oscillators NNS 1 1 UNK O
. . 0 0 12 O

Longitudinal NNP 0 1 UNK O
study NN 0 1 1 O
. . 0 0 12 O

Amiodarone NNP 0 1 0 B-Drug
an DT 0 0 12 O
iodinated JJ 0 0 UNK O
benzofuran NN 0 1 UNK O
derivative NN 0 1 13 O
with IN 0 0 12 O
predominantly RB 0 0 1 O
class NN 0 1 12 O
III NNP 0 1 2 O
anti SYM 0 0 3 O
- : 0 0 2 O
arrhythmic JJ 0 0 UNK O
effects NNS 1 1 1 O
is VBZ 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
supraventricular JJ 0 0 8 O
and CC 0 0 12 O
ventricular JJ 0 1 8 O
arrhythmias NN 1 1 6 O
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
neferine NN 0 1 UNK B-Drug_n
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
in IN 0 0 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

Experimental NNP 0 1 UNK O
Sprague NNP 0 0 UNK O
- : 0 0 2 O
Dawley NNP 0 0 UNK O
rats NNS 1 1 UNK O
were VBD 1 0 12 O
randomly RB 0 0 UNK O
divided VBN 1 1 1 O
into IN 0 0 12 O
two CD 0 1 12 O
groups NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
purpose NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
to TO 0 0 12 O
assess VB 0 1 1 O
the DT 0 0 12 O
potential NN 0 1 1 O
of IN 0 0 12 O
neferine NN 0 1 UNK B-Drug_n
an DT 0 0 12 O
effective JJ 0 1 1 O
anti NN 0 0 3 O
- : 0 0 2 O
pulmonary JJ 0 1 6 O
fibrosis NN 0 1 6 O
drug NN 0 1 1 O
isolated VBN 1 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
embryo NN 0 1 UNK O
of IN 0 0 12 O
Nelumbo NNP 0 1 UNK O
nucifera NN 0 0 UNK O
Gaertner NNP 0 0 UNK O
's POS 0 1 12 O
seeds NNS 1 1 13 O
to TO 0 0 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
profile NN 0 1 1 O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
. . 0 0 12 O

Blood NN 0 1 2 O
samples NNS 1 1 UNK O
were VBD 1 0 12 O
collected VBN 1 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
orbital JJ 0 1 3 O
venous JJ 0 1 6 O
plexus NN 0 1 8 O
at IN 0 0 12 O
indicated JJ 0 1 1 O
time NN 0 1 12 O
points NNS 1 1 12 O
and CC 0 0 12 O
were VBD 1 0 12 O
analyzed VBN 1 1 13 O
for IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
concentration NN 0 1 1 O
using VBG 1 1 1 O
RP NNP 0 1 13 O
- : 0 0 2 O
HPLC NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
groups NNS 1 1 1 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
amiodarone NN 0 1 0 B-Drug
was VBD 1 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
rats NNS 1 1 UNK O
by IN 0 0 12 O
intragastric JJ 0 1 UNK O
and CC 0 0 12 O
intravenous JJ 0 1 14 O
administration NN 0 1 1 O
respectively RB 0 0 1 O
while IN 0 0 12 O
neferine NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administratered VBN 0 0 UNK O
by IN 0 0 12 O
intragastric JJ 0 1 UNK O
administration NN 0 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
differences NNS 1 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
parameters NNS 1 1 1 O
of IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
administered VBN 1 1 1 O
intravenously RB 0 0 14 O
or CC 0 0 12 O
intragastrically RB 0 0 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
control NN 0 1 1 O
( ( 0 0 2 O
without IN 0 0 12 O
neferine NN 0 1 UNK B-Drug_n
) ) 0 0 2 O
group NN 0 1 12 O
( ( 0 0 2 O
with IN 0 0 12 O
ratios NNS 1 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
in IN 0 0 12 O
all DT 0 0 12 O
experimental JJ 0 1 UNK O
groups NNS 1 1 1 O
) ) 0 0 2 O
suggesting VBG 1 1 1 O
that IN 0 0 12 O
neferine NN 0 1 UNK B-Drug_n
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
plasma NN 0 1 14 O
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
elimination NN 0 1 UNK O
percent NN 0 1 1 O
of IN 0 0 12 O
luteolin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
apigenin NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
after IN 0 0 12 O
9 CD 0 0 2 O
min NN 0 1 16 O
of IN 0 0 12 O
incubation NN 0 0 UNK O
. . 0 0 12 O

China NNP 0 1 UNK O
pharmacopoeia NN 0 1 UNK O
is VBZ 1 0 12 O
a DT 0 0 12 O
civil JJ 0 0 UNK O
code NN 0 1 1 O
which WDT 0 0 12 O
is VBZ 1 0 12 O
to TO 0 0 12 O
ensure VB 0 1 1 O
pharmaceutical JJ 0 1 13 O
quality NN 0 1 1 O
and CC 0 0 12 O
protect VBP 0 0 1 O
people NNS 0 1 12 O
's POS 0 1 12 O
drug NN 0 1 1 O
safety NN 0 1 1 O
and CC 0 0 12 O
effectiveness NN 0 1 UNK O
. . 0 0 12 O

[ JJ 0 0 2 O
Summary NNP 0 1 2 O
of IN 0 0 12 O
revised JJ 0 1 16 O
contents NNS 1 1 1 O
of IN 0 0 12 O
medical JJ 0 1 1 O
standards NNS 1 1 UNK O
of IN 0 0 12 O
preparation NN 0 1 1 O
recorded VBN 1 1 12 O
in IN 0 0 12 O
Chinese JJ 0 1 UNK O
Pharmacopeia NNP 0 1 UNK O
( ( 0 0 2 O
I PRP 0 1 12 O
division NN 0 1 1 O
9 CD 0 0 2 O
edition NN 0 1 UNK O
) ) 0 0 2 O
] NN 0 0 2 O
. . 0 0 12 O

This DT 0 0 2 O
nitric JJ 0 0 13 O
oxide SYM 0 1 14 O
- : 0 0 2 O
mediated VBN 1 1 13 O
signaling VBG 1 1 UNK O
dramatically RB 0 0 1 O
increases VBZ 1 1 1 O
Kv9 NNP 0 0 UNK O
currents NNS 1 1 UNK O
in IN 0 0 12 O
both DT 0 0 12 O
the DT 0 0 12 O
auditory NN 0 1 6 O
brain NN 0 1 6 O
stem NN 0 1 3 O
and CC 0 0 12 O
hippocampus NN 0 1 8 O
( ( 0 0 2 O
& CC 0 0 2 O
gt NN 0 1 13 O
; : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
) ) 0 0 2 O
transforming VBG 1 1 UNK O
synaptic JJ 0 0 UNK O
integration NN 0 1 13 O
and CC 0 0 12 O
information NN 0 1 1 O
transmission NN 0 1 1 O
but CC 0 0 12 O
with IN 0 0 12 O
only RB 0 1 12 O
modest JJ 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
action NN 0 1 13 O
potential JJ 0 1 1 O
waveform NN 0 1 13 O
. . 0 0 12 O

We PRP 0 0 12 O
conclude VBP 0 1 1 O
that IN 0 0 12 O
nitric JJ 0 0 13 O
oxide NN 0 1 14 O
is VBZ 1 0 12 O
a DT 0 0 12 O
homeostatic JJ 0 1 UNK O
regulator NN 0 1 UNK O
tuning VBG 1 0 UNK O
neuronal JJ 0 1 13 O
excitability NN 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
recent JJ 0 1 12 O
history NN 0 1 12 O
of IN 0 0 12 O
excitatory JJ 0 0 UNK O
synaptic JJ 0 0 UNK O
inputs NNS 1 1 UNK O
over IN 0 1 12 O
intervals NNS 1 1 1 O
of IN 0 0 12 O
minutes NNS 1 1 12 O
to TO 0 0 12 O
hours NNS 1 1 12 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
thought VBN 1 1 12 O
that IN 0 0 12 O
homeostatic JJ 0 1 UNK O
mechanisms NNS 1 1 UNK O
match VBP 0 1 13 O
intrinsic JJ 0 1 1 O
excitability NN 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
incoming JJ 0 0 UNK O
synaptic JJ 0 0 UNK O
drive NN 0 1 12 O
but CC 0 0 12 O
evidence NN 0 1 1 O
for IN 0 0 12 O
involvement NN 0 1 1 O
of IN 0 0 12 O
voltage NN 0 1 1 O
- : 0 0 2 O
gated JJ 0 0 UNK O
conductances NNS 1 0 UNK O
is VBZ 1 0 12 O
sparse JJ 0 0 1 O
. . 0 0 12 O

Here RB 0 0 2 O
we PRP 0 0 12 O
show VBP 0 1 12 O
that IN 0 0 12 O
glutamatergic JJ 0 0 UNK O
synaptic JJ 0 0 UNK O
activity NN 0 1 1 O
modulates VBZ 1 1 UNK O
target VBP 0 1 1 O
neuron JJ 0 1 13 O
excitability NN 0 1 UNK O
and CC 0 0 12 O
switches VBZ 1 1 UNK O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
action NN 0 1 13 O
potential JJ 0 1 1 O
repolarization NN 0 0 UNK O
from IN 0 0 12 O
Kv9 NNP 0 0 UNK O
to TO 0 0 12 O
Kv9 NNP 0 0 UNK O
potassium NN 0 1 14 O
channel NN 0 1 1 O
dominance NN 0 1 UNK O
thereby RB 0 0 UNK O
adjusting VBG 1 0 1 O
neuronal JJ 0 1 13 O
signaling VBG 1 1 UNK O
between IN 0 0 12 O
low JJ 0 1 1 O
and CC 0 0 12 O
high JJ 0 1 1 O
activity NN 0 1 1 O
states NNS 1 1 1 O
respectively RB 0 0 1 O
. . 0 0 12 O

Nitric NNP 0 0 UNK B-Drug
oxide NN 0 1 14 I-Drug
is VBZ 1 0 12 O
an DT 0 0 12 O
activity NN 0 1 1 O
- : 0 0 2 O
dependent JJ 0 1 1 O
regulator NN 0 1 UNK O
of IN 0 0 12 O
target NN 0 1 1 O
neuron NN 0 1 13 O
intrinsic JJ 0 1 1 O
excitability NN 0 1 UNK O
. . 0 0 12 O

Activity NNP 0 1 2 O
- : 0 0 2 O
dependent NN 0 1 1 O
changes NNS 1 1 1 O
in IN 0 0 12 O
synaptic JJ 0 0 UNK O
strength NN 0 1 1 O
are VBP 1 0 12 O
well RB 0 1 12 O
established VBN 1 1 1 O
as IN 1 0 12 O
mediating NN 0 1 UNK O
long JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
plasticity NN 0 1 UNK O
underlying VBG 1 0 1 O
learning NN 0 1 13 O
and CC 0 0 12 O
memory NN 0 1 1 O
but CC 0 0 12 O
modulation NN 0 1 13 O
of IN 0 0 12 O
target NN 0 1 1 O
neuron NN 0 1 13 O
excitability NN 0 1 UNK O
could MD 0 0 12 O
complement VB 0 1 UNK O
changes NNS 1 1 1 O
in IN 0 0 12 O
synaptic JJ 0 0 UNK O
strength NN 0 1 1 O
and CC 0 0 12 O
regulate VB 0 0 UNK O
network NN 0 1 UNK O
activity NN 0 1 1 O
. . 0 0 12 O

As IN 0 0 2 O
such JJ 0 0 1 O
interactions NNS 1 1 UNK O
impact VBP 0 1 1 O
the DT 0 0 12 O
health NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
action NN 0 1 13 O
and CC 0 0 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
physicians NNS 1 1 6 O
and CC 0 0 12 O
pharmacists NNS 1 1 UNK O
should MD 0 0 12 O
pay VB 0 1 12 O
more JJR 0 1 12 O
attention NN 0 1 12 O
to TO 0 0 12 O
such JJ 0 0 1 O
interactions NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
future NN 0 1 12 O
. . 0 0 12 O

Since IN 0 1 2 O
more JJR 0 1 12 O
and CC 0 0 12 O
more JJR 0 1 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
used VBN 1 1 12 O
for IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
patients NNS 1 1 6 O
this DT 0 0 12 O
topic NN 0 1 13 O
is VBZ 1 0 12 O
increasingly RB 0 0 1 O
relevant JJ 0 1 1 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
between IN 0 0 12 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
have VBP 0 0 12 O
received VBN 1 1 12 O
only RB 0 1 12 O
little JJ 0 1 12 O
or CC 0 0 12 O
no DT 0 0 12 O
attention NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
medical JJ 0 1 1 O
and CC 0 0 12 O
pharmaceutical JJ 0 1 13 O
world NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
past NN 0 1 12 O
. . 0 0 12 O

[ JJ 0 0 2 O
Vitamin NNP 0 1 2 B-Group
D NNP 0 1 2 I-Group
and CC 0 0 12 O
drugs NNS 1 1 6 O
] NNP 0 0 2 O
. . 0 0 12 O
; : 0 0 2 O

Beside IN 0 0 UNK O
this DT 0 0 12 O
the DT 0 0 12 O
medication NN 0 1 6 O
oriented VBD 1 1 1 O
supplementation NN 0 1 14 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
can MD 0 0 12 O
also RB 0 0 12 O
ameliorate VB 0 0 6 O
the DT 0 0 12 O
pharmacologic JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
many JJ 0 0 12 O
drugs NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
bisphosphonates NNS 0 1 13 B-Group
statins NNS 1 1 UNK B-Group
and CC 0 0 12 O
cytostatic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

PXR NNP 0 1 UNK O
- : 0 0 2 O
ligands VBZ 0 1 UNK O
include VBP 0 1 1 O
a DT 0 0 12 O
wide JJ 0 1 3 O
variety NN 0 1 1 O
of IN 0 0 12 O
pharmaceutical JJ 0 1 13 O
agents NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
antiepileptic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
taxol VBP 0 1 13 B-Brand
rifampicin NN 0 1 UNK B-Drug
and CC 0 0 12 O
human JJ 0 1 1 B-Group
immunodeficiency NN 0 1 14 I-Group
virus NN 0 1 6 I-Group
protease NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
ritonavir NN 0 1 16 B-Drug
and CC 0 0 12 O
saquinavir NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
drug NN 0 1 1 O
- : 0 0 2 O
induced JJ 0 1 6 O
activation NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
pregnane NN 0 1 UNK O
X NNP 0 0 2 O
receptor NN 0 1 14 O
( ( 0 0 2 O
PXR NNP 0 1 UNK O
) ) 0 0 2 O
is VBZ 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
enhance VB 0 1 UNK O
CYP9 NNP 0 0 UNK O
expression NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
catabolism NN 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
OH NNP 0 1 UNK O
) ) 0 0 2 O
D NNP 0 1 2 O
leading VBG 1 1 1 O
to TO 0 0 12 O
vitamin VB 0 1 6 O
D NNP 0 1 2 O
deficiency NN 0 1 6 O
. . 0 0 12 O

A DT 0 0 2 O
number NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
can MD 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
vitamin NN 0 1 6 B-Group
D NNP 0 1 2 I-Group
and CC 0 0 12 O
bone NN 0 1 6 O
metabolism NN 0 1 16 O
. . 0 0 12 O

Evaluation NN 0 1 2 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
clearance NN 0 1 16 O
and CC 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
luteolin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
apigenin NN 0 1 UNK B-Drug_n
by IN 0 0 12 O
using VBG 1 1 1 O
primary JJ 0 1 1 O
cultured JJ 0 0 14 O
rat NN 0 1 13 O
hepatocytes NNS 0 1 UNK O
. . 0 0 12 O

Druce NNP 0 0 UNK O
subsp NN 0 0 UNK O
. . 0 0 12 O

Luteolin NNP 0 1 UNK B-Drug_n
and CC 0 0 12 O
apigenin NN 0 1 UNK B-Drug_n
experienced VBD 1 0 12 O
extensive JJ 0 1 1 O
first JJ 0 1 12 O
- : 0 0 2 O
pass NN 1 1 12 O
metabolism NN 0 1 16 O
. . 0 0 12 O

Inappropriate NNP 0 1 UNK O
dosing NN 0 0 14 O
of IN 0 0 12 O
colchicine NN 0 1 0 B-Drug
occurred VBN 1 1 1 O
frequently RB 0 1 1 O
and CC 0 0 12 O
was VBD 1 0 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
death NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
predicted VBN 1 1 1 O
% NN 0 0 18 O
liver NN 0 1 6 O
blood NN 0 1 6 O
flow NN 0 1 1 O
was VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
for IN 0 0 12 O
luteolin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
apigenin NN 0 1 UNK B-Drug_n
respectively RB 0 0 1 O
. . 0 0 12 O

Total JJ 0 1 2 O
glucuronidated VBD 0 0 UNK O
/ NNP 0 0 2 O
sulfated VBD 1 1 UNK O
conjugates NNS 1 1 UNK O
of IN 0 0 12 O
luteolin NN 0 1 UNK O
/ NNP 0 0 2 O
apigenin NN 0 1 UNK O
were VBD 1 0 12 O
determined VBN 1 1 1 O
by IN 0 0 12 O
an DT 0 0 12 O
enzyme JJ 0 1 14 O
hydrolysis NN 0 1 UNK O
method NN 0 1 13 O
. . 0 0 12 O

Compared VBN 0 1 2 O
with IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
pure JJ 0 1 13 O
luteolin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
apigenin VB 0 1 UNK B-Drug_n
the DT 0 0 12 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
luteolin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
apigenin NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
much JJ 0 0 12 O
lower JJR 1 1 1 O
in IN 0 0 12 O
hydrolyzed JJ 0 0 UNK O
Flos NNP 0 1 UNK O
Chrysanthemi NNP 0 0 UNK O
extract NN 0 1 13 O
( ( 0 0 2 O
FCE NNP 0 0 UNK O
) ) 0 0 2 O
containing VBG 1 1 1 O
comparable JJ 0 0 1 O
amounts NNS 1 1 1 O
of IN 0 0 12 O
luteolin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
apigenin NN 0 1 UNK B-Drug_n
. . 0 0 12 O

Thus RB 0 0 1 O
these DT 0 0 12 O
findings NNS 1 1 1 O
may MD 0 0 1 O
support VB 0 1 1 O
the DT 0 0 12 O
validity NN 0 1 UNK O
of IN 0 0 12 O
acute JJ 0 1 6 O
MPTP NNP 0 1 UNK B-Drug_n
treatment NN 0 1 6 O
model NN 0 1 UNK O
for IN 0 0 12 O
unraveling VBG 1 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
neurodegenerative JJ 0 0 UNK O
processes NNS 1 1 1 O
in IN 0 0 12 O
PD NNP 0 0 13 O
. . 0 0 12 O

At IN 0 0 2 O
least JJS 0 1 12 O
four CD 0 1 12 O
key JJ 0 0 13 O
determinants NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
chemical NN 0 1 13 O
structures NNS 1 1 1 O
of IN 0 0 12 O
flavonoids NNS 1 1 UNK B-Drug_n
are VBP 1 0 12 O
necessary JJ 0 0 1 O
for IN 0 0 12 O
exerting VBG 1 1 UNK O
the DT 0 0 12 O
inhibitory JJ 0 1 UNK O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
conjugation NN 0 1 14 O
: : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
catechol NN 0 1 UNK O
structure NN 0 1 1 O
( ( 0 0 2 O
9' CD 0 0 UNK O
9' CD 0 0 UNK O
- : 0 0 2 O
dihydroxylation NN 0 0 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
B NNP 0 0 2 O
- : 0 0 2 O
ring NN 0 1 3 O
; : 0 0 2 O

Colchicine NNP 0 1 0 B-Drug
toxicity NN 0 1 6 O
was VBD 1 0 12 O
frequent JJ 0 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
cohort NN 0 1 UNK O
and CC 0 0 12 O
may MD 0 0 1 O
have VB 0 0 12 O
contributed VBN 1 1 1 O
to TO 0 0 12 O
about IN 0 1 12 O
one CD 0 1 12 O
- : 0 0 2 O
third NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
deaths NNS 1 1 UNK O
. . 0 0 12 O

Three CD 0 1 2 O
thousand CD 0 1 12 O
six CD 0 1 12 O
hundred VBD 0 0 UNK O
ninety SYM 0 1 UNK O
- : 0 0 2 O
two CD 0 1 12 O
veterans NNS 1 1 UNK O
aged VBD 1 1 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
older JJR 1 1 12 O
admitted VBN 1 1 12 O
between IN 0 0 12 O
January NNP 0 1 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
June NNP 0 1 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
with IN 0 0 12 O
long JJ 0 1 12 O
stays NNS 1 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

Most JJS 0 0 2 O
insights NNS 1 1 UNK O
into IN 0 0 12 O
pathogenesis NN 0 1 UNK O
of IN 0 0 12 O
PD NNP 0 0 13 O
come VBP 0 0 12 O
from IN 0 0 12 O
investigations NNS 1 1 1 O
performed VBN 1 1 1 O
in IN 0 0 12 O
experimental JJ 0 1 UNK O
models NNS 1 1 UNK O
of IN 0 0 12 O
PD NNP 0 0 13 O
especially RB 0 0 12 O
those DT 0 0 12 O
produced VBN 1 0 1 O
by IN 0 0 12 O
neurotoxins NNS 1 1 UNK O
. . 0 0 12 O

Seventeen JJ 0 1 UNK O
patients NNS 1 1 6 O
received VBD 1 1 12 O
interacting JJ 0 0 1 O
medications NNS 1 1 6 O
including VBG 1 1 1 O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
cases NNS 1 1 UNK O
of IN 0 0 12 O
death NN 0 1 12 O
classified VBN 1 1 13 O
as IN 1 0 12 O
possible JJ 0 1 1 O
or CC 0 0 12 O
higher JJR 1 1 1 O
. . 0 0 12 O

